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    Pneumocystis (PC) pneumonia is a life-threatening opportunistic fungal infection 
observed in individuals with severe immunodeficiencies, such as AIDS.   This dissertation 
evaluates functions of antibodies and conserved fungal cell wall carbohydrate antigens in host 
defense against PC.  We demonstrate that a novel recombinant protein consisting of the 
extracellular domain of the β-glucan receptor dectin-1 fused to the constant portion of murine 
IgG1, binds β-glucan and recognizes Fc-γ receptors; and functionally, impairs growth of PC in 
the lungs of immunocompromised mice.   As an antibody-like molecule targeting a conserved 
fungal cell wall carbohydrate enhanced host defense against PC, we questioned whether the host 
produces similar antibodies.  We identified natural IgM antibodies, conserved across species and 
not requiring microbial stimulation for production, that recognize fungal cell wall carbohydrates 
β-glucan and chitosan/chitin.   In mice, naïve serum containing natural antibodies impairs the 
growth of PC organisms in the lungs at intermediate stages of infection, while at earliest stages 
limits pulmonary neutrophil recruitment.  Mice unable to secrete IgM, sIgM(-/-), manifest 
similar impairments in pathogen clearance at intermediate stages of infection.   Additionally, 
sIgM(-/-) mice demonstrate diminished trafficking of fungal cell wall carbohydrate antigen by 
CD11c+ cells to draining lymph nodes, impaired production of Th2 and Th17 cytokines in 
 v 
lymph nodes after PC challenge, and altered adaptive antibody responses, with diminished anti-
PC IgG1 (Th2 associated) while enhanced IgG2a (Th1 associated) adaptive antibody 
responses.  Thus, sIgM, of which a significant component is natural antibody, influences PC Ag 
presentation at earliest stages of infection, enhancing host defense and biasing the host towards 
Th2 adaptive responses.   Additionaly, we observe that β-glucan and chitosan/chitin are targets of 
induced antibody responses.  PC challenge leads to the induction of specific serum IgG, and 
increased quantities of multiple isotypes at the lung mucosa against these 
carbohydrates.   Mucosal responses against β-glucan and chitosan/chitin after PC challenge are 
regulated by CD4+ T cells, and we provide evidence that functional memory B cell responses 
against fungal wall carbohydrates are generated as a consequence of PC challenge.   Collectively, 
these studies demonstrate the importance of conserved fungal cell wall carbohydrate antigens, 
and primitive antibody isotypes, in host defense responses against PC.    
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1. INTRODUCTION 
 
 
 
 
1.1 PNEUMOCYSTIS PNEUMONIA: HUMAN DISEASE & BASIC 
ASPECTS OF PNEUMOCYSTIS ORGANISMS 
 
 
1.1.1 Epidemiology of Pneumocystis pneumonia 
 
 
Pneumocystis pneumonia is a common, often fatal opportunistic infection observed in 
individuals with a variety of severe immunodeficiencies, either genetic or acquired.   The 
etiologic agent underlying infection in humans, Pneumocysis jirovecii (previously named 
Pneumocystis carinii f. sp. hominis), is a fungal pathogen, with its primary mechanism of 
transmission and reservoir(s) poorly characterized.  Multiple lines of evidence support the 
likelihood of person-to-person transmission, such as the observation that genotypically similar 
Pneumocystis jirovecii isolates are associated with cluster outbreaks among hospitalized 
immunocompromised patients, and the observation that cohousing Pneumocystis infected mice 
with uninfected mice leads to transmission of infection (1-3).  However, Pneumocystis jirovecii 
nucleic acids have been detected outside of the mammalian host, such as in ambient air and in 
spore traps in rural locations (4, 5), suggesting that an environmental reservoir may exist for this 
opportunistic pathogen and may play a significant role in transmission.  Regardless of the route 
of exposure, it is suspected that Pneumocystis jirovecii is encountered frequently by humans, as 
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most individuals possess antibodies against the fungal organism by three years of age, and rates 
of seropositivity continue to increase with age (6).    
The incidence of Pneumocystis pneumonia has increased dramatically since the 1980’s 
and the emergence of the global acquired immunodeficiency syndrome (AIDS) pandemic.  In 
1981, Morbidity and Mortality Weekly Report, Gottlieb et al described a case series of 5 young 
homosexual male patients in Los Angeles hospitals, over the span of seven months, presenting 
with Pneumocystis pneumonia, but without any known immunodeficiency (7).   The authors 
postulated that the patients had a cellular immune dysfunction secondary to a sexually 
transmitted infection, which was later discovered to be caused by human immunodeficiency 
virus (HIV) infection, which at advanced stages of illness leads to AIDS and susceptibility to 
Pneumocystis pneumonia.   The diagnosis of Pneumocystis pneumonia was later realized to be a 
strong indicator of progression to advanced stages of HIV infection and is now considered an 
AIDS-defining illness.  The probability of the development of Pneumocystis pneumonia in 
individuals with HIV-AIDS is inversely correlated with quantities of CD4+ T cells in the blood, 
with a quantity of less than 200 CD4+ T cells/µL a major indicator of Pneumocystis jirovecii 
susceptibility, though dysfunction occurs within multiple cell types of the immune system, such 
as macrophages, CD8+ T cells, dendritic cells, and B cells (8-15).   At the onset of the HIV 
pandemic in the United States, the incidence of Pneumocystis jirovecii was 20 per 100 person-
years among individuals with a CD4+ T cell count below 200/µL (16).   With the introduction of 
co-trimoxazole chemoprophylaxis to specifically prevent Pneumocystis pneumonia, and further 
with the development and widespread use of combined antiretroviral therapy (cART) to 
specifically inhibit HIV replication, a significant decline in the Pneumocystis pneumonia 
incidence was observed in populations where these treatments were available.    As of 2001, the 
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incidence of Pneumocystis pneumonia among HIV infected individuals has declined to 
approximately 30 per 1000 person-years, though it still remains the most common serious 
opportunistic infection among individuals with HIV in Europe and North America (17, 18).     
The population of HIV-infected individuals globally is estimated to range from 30 to 35 
million (19), and 95% of those estimated to be infected are living in developing countries.  Only 
an estimated 27-34% of patients who require antiretroviral therapy are actually receiving it (20), 
demonstrating the extraordinary limitation in accessibility of these medications and the need to 
develop novel strategies to combat opportunistic infections.   While Pneumocystis pneumonia is 
not the most prevalent pulmonary opportunistic infection in developing countries, with 
tuberculosis and bacterial pneumonias often having a higher prevalence, Pneumocystis 
pneumonia is frequent.   For example, in Thailand a Pneumocystis pneumonia prevalence of 27% 
to 40% was observed among HIV-infected individuals seen in a clinic setting, and it is reported 
to be one of the most prevalent opportunistic infections in the country (21, 22).    In Kenya 
among acid-fast bacilli smear negative patients with chronic cough, Pneumocystis pneumonia 
was detected in the most patients, thereafter followed by bacterial pneumonia and Mycobacterial 
tuberculosis (23).    Additionally, Pneumocystis pneumonia is particularly common in HIV-
infected infants in developing countries, and is a frequent cause of death in these populations 
(24-26).    
Besides HIV status, there are multiple other risk factors for Pneumocystis pneumonia.  
Primary immunodeficiencies leading to Pneumocystis pneumonia susceptibility include severe 
combined immunodeficiency, X-linked hyper-IgM syndrome, and Wiskott-Aldrich syndrome.   
Individuals taking chronic immunosuppressive medications for rheumatologic conditions or 
organ transplantation are a rapidly growing population of individuals at risk for Pneumocystis 
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pneumonia (27-30).  Additionally at risk are individuals with malignancies, hematologic or 
otherwise, as well as patients receiving immunosuppressive chemotherapeutics for cancer 
treatment (31-33).     The large  population of individuals at risk for this illness makes critical a 
greater understanding of the immunologic processes underlying resistance and susceptibility.  
 
1.1.2 Clinical features of Pneumocystis pneumonia 
 
Symptoms of Pneumocystis pneumonia include shortness of breath, progressive exertional 
dyspnea, low-grade fever, non-productive cough, and chills.  Patients often demonstrate an 
elevated serum lactate dehydrogenase, which is highly sensitive for infection, though of poor 
specificity.  Early in the course of the illness the chest radiograph may be normal despite a 
widened alveolar-arterial O2 gradient, however in most cases chest x-ray demonstrates diffuse 
bilateral infiltrates.  Qualitative and quantitative differences exist in the Pneumocystis 
pneumonias experienced in the setting of HIV infection and in the absence of HIV infection, as 
summarized by Limper et al. (27).   In the absence of HIV, Pneumocystis pneumonia is often 
associated with the abrupt onset of respiratory insufficiency, rather than a progressive indolent 
course as seen in the setting of HIV.  Additionally, there are increased quantities of neutrophils 
and decreased quantities of Pneumocystis organisms in the bronchoalveolar lavage fluid (BALF) 
in non-HIV Pneumocystis patients.   The mortality rate for patients with Pneumocystis 
pneumonia is higher in non-HIV patients compared to patients with AIDS and Pneumocystis 
pneumonia.  Given the difference in the quality of the illness as a function of host predisposing 
factors, it has led many to speculate that the quality of the host’s specific immunodeficiency 
significantly influences the course of the infection, and that prognosis is not simply a function of 
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the growth of Pneumocystis organisms within the lungs.  Indeed, treatment with corticosteroids 
prior to initiating co-trimoxazole is aimed at inhibiting the host’s inflammatory response against 
degraded Pneumocystis organisms, suggesting that the pulmonary pathology attributed to the 
infection is partially a function of an ineffective, overabundant host inflammatory process and 
that limitation of this process improves patient outcomes.  
 
1.1.3 Limitations of therapeutic strategies against Pneumocystis pneumonia 
 
Cotrimoxazole, pentamidine, and dapsone are preventative and therapeutic agents that inhibit the 
growth of Pneumocystis organisms.  Specifically, cotrimoxazole, the primary agent used in 
prevention and treatment, targets the enzymes dihydropteroate synthase and dihydrofolate 
reductase which are key enzymes in the foliate utilization pathway in Pneumocystis.  As 
Pneumocystis organisms cannot uptake folic acid from the environment, cotrimoxazole starves 
the opportunistic pathogen of nucleotides required for cell division.   Similarly, dapsone targets 
dihydrofolate reductase, whereas the mechanism of pentamidine is unknown but possesses broad 
function against numerous protozoan parasites as well as Candida sp.  Nonsynonymous 
mutations have been detected among Pneumocystis jirovecii isolates in the dihydrofolate 
reductase gene, and notably the presence of these mutations was correlated with cotrimoxazole 
prophylaxis failure (34).  Additionally, the likelihood of dihydropteroate synthase mutations is 
correlated with prior use of dapsone or cotrimoxazole, and treatment of existing Pneumocystis 
pneumonia with cotrimoxazole failed more frequently in patients whose isolates had 
dihydropteroate synthase mutations than in those whose isolates had the wild-type gene  (35, 36).   
These observations suggest the potential functional limitation of these medications in that the 
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widespread emergence of resistant organisms may occur, particularly given the global prevalence 
of this fungal organism, its long-term prophylactic use in many patients, and the widespread risk 
factor of HIV-AIDS infection.    Of note, there are no immunotherapeutic strategies or vaccines 
in clinical use against any fungal pathogen.   
 
1.1.4 Diversity of  Pneumocystis species and limitations to their study 
 
Pneumocystis sp. encompass a broad genus of organisms which display significant functional 
and genetic variation, with infection exclusive to mammals.  The argument that Pneumocystis 
organisms isolated from different hosts are separate species relies solely on the observations of 
strong functional and genetic diversity between them.   Functional diversity is exhibited at the 
level of host infectivity, as it has been demonstrated that Pneumocystis organisms isolated from 
one immunocompromised mammalian host are unable to establish infection in a host of a 
different species.  For example, Pneumocystis isolates from immunosuppressed humans and 
ferrets are unable to infect immunosuppressed mice (37, 38).    Additionally, functional diversity 
of Pneumocystis sp. is demonstrated at the level of antigen diversity.  Mice challenged with 
Pneumocystis organisms from ferrets do not induce a protective antibody response in mice, 
whereas Pneumocystis organisms isolated from murine hosts do (39), suggesting that diversity 
exists at the level of immunoprotective antigens, with such diversity influencing the 
programming of the host adaptive immune response.    Great genetic diversity between species is 
also observed.   For example, significant sequence differences for genes encoding 5 different 
Pneumocystis isoenzymes, occurred between isolates from different hosts such as rabbits, rats, 
mice, and humans (40).  In this study, the authors argue that population-genetic testing and 
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phylogenetic analysis demonstrate that Pneumocystis genotypes are host-specific, and that no 
genetic exchange occurs between isolates from different species at these loci.   Additionally, the 
genomes of Pneumocystis mouse, human, rat, and ferret have been estimated to be 6.5, 7.0, 7.7, 
and 11 Mb of DNA, respectively, suggesting major host-species specific diversity at the genetic 
level (41).    
A major limitation in understanding Pneumocystis organisms is the lack of a culture 
system that allows for propagation of organisms.  Hence, it is only from analyzing isolated, 
concentrated organisms from infected lung tissue that our understanding of Pneumocystis 
organism biology, genetics, and immunology has progressed.  Methods for assessing infection 
quantitatively, for assessing in vitro viability, as well as for cloning specific Pneumocystis genes 
have required more complex strategies compared to more standard methods used in the study of 
bacterial pathogens.     
The lack of a culture system has severely curtailed our understanding of the organisms 
life cycle.   While there are two predominant forms of Pneumocystis organisms observed in 
infected tissues, a large cyst with multiple intracystic bodies and a significantly smaller amorphic 
trophozoite, their interrelation is presumed given their appearance together in infected lungs.   
The current hypothesis suggests that trophic forms are generated from rupture of the cyst, with 
trophic forms later undergoing fusion to regenerate cyst forms.  Cyst forms undergo a maturation 
process leading to increased numbers of intracystic bodies, leading to another cycle of cyst 
rupture. However, trophozoites are approximately 10 times more predominant in infected lung 
tissues, making it questionable as to whether the cyst form is required for continued infection.   It 
is additionally unclear as to whether one form is infectious or both forms.  However, neither of 
these controversies can be addressed with the existing knowledge and without a system allowing 
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for propagation of Pneumocystis organisms and the isolation of the distinct morphologic forms 
of the fungal pathogen.  
 
1.1.5 Animal Models of Pneumocystis Pneumonia 
 
Animal models of infection have provided significant insight into the pathogenesis of 
Pneumocystis pneumonia.  Rats and mice are most often used in modeling Pneumocystis 
pneumonia, and have been useful in identifying important immune effector mechanisms in host 
defense.   In wild type immunocompetent rodents, Pneumocystis pneumonia can be induced, 
peaking in mice around 3-4 weeks after infection, and is thereafter rapidly cleared, while in 
immunosuppressed rodents, infection continues to grow leading to death if allowed to continue.  
High quantities of Pneumocystis organisms can be isolated from the infected lungs of 
immunosuppressed rodents, such as athymic, SCID, RAG2 (-/-), or chronically corticosteroid 
treated hosts and used to infect other hosts, as well as used for direct study.  While genetic and 
functional diversity between species may make questionable the extrapolation between them in 
the analysis of protective immunologic responses, rodent models can be made susceptible to 
Pneumocystis infection by many of the same factors that lead to susceptibility in humans, 
suggesting that basic host defense mechanisms are similar and when breached bear similar 
consequences.   For example, the SCID mutation in humans, the CD40L mutation leading to the 
X-linked hyper-IgM syndrome, and chronic corticosteroid use leads to susceptibility to 
Pneumocystis infection in humans and in mice.  Chronic CD4+ T cell depletion in mice using 
monoclonal antibodies targeting CD4, mirroring the CD4+ T cell depleted status of individuals 
in late stages of AIDS, also leads to Pneumocystis susceptibility in mice and rats (42-44).   
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 Pneumocystis isolates from these different mammalian hosts  also produce a qualitatively 
similar, slowly progressing, focal or diffuse pneumonia involving masses of Pneumocystis 
trophozoites clustered in airspace filling eosinophilic exudates, single or clustered Pneumocystis 
cysts identifiable with Gomori-methenamine silver stain, and thickened alveolar septa; without 
systemic dissemination of infection (45).   Additionally, infection in rodent and human hosts 
leads to elevated serum lactate dehydrogenase, significantly decreased PaO2, and pulmonary 
neutrophilia at late stages of disease.        
More recently, a primate model of Pneumocystis infection has been established, whereby 
simian immunodeficiency virus (SIV) infected macaques inoculated with Pneumocystis 
organisms experienced an often prolonged period of organism colonization followed by 
development of infection, coiniciding with significantly enhanced CD8+ T cells and neutrophils 
recruited into the lungs, while other macaques become colonized but developed resistance to 
infection (46).  This model may be of particular benefit in studying HIV associated Pneumocystis 
disease.      
 
1.1.6 Summary 
 
Pneumocystis pneumonia is seen in states of immunodeficiency, and has emerged as a major 
medical problem as a consequence of the global AIDS epidemic and the number of individuals 
that are immunosuppressed secondary to treatment of cancer, autoimmune disease, and organ 
transplantation.   While a slow-growing opportunistic fungal infection, disease is often lethal, 
and current chemotherapeutic strategies show evidence for the potential development of 
widespread resistance.  There are no immune therapies or vaccines in clinical use against fungal 
 10 
organisms, and little precedent in design for these strategies in the immunosuppressed.     The 
Pneumocystis genus consists of multiple species with great genetic and functional diversity, with 
various species displaying a host-specific propensity.   Rodent models are an attractive system 
for the study of immunity to Pneumocystis, as clinically and histologically the pneumonia 
experienced is similar, and susceptibility phenotypes in rodents, such as the CD40L mutation or 
chronic corticosteroid immunosuppression, also lead to disease in humans.   
 
1.2 HOST DEFENSE AGAINST PNEUMOCYSTIS 
    
1.2.1 Role of innate immune defenses against Pneumocystis 
 
The adult human respiratory tract contains an estimated 70 m
2
 of space in direct contact with 
external environment, and antigens are continually exposed to this surface.  Host defense against 
fungal pathogens involves the interplay of multiple immune responses, including innate or 
preexisting defenses that are programmed into the host prior to antigen exposure, as well as 
adaptive or induced responses which are selected as a consequence of antigen (Ag) exposure.    
When Pneumocystis organisms are inhaled into the lungs, multiple innate defense mechanisms 
are involved in antigen recognition, degradation, and clearance.  Non-specific mechanical 
defenses such as mucus trapping and mucocilary transport may inhibit establishment of infection 
by confining Pneumocystis organisms and eliminating them from the distal lung, as has been 
demonstrated for various bacterial and viral pathogens.  Of note, 90% of the resident cells in the 
airways are macrophages, and these alveolar macrophages are critical in binding, internalizing, 
and degrading Pneumocystis organisms, likely acting at the very earliest points after 
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Pneumocystis inhalation.  Significantly impaired clearance of Pneumocystis from the lungs is 
observed in rats depleted of alveolar macrophages, and clearance of one of the most predominant 
Ags at the surface of Pneumocystis, msgA was also dramatically decreased (47).    Mannose 
receptors, β-glucan receptors, scavenger receptors and toll-like receptors (TLRs) are all found on 
alveolar macrophages and are implicated in affecting processes of recognition, internalization, 
and inflammatory responses against Pneumocystis (48-54).    While superoxide dismutaion or the 
impairment  of nitric oxide production did not affect alveolar macrophage effector function 
against Pneumocystis in vitro, catalase inhibited Pneumocystis killing by macrophages, 
suggesting that hydrogen peroxide-dependent killing mechanisms are directly involved in the 
degradation and killing of Pneumocystis organisms (55).   
 Dendritic cells are also resident cells of the lung, which have a central function in 
trafficking antigen from tissue sites towards secondary lymphoid organs, such as pulmonary 
lymph nodes.  In the lung, myeloid DC predominate over plasmacytoid DC populations (56).   It 
has been demonstrated that administration of bone marrow derived, CD40L expressing, DCs 
pulsed with Pneumocystis Ags leads to the induction of protective B cell responses against these 
Ags, underscoring the role of DC in initiating and guiding adaptive immune responses (57).   It 
has also been shown that pulsing DC with Pneumocystis leads to the elicitation of IL-4, with 
very little IL-12 or TNF-α production (58), which could potentially influence Th1 vs Th2 
polarity determination in T cell priming.   
 Neutropenia is a major susceptibility factor for infectious disease caused by variety of 
fungal pathogens including Aspergillus fumigatus, Candida glabrata, Candida albicans, and 
Fusariam solani, yet susceptibility to Pneumocystis is not directly correlated with neutropenia.     
In Pneumocystis infection, neutrophil influx into the airspaces appears to occur at late stages of 
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infection, in the setting of high pathogen burden, with timing coinciding with lung pathology 
(59-61).  Some data partially suggest that these cells may not be required for host defense against 
Pneumocystis.  For example, mice deficient in gp91(phox), required for NADPH oxidase 
function, mice deficient in CXCR2 which have impaired neutrophil chemotaxis to sites of 
infection, and mice partially depleted of neutrophils with a monoclonal antibody have similar 
quantities of Pneumocystis in the lungs relative to controls (62).   Neutrophils recruited into the 
airways presumably bind and phagocytose Pneumocystis using a similar array of pattern 
recognition receptors, though there have been no studies evaluating neutrophil innate recognition 
of Pneumocystis.   
 Epithelial cells may also be involved in some of the earliest responses against 
Pneumocystis.  It has been demonstrated that β-glucan isolated from the Pneumocystis cell wall 
can stimulate airway epithelial cells to secrete MIP-2, the rodent homolog of IL-8 and major 
neutrophil chemoattractant, by signaling at lactosylceramide receptors (63).   Additionally, MCP-
1 is produced by epithelial cells upon exposure to Pneumocystis (64).  These data suggest that 
the epithelium is a critical sensor of infection, and may be involved in the very earliest stages of 
leukocyte recruitment after Pneumocystis exposure.   
 Finally, multiple proteins that are part of the normal pulmonary environment have 
affinity for Pneumocystis and influence innate recognition and defense pathways.  It has been 
demonstrated that fibronectin and vibronectin, serum proteins but also synthesized by alveolar 
macrophages, bind Pneumocystis organisms and enhance their adhesion to the airway 
epithelium, with vitronectin additionally enhancing adhesion to alveolar macrophages (65-67).   
Through opsonization, both fibronectin and vitronectin have been demonstrated to enhance the 
alveolar macrophage TNF-α response against Pneumocystis (68).   It was later demonstrated that 
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these proteins bind Pneumocystis cell wall β-glucan, and that quantities of these proteins increase 
in the course of infection in an IL-6 dependent manner, IL-6 in turn released by alveolar 
macrophages in response to Pneumocystis (69).    Additionally, surfactant proteins A and D, 
secreted by type II pneumocytes of the lung and members of the collectin family of proteins, 
have been demonstrated to accumulate in the lungs during infection, bind Pneumocystis 
organisms and differentially affect their clearance.  Mice deficient in surfactant protein A 
expression significantly limit Pneumocystis infection, whereas transgenic mice overexpressing 
surfactant protein D have enhanced growth of Pneumocystis (20, 70, 71).   It has been 
demonstrated that surfactant protein A and D specifically bind the oligosaccharides associated 
with the Pneumocystis glycoprotein msgA, leading to enhanced interaction of Pneumocystis with 
alveolar macrophages (72, 73).   Yet, the specific cellular consequences resulting from increased 
macrophage adhesion of these protein-Pneumocystis complexes, for both surfactant protein A 
and D,  leads to impairment of alveolar macrophage phagocytosis in vitro through unknown 
mechanisms (74, 75).   Additionally, it is currently unclear if surfactant coated Pneumocystis is 
recognized by other cells, such as neutrophils or dendritic cells.  It is intriguing that these 
similarly structured proteins share a common affinity for Pneumocystis glycoprotein Ag, have a 
similar function of recruiting Pneumocystis to macrophages, impair phagocytosis, yet surfactant 
protein A has a net contribution to enhancing clearance, while surfactant protein D appears to 
impair clearance .    
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1.2.2 Role of CD4+ T cells and CD8+ T cells in host defense against Pneumocystis 
 
T cell functions represent a central component of the adaptive immune response to a variety of 
fungal pathogens.   Declining absolute quantities of CD4+ T cells leads to increased risk of 
esophageal candidiasis, and CD4+ T cells of a Th1 instead of Th2 profile are thought to have a 
major influence on the outcome of invasive Aspergillus infection (76-79).  The risk of 
Pneumocystis pneumonia increases exponentially with decreasing quantities of CD4+ T cells 
below 200/µL, underscoring the critical functional role of CD4+ T cells in host defense against 
infection (80).   Indeed, mice deficient in CD4+ T cells, either chronically depleted of CD4+ 
bearing cells with a monoclonal antibody targeting the CD4 surface protein (42, 43), or mice 
genetically engineered to be lacking in CD4+ T cells, as in the MHC II KO or H-2I-Aβ KO mice 
(81), are susceptible to the development of Pneumocystis pneumonia in contrast to wild-type 
which are not.    Some data suggest that reconstitution of SCID mice with CD4+ T cells is 
sufficient for clearance of an existing infection, though the reaction is rigorous and is associated 
with excess inflammatory infiltrates in the lung, with many of the mice dying in the course of 
infection clearance (82).   Other findings suggest that SCID reconstitution must occur with CD4+ 
T cells from hosts previously exposed to Pneumocystis or with naïve CD4+ T cells cotransferred 
with naive B cells for significant decreases in Pneumocystis burden in the lungs (83, 84).   As a 
consequence, it is hypothesized that naïve CD4+ T cells must interact with B cells, with the B 
cells acting as essential antigen presenting cells in the generation of protective effector T cells as 
well as memory responses to Pneumocystis.     
The functions of primed, specific, effector CD4+ T cells against Pneumocystis organisms, 
which recognize Pneumocystis infection in the context of MHC II recognition on professional 
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antigen presenting cells, are unclear.  Alveolar macrophages play a central role in the clearance 
of a Pneumocystis challenge, as demonstrated by studies where these cells were depleted with 
liposomal clodronate in rats, and clearance of Pneumocystis organisms was significantly 
inhibited (47).  It is currently hypothesized that primed effector CD4+ T cells migrate into the 
lungs and interact with alveolar macrophages so as to enhance their effector function against 
Pneumocystis, probably involving the functions of the central cytokines in host defense against 
Pneumocystis such as IL-1α and TNF-α released by the macrophages.  IL-1R blockade leads to 
an inability to clear Pneumocystis from the lungs (85), and neutralization of TNF-α dramatically 
inhibits clearance of Pneumocystis in the murine model (86), suggesting that these cytokines play 
a critical role in a major effector pathway against Pneumocystis.   IFN-γ likely also plays a role 
in the activation of macrophages and has been demonstrated to enhance killing of Pneumocystis 
by macrophages in vitro (87)  but it has been established not to be required for the clearance of 
infection (86, 88), suggesting that it is not an essential cytokine required for CD4+ T cell effector 
function against Pneumocystis.   However, as exogenous IFN-γ enhanced clearance in mice 
depleted of CD4+ T cells (89), it suggests that this cytokine may have a redundant yet beneficial 
function in enhancing host clearance of Pneumocystis.  
CD8+ T cells are not essentially required cells in host defense against infection, as 
demonstrated in the murine model.  SCID hosts transferred with CD8+ T cells did not influence 
the clearance of Pneumocystis organisms in the lungs (82), and β2-microglobulin (-/-) mice, 
deficient specifically in CD8+ T cells, are fully resistant to infection (81).   Interestingly, mice 
depleted of CD4+ T cells alone had significantly higher physiologic and immunologic correlates 
of  worsening pneumonia, such as increased respiratory rate and increased BALF albumin, 
compared to mice depleted of both CD4+ T cells and CD8 + T cells, suggesting that the CD8 + T 
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cell subset actively contributes to pulmonary damage (60).    However, others have demonstrated 
that the CD8+ T cell subset has two effector populations against Pneumocystis, Tc1 and Tc2, the 
former of which is significantly induced by exogenous IFN-γ, expresses CXCR3, and has 
effector functions that lead to Pnemocystis clearance when transferred into SCID mice infected 
with Pneumocystis (90).    Particularly, in the setting of CD4+ T cell depletion, but not in SCID 
mice, exogenous IFN-γ expression skewed production of CD8+ T cells expressing IFN-γ, and 
significantly enhanced their recruitment into the lungs (89).  Thus, it appears that the CD8 + T 
cell population may be manipulated to enhance clearance of Pneumocystis but that it also may 
significantly contribute towards disease pathogenesis.   
 
 
 
 
1.2.3  Role of B cells in host defense against Pneumocystis 
 
The murine model of Pneumocystis infection has demonstrated that B cells are required for host 
defense against pneumonia.  Mice with a transgenic mutation in the transmembrane exon of the 
IgM µ heavy chain gene arrest B cell development at the pre-B cell stage, leading to a lack of 
antibody and an absence of mature B cells in the periphery.  Notably, these mice are highly 
susceptible to Pneumocystis pneumonia (91).   While it has been argued that B cells are required 
for the development of gp38 expressing stromal cells of the splenic T cell areas, and that this 
may result in a T cell defect precluding effective clearance, this consideration has been ruled out 
with the demonstration that irradiated, reconstituted µMT mice transferred with bone marrow 
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from wt mice clear the infection whereas recipients of bone marrow from µMT mice do not (84).   
Hence, the absence of B cells prevents the clearance of Pneumocystis.  
B cells have been demonstrated to play multiple roles in host defense against 
Pneumocystis infection.  Hyperimmune serum from wild type mice repeatedly challenged with 
Pneumocystis, can significantly clear infection upon transfer into SCID infected hosts, notably 
without the hyperinflammatory response observed with transfer of CD4+ T cells (82).   It has 
additionally been shown that vaccination by presentation of CD4+ T cell depleted mice with 
CD40L expressing dendritic cells loaded with Pneumocystis Ags produces protective antibodies, 
and more recently this observation has been extended to DNA based vaccination against Kexin, a 
specific Pneumocystis antigen that is a surface associated protease (57, 92).   Here, adoptive 
transfer of B cells or serum from vaccinated hosts prevented Pneumocystis growth in SCID hosts 
challenged with Pneumocystis.   Monoclonal antibodies, of primarily the IgG isotype, but also of 
the IgM isotype, derived from B cells from Pneumocystis challenged mice, have been shown to 
provide protection against infection (93, 94).  More recently, it has been demonstrated that the 
IgG1 monoclonal must function in an environment containing an intact complement pathway and 
utilizes its Fc portion for optimal prophylaxis (95).  
In attempting to dissect the specific requirement of B cells in host defense against 
Pneumocystis, one group using µMT mice reconstituted with chimeric bone marrow, 
demonstrated that antibody-secreting function is not required for host defense against 
Pneumocystis (96).    However, mice deficient in FcγRI and FcγRIII had delayed kinetics of 
clearance, suggesting that IgG antibodies directly enhance the rate at which Pneumocystis 
infection is cleared, presumably by increasing numbers of immune complexes and enhancing 
Pneumocystis opsonization and phagocytosis by cells of the innate immune system.   Of note, 
 18 
serum from vaccinated mice is able to potentiate the function of alveolar macrophages against 
Pneumocystis in vitro (55).   
 Additionally, it is postulated that B cells, when appropriately primed can maintain host 
defense against Pneumocystis in the absence of CD4+ T cells.   Mice challenged with 
Pneumocystis and thereafter depleted of CD4+ T cells are able to resist a subsequent challenge 
with Pneumocystis, and this resistance correlates with the presence of high IgG1 titers against 
Pneumocystis antigens, which actually appear to enhance through the secondary challenge (97).   
Mice not receiving Pneumocystis challenge prior to CD4+ T cell depletion, however, succumbed 
to Pneumocystis infection, suggesting that CD4+ T cells can program sufficient memory effector 
mechanisms against Pneumocystis that are functional in the event of future absence of CD4+ T 
cells.  It was later additionally demonstrated that the induction of particular antibody isotypes is 
not a major contributor to this phenomenon, as IL-4 (-/-) mice develop a Th1-type antibody 
isotype response and IFN-γ (-/-) mice develop Th2-type antibody isotype response, and both are 
equally protective upon secondary challenge with Pneumocystis in the setting of CD4+ T cell 
depletion (98).   These studies initially underscore the requirement for CD4+ T cells in the 
development of B cell antibody responses that are sufficient for protecting the host from 
Pneumocystis.    Zheng et al, however demonstrate that a vaccination strategy incorporating 
exogenous CD40L and a gene encoding a specific Pneumocystis Ag  also results in the 
production of B cells secreting Abs against protective Pneumocystis Ags that can be transferred 
to SCID hosts and result in protection (57, 92).    What remains unclear is whether actual 
memory B cells are generated against Pneumocystis after exposure, whether they require CD4+ 
T cells for their functions, such as reactivation in the presence of Ag, and further, whether non-
CD4+ T cell dependent antibodies play a role in host defense against Pneumocystis.   
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Additionally, it is unclear which B cell subsets are involved in anti-Pneumocystis responses, and 
whether these subsets have distinct roles in host defense.   
 Finally, B cells have been demonstrated to play a critical role in the maintenance of bone 
marrow hematopoeisis after Pneumocystis challenge, and this functionality partially involves an 
intact type I IFN receptor signaling pathway on B cells (99).  This observation, coupled with the 
finding that B cells are critical APC’s in priming T cell responses (84) , highlight the potentially 
central involvement of B cells in important host defense mechanisms besides antibody 
production, which for example, could additionally include cytokine and chemokine production, 
as elegantly demonstrated by Lund et al in other infection models (100).   
 
1.2.4 Summary 
 
Utilizing murine and rodent models of Pneumocystis infection, some essential and contributory 
immune defenses are characterized.   These include identification of resident alveolar 
macrophages as essential effector cells in Pneumocystis recognition and clearance, the 
requirement for CD4+ T cells and B cells in host defense mechanisms, the utility of antibody 
based recognition of Pneumocystis, and the ability to skew CD8+ T cell subsets leading to 
differential function in host defense against Pneumocystis but also their implied role in lung 
damage and correlates of clinically severe Pneumocystis pneumonia.  However, much remains to 
be unraveled, such as the specific CD4+ T cell effector pathways leading to immunity, the 
specificities of and the diversity of the B cell antibody responses that contribute to protective 
immunity, as well as the interplay between specific protein, carbohydrate, and lipid antigens of 
Pneumocystis and the multivalent recognition systems provided by the innate and adaptive 
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immune system.    A greater understanding of these pathways will provide a better understanding 
of how healthy individuals are so successful in avoiding Pneumocystis pneumonia, how 
immunodeficiencies specifically affect these defense mechanisms, and how to prevent and treat 
Pneumocystis infection in the setting of immunodeficiency. 
 
1.3 PNEUMOCYSTIS FUNGAL CELL WALL CARBOHYDRATES 
 
1.3.1 Conserved fungal cell wall carbohydrates 
 
Fungal organisms, of which there are an estimated 1.5 million different species, of tremendous 
diversity in habitat and life cycle (101), contain cell walls that are remarkably similar.  The 
function of the extracellular fungal cell wall is multiple, it provides structure and shape to the 
organism, it provides rigidity, it prevents against osmotic stress, it contains hydrolytic enzymes 
or other proteins which assist in aspects of environmental adaptation, and notably it is 
continually remodels itself in the face of growth or stress.   It is estimated that approximately 
90% of the fungal cell wall consists of polysaccharides, and at the very core of this cell wall, for 
almost all fungal organisms exist two carbohydrates, β-glucan and chitin (102).  β-glucan in 
fungal cell walls is a polymer of glucose that is β-1,3 linked predominantly, with branching β-1,6 
linkages.  The length of the typical β-1,3 glucan polymer ranges on the order of  1,500 units per 
chain, and structurally it is thought to resemble and function a coiled chain (103).   β-1,6 linked 
glucan, with an average of 350 units per chain, is more amorphous and functionally provides 
adhesive and flexibility properties (103).  Chitin is often linked to β-glucan chains via β-1,4 
linkages.  Chitin is a linear polymer of N-acetyloglucosamine, linked in a β-1,4 manner.   It 
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forms microfibrils which orient in alternating parallel and antiparallel strands, with the typical 
strand length of 100-190 units (103).   Chitosan, the deacetylated form of chitin, also found in 
fungal cell walls, is a polymer with much greater flexibility than chitin (104-108).     
There is commonly variation on top of this central core of carbohydrate.  For example, in 
the most studied fungal organism, Saccharomyces cervesiae, the cell wall represents 30% of the 
cells dry weight; β-glucan is estimated to consist 80-90%, chitin only 1-2%; and a third 
carbohydrate, mannan, at 10-20% (103).   The bulk of the cell wall, β-glucan , plays a critical 
role in maintaining yeast structure, and degradation of this layer with an enzyme that hydrolyzes 
β-1,3 glucan linkages can lead to cell death secondary to osmotic stress. Together with chitin, β-
glucan forms the inner cell wall and is termed the “electron lucent layer” as a function of its 
appearance under scanning electron microscopy.  Chitin, while constituting a small percent of 
the total carbohydrate presence, plays significant role in the process of cellular reproduction. 
Chitin and chitosan accumulate initially where the daughter bud is forming (102, 109).  These 
carbohydrates are then laid down linearly to generate the septum between mother and daughter 
cell.  After cytokinesis, chitin is degraded by chitinases, though a bud scar of chitin remains at 
the surface of mother and daughter cell.    In S. cervesiae, mannan is found at the very exterior 
portion of the cell wall, composing the “electron dense” layer.   Mannan fibrils are formed in 
concert with protein synthesis.   Cell wall proteins can be O-mannosylated with short chains of 
α-mannose averaging 5 units in length, containing α-1,2 and α-1,3 linkages.  These short mannan 
fibrils bury into the β-glucan core, strengthening the cell wall (103).  Additionally, cell wall 
proteins can be N-mannosylated, containing up to 50 α-1,6 mannan units per fibril, with multiple 
short α-1,2 and α-1,3 mannan branches, resulting in a mannose polymer of up to 200 units (103).    
Mannoproteins can be dissolved without disruption of the cell wall (110).  As the S. cervesiae 
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cell wall is the best characterized among fungal cell walls, it is a useful model for comparison in 
the understanding of the exterior surface of the somewhat atypical fungal organism 
Pneumocystis.  
 
1.3.2  Carbohydrates of the Pneumocystis cell wall: Organization and Function 
 
While Pneumocystis sp. share many features with both protozoa and fungi, Pneumocystis 
organisms are classified within the fungal kingdom as a consequence of genetic analysis of the 
mitochondrial 16s rRNA subunit and noting significant sequence homology with other fungal 
pathogens.   In line with its classification as a fungal organism, Pneumocystis contains the β-
glucan and chitin core in its cell wall as described, as well as a layer of mannoprotein, and these 
are observed in all Pneumocystis species.    An electron dense layer, as in S. cervesiae, is 
observed in both the cyst and trophozoite forms of the organism, whereas the electron lucent 
layer is only found in the cyst form (111).   Aniline blue, a dye which selectively stains β-1,3 
glucan, stains the inner cell wall of the Pneumocystis cyst (112).  Additionally, treatment of the 
Pneumocystis cyst with zymolase, which has enzymatic function against primarily against β-1,3 
linked glucans, leads to loss of the electron dense and electron lucent portions of the cell wall, as 
well as a loss of Aniline Blue staining.  Notably, staining with the Gomori Methenamine Silver 
stain which is used in the diagnosis of human Pneumocystis pneumonia, is also lost from cysts 
with zymolase treatment.   Using an antiserum raised against laminarin,  a β-1,3 rich beta glucan 
isolated from brown algae, it was observed that the electron lucent layer of the Pneumocystis cyst 
stained brightly, and that staining was absent in intracystic bodies and trophozoite forms of the 
organism (113).  Truly underscoring the relevance of this carbohydrate in Pneumocystis viability, 
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inhibitors of glucan-synthetase, the enzyme responsible for β-glucan synthesis, have been shown 
to prevent and to significantly inhibit Pneumocystis growth in rodent models  (114, 115) though 
there is controversy in this effect.   
Chitin has also been identified in the Pneumocystis cell wall by immunostaining and 
substrate specific binding studies (116).  It is found in the cyst cell wall and, interestingly, 
surrounding intracystic bodies.  Additionally, it is found in the trophozoite.  Beyond 
identification of its presence in both life stages of the organism, the function of chitin in 
Pneumocystis biology is unclear.  Of note, chitin is typically not found in the trophozoite stage of 
various protozoa.    Chitin synthesis inhibitors have not been tested in host defense against this 
infection, so its requirement for the life cycle of the organism is unknown.  
Mannoprotein is present at the very exterior of the cell wall of the Pneumocystis cyst, 
which is also the site of the well studied antigen gpA/Major Sruface Glycoprotein (73, 117).    
gpA is among the most abundant proteins at the surface of Pneumocystis and its association with 
mannan is well described.  While no studies have been performed to immunolocalize mannan, 
given its association with the surface associated gpA, and the fact that the mannose receptor 
binds gpA, mediated specifically through interactions with mannan (48), and the fact that gpA is 
found on both cyst and trophoizoite forms of the organisms (118), these observervations 
collectively suggest that mannan is found at the very surface of the cell wall of cyst and 
trophozoite forms.   Benanomicin A, a compound known to directly bind mannan in the cell 
walls of fungi, when used to treat Pneumocystis infection in nude mice, significantly reduced 
cysts in the lungs and improved survival (35).   This data suggests that freedom of mannan 
moieties is essential for the persistence of Pneumocystis organisms in the lungs.     
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Collectively these studies underscore the conserved nature of fungal cell wall 
carbohydrates as the localization, structure, and composition between S. cervesiae and 
Pneumocystis sp. are similar.  Additionally, the utility of targeting Pneumocystis carbohydrates 
in chemotherapeutic strategies suggest that immune-based strategies against these carbohydrates 
may be of benefit.   
 
1.3.3  Beta-glucan in immune responses 
 
β-glucan has long been noted for its anti-infective and anti-tumorigenic properties to activate 
leukocytes, though its mechanisms of action are poorly characterized.   Notably, β-glucan is not 
synthesized by animals, and these carbohydrate structures are truly pathogen associated 
molecular patterns, found not only in fungi, but plants and certain bacteria.   There is evidence 
that β-glucans activate macrophages, neutrophils, and NK cells, leading to the phagocytosis, and 
release of cytokines and anti-microbial molecules (119-121).  Multiple pattern recognition 
receptors are implicated in the identification of β-glucans, such as complement receptor 3 (CR3), 
dectin-1, scavenger receptors, and lactosylceramide (122).  Additionally, it has been 
demonstrated that β-glucans prime CR3 expressing cells to improve detection of complement 
coated targets such as tumor cells targeted by natural antibodies (123, 124).    As well, infections 
are modulated by β-glucans.  For example, a Trypanosoma cruzi vaccine had significantly 
enhanced efficacy when coadministered  with β-1,3 glucan (125).  While activation of innate 
cells are surely part of these responses, the pathways likely involved in enhancing intrinsic 
functions of the innate, and potentially adaptive,  immune responses are in need of greater 
characterization.  For example, how does activation of innate cells change their effector 
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functions against antigens the host was previously blind to?   Are B or T cells activated by β-
glucans? What are the contributions of serum components in the recognition of β-glucans?    
 
1.3.4 Mannan in immune responses 
 
Mannan, a sizable polymer in fungal walls and distinct from the relatively low level of 
mannosylation observed on proteins from mammalian cells, is also immunogenic.  Multiple 
studies have demonstrated that mannosylated proteins have enhanced MHC I and MHC II 
protein Ag presentation and increased T cell activation and proliferation against particular 
protein Ags relative to protein Ag alone (126, 127).  It has recently been demonstrated that 
mannosylated Ag traffics through C-type lectin recognition pathways, such as the mannose 
receptor and DC-SIGN, leading to differential activation of dendritic cells and stronger 
activation of T cells (128, 129).    Additionally, soluble proteins such as surfactant A and D, as 
well as mannose-binding lectin, recognize mannan.  TLR2 has affinity for lipomannan, but only 
mannan of sufficiently long chain length (130).  It is unclear whether mannan is itself recognized 
by components of the adaptive immune system.  As some mannosylation of mammalian patterns 
is somewhat similar to that seen in fungal organisms, it is unclear whether mannosylation is used 
by fungi as a host evasion strategy.     
 
1.3.5  Chitin in immune responses 
 
Chitin is one of the most abundant carbohydrate polymers in nature, and is found in the 
exoskeletons of insects and crustaceans and in the sheaths of various parasites.   The biosynthetic 
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machinery for making chitin, and the structurally similar deacetylated form chitosan found in 
fungal cell walls, is absent in mammalian cells, making chitin a non-self antigen upon encounter.  
An ancient, preserved defense mechanism against chitin is the degradation of chitin by chitinase 
enzymes of the host, and in humans, the Acidic Mammalian Chitinase (AMCase) protein has 
been described, with such function.   Of note, AMCase is induced as a consequence of Th2 
responses, in an IL-13 dependent manner, and contributes to the signaling pathway of IL-13 and 
Th2 inflammation (131).  Interestingly, it has also been shown that chitin administration into the 
airways of mice leads to the recruitment of arginase expressing alternatively activated 
macrophages, basophils, and eosinophils (132).  Of note, pre-treatment of chitin with AMCase 
inhibited these responses, suggesting that the specific pathogen associated molecular pattern 
chitin activates recognition pathways leading to the recruitment of these cells.  These studies 
underscore the observations that chitin is a potent molecular pattern with the capacity to interact 
with host degradation proteins such as AMCase and the balance of these molecules may 
influence the host Th1 vs Th2 response.   From another perspective, chitin and chitosan are being 
evaluated as vaccine adjuvants, for their intrinsic ability to stimulate the host immune response.   
For example, formulation of CRM197-Diphtheria toxin with chitosan enhanced antibody 
responses and Th2 responses such as the production of IL-5 by splenocytes restimulated with 
vaccine, relative to CRM197-Diphtheria toxin as standardly prepared in formalin (133).   Other 
groups have shown that both Th1 and Th2 responses are stimulated with chitosan-based vaccine 
preparations (134-136).   The observation that chitosan is an effective adjuvant may be partly 
attributed to its physical features in enhancing antigen deposition, but its capacity to skew 
responses towards Th2 suggests that it is recognized by specific components of the host’s 
immune system.  Additionally, the observation that chitin inhalation leads to the accumulation of 
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innate cells such as eosinophils and basophils, and that alternatively activated macrophages are 
generated suggest that sensors, such as innate receptors, or soluble proteins, with the capacity to 
do more than degrade signal may be involved in chitin recognition.  It is unclear how AMCase 
signals, besides requiring IL-13 for its induction and downstream activities, and actually 
functions to influence the inflammatory response. Is it the first sensor of chitin? Currently there 
are no membrane bound pattern recognition receptors or soluble opsonic proteins discovered 
with specificity for chitin or chitosan.  Only uncovered thus far in chitin recognition are the 
enzymes chitinase and chitotriosidase, the former expressed by airway epithelial cells and 
macrophages, the latter expressed by professional and released by phagocytes.   It is likely that 
other host molecules participate in identifying this abundant environmental Ag. 
 
1.3.6 Summary 
 
Despite the tremendous diversity of fungal organisms, almost all contain three major conserved 
carbohydrates in the extracellular matrix known as the cell wall.  The cell wall structure is 
dynamic, and provides structure, organization, and essential functions to the cell. The bulk of the 
cell wall consists of β-1,3 glucan intermeshed with chitin which is together covered with a thin 
layer of mannoprotein.  Pneumocystis organisms are classified as fungi, and fitting with this 
classification is the presence of the conserved fungal cell wall carbohydrates, β-glucan, chitin, 
and mannan in various forms of the organism.  Notably, the cyst form contains β-glucan, chitin, 
and mannan in a similar pattern to the S. cervesiae cell wall, with chitin notably lining intracystic 
bodies, whereas the trophozoite form contains only chitin and mannan.  Of note, the fungal cell 
wall carbohydrates found in fungi, by themselves, and in concert with protein Ag, possess great 
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immunostimulatory capacity.  However, data regarding their innate recognition and contribution 
to host defense pathways, as well as allergy, are slowly emerging.   Of these, it is believed that β-
glucan is recognized by a wide array of membrane bound PRR as well as soluble proteins, and 
one mechanism whereby it contributes to anti-tumor/anti-infective responses is to prime 
macrophages in the recognition of Ab-coated targets.  Mannoprotein has been shown to directly 
enhance priming of T cells relative to T cells alone, and is recognized by a variety of pattern 
recognition receptors.  Finally, chitin has no known traditional membrane-bound pattern 
recognition receptors, though it appears that enzyme based signaling may contribute to its 
recognition, and it appears to promote Th2 and antibody responses.   The immunostimulatory 
properties of these fungal cell wall carbohydrate antigens suggest that multiple mechanisms 
contribute to their recognition and how they potentially influence adaptive immune responses.  
 
1.4 DECTIN-1 RECEPTOR IN RECOGNITION OF PNEUMOCYSTIS BETA-GLUCAN 
AND HOST DEFENSE AGAINST PNEUMOCYSTIS 
 
1.4.1 β-glucan recognition 
 
β-glucan is a major component of the cell wall of the Pneumocystis cyst and has come under 
scrutiny as a molecule recognized by innate host defenses.  A crucial component in 
Pneumocystis host defense is the resident alveolar macrophage, and early on, cell wall β-glucan 
was implicated as a molecular pattern mediating macrophage recognition and downstream 
effector functions against Pneumocystis organisms.  For example, binding of Pneumocystis 
organisms and the release of TNF-α from alveolar macrophages can be blocked by pre-
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incubation with soluble β-glucans (52).   Additionally, administration of isolated Pneumocystis 
β-glucan into the lungs of rats provoked the production of TNF-α and the recruitment of 
neutrophils into the lungs (137).  Thus, there appeared to be a pattern-recognition receptor or set 
of recognition molecules with specificity for β-glucan that promotes inflammation, cytokine and 
chemokine production.  It was recently determined that the dectin-1 receptor is the primary 
receptor on alveolar macrophages for the recognition of Pneumocystis β-glucan, and it is 
involved in recognition and the initiation of signaling cascades leading to the production of 
reactive oxide species involved in organism death. (49, 138).    
 
1.4.2 Dectin-1 receptor: Molecular biology, signaling, and recognition  
 
The dectin-1 receptor (dendritic-cell-associated C-type lectin-1) is a recently cloned, small, type 
II, C-type lectin receptor with a single carbohydrate recognition domain, and a single 
transmembrane portion, first reported by Ariizumi et al (139).   It has two N-glycosylation sites 
on the lectin portion of the receptor, and it contains an immunoreceptor tyrosine-based activation 
motif (ITAM) towards its N-terminus, which is involved in signaling.  It was later shown that 
dectin-1 based signaling additionally involves the spleen tyrosine kinase (Syk) which is 
specifically involved in mediating macrophage reactive oxygen production, and influencing the 
differential production of cytokines from DCs (140, 141).   Additionally, Card9 has been 
identified as a key signaling transducer of dectin-1 that is involved in myeloid cell activation and 
cytokine production, coupling with Bcl-10 and Malt1 to influence NF-κB activation (142).     
Dectin-1 is expressed by a number of cells, including dendritic cells, monocytes, and T 
cells, with greatest levels of expression in neutrophils and macrophages (143).    It is particularly 
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enriched in lung tissue and the liver (144).  Of note, expression of the receptor seems to be 
influenced by the Th environment, as upregulation of the dectin-1 receptor occurs in the presence 
of Th2 cytokines such as IL-4 and IL-13, while LPS and dexamethasone suppress dectin-1 
expression (143).   
The dectin-1 receptor has greatest affinity for β-1,3 and β-1,6 linked glucans, as these 
carbohydrates most significantly inhibited binding of zymosan by NIH3T3 cells exogenously 
expressing dectin-1 (144).  Of note, dectin-1 has no apparent reactivity with any 
monosaccharides, demonstrating that it is the large structural polymer and the specific 
arrangement generated by the glycosidic bond that generates the reactive β-glucan antigen.   
Additionally, it was demonstrated that dectin-1 mediates non-opsonic phagocytosis, as NIH3T3 
cells overexpressing dectin-1 could internalize zymosan particles and heat-killed Candida.   
Hence, the dectin-1 receptor has the capacity to preferentially recognize the predominant 
carbohydrate in fungal cell walls, β-1,3 glucan, and initiate signaling pathways promoting 
phagocytosis.  
 
1.4.3 Dectin-1 Receptor and Host defense Against Pneumocystis 
 
The dectin-1 receptor has an integral role in macrophage recognition of Pneumocystis as 
demonstrated utilizing Pneumocystis isolated from mice.  Blockade of the dectin-1 receptor with 
a mAb targeting the dectin-1 carbohydrate recognition site (145) on murine alveolar or induced 
peritoneal derived macrophages, or incubation of macrophages with β-glucan, inhibited 
macrophage killing of Pneumocystis organisms (49).   Binding of Pneumocystis organisms was 
enhanced by overexpression of the dectin-1 receptor on macrophages, suggesting that this pattern 
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recognition receptor has excellent ability to recognize Pneumocystis organisms and recruit them 
to macrophages.   Additionally, internalization of Pneumocystis organisms is impaired in 
alveolar macrophages upon dectin-1 receptor blockade.  Thus, binding of Pneumocystis, 
internalization, and release of hydrogen peroxide is an important pathway for the degradation of 
Pneumocystis organisms, and the dectin-1 receptor influences all of these processes.    It is likely 
that some of these processes may be redundant with other pattern recognition receptors, such as 
binding of Pneumocystis organisms, or cytokine production, as TLRs and TLR signaling have 
been implicated in some of these processes (54, 138, 146).  However, it was demonstrated that in 
the absence of MyD88, which is absolutely required for signaling by all known TLR receptors 
except TLR3, that reactive oxygen species production was unaffected, whereas in the dectin-1 
deficient mouse reactive oxygen species production in response to Pneumocystis is significantly 
impaired (138).   Hence dectin-1 appears to control a predominant killing mechanism utilized by 
alveolar macrophages against Pneumocystis.   Of note, the dectin-1 knockout mouse has delayed 
clearance and worsened pulmonary Pneumocystis burden in the setting of corticosteroid 
treatment (138).    Collectively, these studies underscore the importance of the non-TLR dectin-1 
in recognition of Pneumocystis and the initiation and activation of killing pathways utilized by 
macrophages in defense against the organism.   We believe that properties of the dectin-1 
receptor, such as β-glucan recognition, could be utilized in the design of new therapies against 
Pneumocystis.   
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1.4.4 Summary 
 
Isolated β-glucan from the cell wall Pneumocystis organisms leads to inflammatory responses 
from macrophages and leads to the recruitment of inflammatory cells such as neutrophils in the 
lung.  The recently described C-type lectin receptor dectin-1 has affinity for β-1,3 and β-1,6 
linked glucan polymer found in fungal cell walls and is significantly involved in binding 
Pneumocystis organisms to macrophages.   The receptor is compact, contains one lectin domain, 
one transmembrane domain, and an ITAM motif and signals through multiple transducer 
proteins distinct from the machinery involved in TLR signal transduction.  Additionally, the 
dectin-1 receptor is phagocytic and can internalize fungi, and controls the release of reactive 
oxygen species by macrophages in response to Pneumocystis organisms.  More recently, while it 
has been demonstrated that the dectin-1 receptor is not absolutely required for host defense 
against infection, it inhibits growth of the organism in immunosuppressed rodents and affects the 
rate of clearance of infection in healthy rodents.  Thus, host defense against Pneumocystis 
involves the dectin-1 receptor, which has the capacity to identify, internalize, and initiate 
pathways leading to organism degradation, suggesting that molecular therapeutics that 
incorporate aspects of the dectin-1 receptor in its recognition properties, or that can influence the 
receptor’s signaling pathways, could potentially enhance host defense against Pneumocystis.   
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1.5 ROLE OF ANTIBODIES IN HOST DEFENSE AGAINST FUNGAL PATHOGENS 
 
1.5.1 Precedent for antibodies targeting protein and carbohydrate antigens of fungi 
mediating host defense 
 
While a controversial concept just one decade ago (147), there is now ample evidence that 
antibodies are critical effector molecules that could be of benefit in the design of therapies 
against opportunistic fungal infection (148).  Many models have demonstrated that protein and 
carbohydrate antigens are important targets of protective antibodies against fungi.  For example, 
antibodies against the protein Hsp60 of Candida albicans (149) are protective against infection, 
as are antibodies against the histone-H2B like surface protein of Histoplasma capsulatum (150).  
As multiple carbohydrate antigens are present at the fungal cell wall surface, it has been 
demonstrated that these too, are useful targets of antibody-based defense against fungi.  Among 
the most definitive examples of antibodies recognizing carbohydrates in anti-fungal host defense 
include antibodies directed against the polysaccharide glucuronoxylmannan, the carbohydrate 
comprising the capsule of Cryptococcus neoformans.  When this carbohydrate is conjugated to 
the protein carrier tetanus toxoid and administered to rodents, it results in the production of 
antibodies reactive with the fungal capsule that prevent infection (151, 152).  Additionally 
monoclonal antibodies specific for the glucuronoxylmannan antigen, such as the IgG1 mAb first 
described by Dromer et al induce dose-dependent inhibition of infection (153).   More recently, 
it has been demonstrated that a vaccine consisting of laminarin, primarily a β-1,3 linked glucan, 
linked to the carrier protein diphtheria toxoid, produced antibodies that could significantly 
prevent against systemic and vaginal candidiasis; and significantly increased survival in systemic 
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Aspergillus fumigatus infection (154).  It was additionally demonstrated that passive transfer of 
the induced antibodies could transfer the phenotype of enhanced immunity, and further, the 
antibodies when incubated with Aspergillus fumigatus and Candida albicans directly inhibited 
the growth of the organisms.    Thus, defense against these pathogens was partly attributed to 
binding cell wall β-glucan, perhaps interfering with cell wall structure and/or remodeling, and 
inhibiting the life cycle of the organism.  However, it is possible, if not likely, that these 
antibodies have multiple functions in host defense, in shaping the strategy of the host to diminish 
infection.   
 
1.5.2 Mechanisms of antibody-mediated defense against fungal organisms 
 
There are multiple mechanisms whereby antibodies influence host defense against fungal 
infections.  Antibody neutralization, or the prevention of virulent pathogen components from 
interaction with host components secondary to antibody binding, is one of the earliest described 
functions of antibodies.    While most commonly described in the setting of viral infection or in 
the interaction with bacterial toxins, antibody neutralization also occurs against fungi.  For 
example, a monoclonal antibody targeting C. albicans mannoprotein demonstrated an ability to 
inhibit binding of organisms to human epithelial cells, which is required for the establishment of 
mucosal infection (155)   Direct opsonization of pathogen with antibody, priming immunologic 
cells for recognition of antigen through the identification of Fc portions of antibodies, is another 
common strategy whereby antibodies enhance anti-fungal host defense.   Many reports are 
described of antibodies with the capacity to enhance macrophage recognition of fungi.  For 
example, antibodies from humans vaccinated with the glucuronoxylomannan conjugate 
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significantly enhance phagocytosis of C. neoformans by peripheral blood mononuclear cells 
(156).  Antibodies also have the capacity to enhance binding of complement proteins to their 
surface, mediating recognition of pathogen by interaction of complement proteins/split products 
with complement receptors at the surface of phagocytic cells.  Antibody-Antigen interaction 
initiates the classical pathway of complement activation, and the IgM isotype complexed with 
antigen is considered the most potent isotype in initiating this process. With complement cascade 
activation, complement protein 3 and its cleavage products C3b, iC3b, and C4b bind the surface 
of pathogens, facilitating recognition by complement receptors 1-4 (CR1-4) on phagocytic cells.  
It has been demonstrated that complement plays an important role in antibody-mediated host 
defense against fungi, as for example, monoclonal antibodies targeting C. albicans β-mannan 
have protective function only in the setting whereby the complement cascade is intact (156).    
Additionally, antibodies can be directly fungicidal, as demonstrated with the laminarin conjugate 
vaccine and been seen in the study of antibodies targeting Candida sp., with antibodies directly 
capable of inhibiting growth and suppressing respiration (155, 157).   
 More recently, antibodies have been demonstrated to have a role in the shaping the 
broader host response to fungal infection.   For example, B cell deficient mice transferred with an 
antibody that normally enhances immunity against Cryptococcus have a significantly higher 
pathogen and diminished survival, along with enhanced IFN-γ and MCP-1 relative to wild type 
controls (158).  While the mechanism of action is unclear, it suggests that antibody effector 
function specifically requires B cells, which in turn guides the cytokine response against 
infection and influences pathogen clearance.  It has also been demonstrated, in this infection, that 
transfer of a normally protective IgG1 against cryptococcal infection is only functional in the 
presence of CD4+ T cells, and additionally requires IFN-γ, suggesting that somehow the IgG1-
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Ag complexes enhance CD4+ T cell effector function leading to clearance (159).  In the study of 
the monoclonal antibody targeting a histone-like protein of H. capsulatum that enhances host 
defense against this pathogen, it was observed that the antibody elevates quantities of IL-6, IL-4, 
and IFN-γ in the lungs (150), suggesting that antibody may enhance antigen presentation, and 
perhaps adaptive immune responses such as T cell priming given the increases in IL-4 and IFN-γ 
production.   Thus antibodies may influence aspects of inflammation and the functions of 
adaptive immune cells such as B and T cells.   Net consequences of this, may be for example, 
enhanced recognition of fungal antigen, or the avoidance of detrimental inflammatory responses.   
 
1.5.3 Complexities of Antibody Interactions with Fungi 
 
Antibodies against multiple fungal antigens are observed in the setting of health and infection, 
hence dissection of their functions in host defense is complicated.    Are the antibodies observed 
against fungi, in the serum of healthy individuals, merely bystanders in immune responses, do 
they enhance host defense, or still, can they actually impair recognition?  It is most likely that 
these responses cannot be considered in the bulk, but rather according to exact specificities and 
cross-reactivities, strength of antigen binding, isotype, and concentration.   
In the murine model of Cryptococcus infection, it has been demonstrated that antibody 
isotype critically influences host defense against fungi.  Monoclonal antibodies administered at 
the same dosage and having the exact same antigen recognition portion but differ in isotype only 
(160, 161),  have differing capacities to clear infection , and it was later determined that part of 
this issue is secondary to differences in isotype influencing the ability of this identical 
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recognition site to bind antigen, perhaps due to steric aspects of interaction, suggesting that 
isotype influences Ag:Ab interaction in this model of protein:polysaccharide interaction (162).   
Studies with monoclonal antibodies against glucuronoxylmannan have demonstrated that 
protective antibodies administered at particularly high doses may actually impair host defense 
against Cryptococcus.   This phenomenon is known as a “prozone-like effect.”    The prozone-
like effect for protective monoclonal antibodies was first observed for the IgM isotype but is 
extended to IgG subclasses as well (163, 164).  It is unclear why this effect occurs, but perhaps 
high doses of protective antibodies impairs recognition of pathogen by multiple alternate defense 
pathways that additionally are required for defense against infection.   
 The concept of non-neutralizing antibodies facilitating infection and pathology has 
emerged as a pathologic mechanism in viral diseases such as dengue (165, 166).  This 
phenomenon has not been evaluated in the setting of fungal infection, but could potentially 
contribute to pathophysiology of fungal diseases that contain an intracellular growth phase, such 
as H. capsulatum.   The factors described add complexity to the analysis of the relevance of 
antibodies in host defense against fungi, and in the design of antibody-based immunotherapies.  
 
1.5.4 Operative, identified antibody-mediated defense mechanisms against Pneumocystis 
 
In the setting of CD4+ T cell or B cell deficiency, macrophage effector function against 
Pneumocystis is insufficient in limiting growth of the organism in the lungs.  However, 
exogenous administration of antibodies significantly enhances clearance of Pneumocystis, 
through mechanisms that are only partially defined.   One operative mechanism involved in this 
defense is the activity of IgG at FcγRs on macrophages, neutrophils, and dendritic cells.  
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Preopsonization of Pneumocystis organisms with serum from mice immunized with 
Pneumocystis specifically enhanced macrophage effector function against the organism, leading 
to decreased pathogen viability (49).   Mice deficient in FcγRI, FcγRIII, and the FcεR (via FcγR 
deletion) have a delayed rate of clearance of Pneumocystis infection suggesting that signaling of 
antibody:antigen immune complexes at these receptors facilitates more efficient Pneumocystis 
clearance (96).  It was additionally demonstrated that absence of the C3 protein, central to the 
complement cascade, does not influence the rate of clearance of Pneumocystis, suggesting that 
antibodies may not necessarily require complement function for effective signaling at FcγR 
leading to the enhanced rate of clearance.  However, a study evaluating the efficacy of a 
monoclonal IgG1 antibody in prophylaxis against Pneumocystis demonstrated that an intact 
complement pathway was needed for host defense against the organism, as depletion of 
complement impaired efficacy (95).  This study additionally underscored the importance of FcγR 
signaling, as the Fab portion of this protective IgG1 was also not as efficacious as the intact 
protein in preventing infection.  However, this could be attributed to the fact that the IgG1 
longevity is influenced by the presence of the Fc portion of the antibody, which was not 
addressed by the authors.   
As described, transfer of hyperimmune serum obtained from Pneumocystis challenged 
mice was associated with pathogen clearance, but without excessive inflammation, as seen with 
transfer of CD4+ T cells (82, 167).   Efficacy was observed both in prevention of infection, as 
well as significant inhibition of growth at early, intermediate, and late stages of pneumonia.    
The observation that clearance mediated by antibodies does not lead to deleterious inflammatory 
responses suggests that antibody-dependent clearance mechanisms likely involve different 
signaling and degradation pathways.   In a model of passive immunization, where Pneumocystis 
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clearance was assessed in neonatal mice, it was observed that mice born to mothers who had 
been immunized against Pneumocystis had enhanced clearance of pathogen from the lungs, with 
significantly increased quantities of Pneumocystis specific Ig in the blood and BALF, and 
without differences in recruitment of CD4+ or CD8+ T cells, or B cells, or quantities of 
inflammatory cytokines/chemokines such as TNF- , IFN , MCP-1, and IL-6 (168).    It is 
unclear whether the cytokines that appear to be suppressed occurred merely as a function of 
reducing quantities of pathogen in the lungs.  However, in contrast to T cell mediated clearance 
strategies, non-pathologic inflammatory responses are utilized in antibody-dependent clearance.   
This is an attractive aspect of antibody based defense against Pneumocystis as a potential therapy 
in settings such as AIDS, where the immune system is in a chronic state of activation and the 
limitation of inflammatory response to an infection may result in a better outcome for the host.  
 
1.5.5 Summary 
 
 Fungal pathogens can be targeted by specific antibodies against protein and carbohydrate 
antigens.  High affinity antibodies generated from conjugation of polysaccharide to protein 
carriers resulted in protective antibodies targeting Cryptococcus glucuronoxylmannan and as 
well as the common conserved fungal cell wall β-glucan.    Antibodies function through multiple 
mechanisms, and in the case of the β-glucan conjugate vaccine, one function was simply 
inhibiting the life cycle of target pathogens such as Candida and Aspergillus.   Other 
mechanisms employed by antibodies include neutralization, opsonophagocytosis, and enhanced 
complement fixation.  Additionally, antibodies may shape inflammatory responses, or may 
require the presence of certain adaptive immune system cells, such as B and T cells, for function, 
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suggesting a coordinate interaction.    Besides these beneficial functions, antibodies seem to 
potentially have detrimental functions in host defense, as in Cryptococcus infection certain 
specific isotypes were demonstrated to be ineffectual if not capable of worsening infection, 
whereas antibodies with the same Fab portion but of a different isotype were protective.     
 In Pneumocystis host defense, antibodies have been demonstrated to enhance clearance of 
infection.  It has been demonstrated that they can enhance alveolar macrophage effector function 
against Pneumocystis organisms.  Additionally, they appear to operate in a manner, which 
relative to CD4+ T cell based clearance, is less inflammatory, presumably by utilizing 
degradation pathways that are very different.   
   
1.6  NATURAL ANTIBODIES IN HOST DEFENSE AGAINST MICROBES 
 
1.6.1 Definition of natural antibodies and cellular origins 
 
Natural antibodies are defined as antibodies generated in the absence of exogenous antigenic 
stimulation.   Practically, they could be considered to be antibodies found in germ-free mice, in 
cord blood, or more loosely, antibodies found in individuals in the absence of apparent 
immunization (169).  Mice reared under germ-free or axenic conditions, free of all demonstrable 
associations with fungi, viruses, protozoa and bacteria, and maintained on a chemically defined 
“antigen-free” diet, have nearly identical quantities of IgM in the serum, but significantly 
reduced quantities of IgG in the serum and IgA at the mucosa, compared to mice reared under 
specific pathogen free conditions (170).   The lack of difference in quantities of IgM in the 
absence of antigenic stimulation is suggestive of the likelihood that the majority of IgM isotype 
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found in the serum is made in a different manner than by B cells secreting the majority of the 
IgG and IgA isotypes, and is likely the representative isotype comprising natural antibodies.   
Indeed, it has been demonstrated that a particular subset of B cells, B-1 cells, localized to the 
pleural and peritoneal spaces in rodents, are responsible for the majority of the production of 
serum IgM (as well as natural IgA found in the gut, with both natural and “induced” i.e. bacterial 
exposure dependent IgA derived from B-1 cells) (171-174).   Additionally, IgG natural 
antibodies have been described (175).   
B-1 cells are the first B cell lineage produced in the neonate, in contrast to traditional B-2 
cells which are generated later in development from the bone marrow.  B-1 cells are produced 
from progenitors in the fetal omentum and liver and are notably absent from the bone marrow, 
and are a self-replenishing population in the periphery thereafter (176).  It is assumed that 
selection or maintenance of B-1 cells occurs against self-antigen, as B cells require a positive 
selection signal through the IgM receptor to survive in the periphery (177).  As such, natural 
antibodies have reactivity against a variety of self-Ags, including to Thy-1, rheumatoid factor, T 
cell receptors, keratin, and single stranded DNA (169, 178, 179).    It is speculated that these 
antibodies may have function in aiding the clearance of apoptotic cells (180) or function in other 
physiologic processes.  However, it is also clear that natural antibodies react strongly with 
conserved pathogen associated molecular patterns, such as α-1,3 linked dextran, 
phosphorylcholine, and hemagglutinin, suggesting that the selection of natural antibody 
specifities may be linked to their functional utility in host defense.    It has been demonstrated 
that  perturbation or absence of the B-1 subset leads to impaired production of natural antibodies 
targeting Streptococcus pneumoniae (181) or Borrelia hermesiae (182), which has significant 
consequences for host defense against these infections.   Furthermore, these studies have 
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demonstrated that the B-1 subset is further partitioned based on functionality, with the B-1a 
subset (CD5+) demonstrated to have more of a role in the production of natural antibody, while 
the B-1b (CD5-) subset demonstrated to have more of a role in the induction of antibodies 
targeting carbohydrate antigen (183).   
Natural antibodies may play multiple roles in host homeostasis.  Antibody specificities 
may be present or absent depending on the species and the potential for autoimmune reactivity.  
For example, hyperacute rejection of xenotransplants occurs in humans receiving transplants of 
porcine origin, and this is mediated by the host possessing natural IgG and IgM targeting the 
carbohydrate Gal 1–3Gal 1–4GlcNAc (abbreviated as α1,3Gal), expressed on porcine 
epithelium.  Of note, these natural antibodies are entirely absent in mice and in pigs, as these 
animals have the enzyme, 1,3-galactosyltransferase to make this antigen, whereas humans do 
not.  When the enzyme is deleted from the mouse, the mice spontaneously make high quantities 
of this natural IgM specificity (184), and it appears that reintroduction of the enzyme via mixed 
bone marrow chimerism inhibits production of this particular antibody (185).  Hence, the natural 
antibody repertoire is exquisitely regulated, and particularly deleterious natural antibody 
reactivities are selected against.  Of note, natural α1,3Gal IgG antibodies observed in humans 
were found to be cross-reactive with LPS, and with bacteria such as Escherichia, Klebsiella, and 
Salmonella, as well as with Trypanosoma and Leishmania parasites (186, 187).  The authors of 
these papers argue that it is likely these natural antibodies are continually induced by the normal 
flora of the host.  Thus, their definition of natural antibody partially implicates exogenous 
antigenic stimulation in the production and maintenance of B cells with these specificities.  
Indeed, it is likely that if natural antibodies are selected partially as a function of their potential 
to interface with pathogen associated molecular patterns, that exogenous antigens could 
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influence the functions of these B cells.  For example LPS or TLR stimulation of peritoneal B 
cells in vivo induces migration of B-1 cells to secondary lymphoid organs such as the spleen, 
where they differentiate into antibody-secreting cells (188, 189).  Hence, a B cell secreting a 
natural antibody may have its baseline activity and functions affected by exogenous antigenic 
stimulation.   
Specificities of natural antibodies are described as polyreactive and encoded by germline 
variable regions without somatic hypermutation; it is also reported that there might be some 
preferred variable genes utilized in the production of these antibodies.    Natural antibodies are 
reported to have a wide range of binding avidities, from as low as 5*10^-3 to as high as 5*10^-
11 M (190).    While the natural antibody repertoire is described as broad and cross-reactive, it is 
clearly limited in its reactivity, and it is likely that specificities of low utility in host defense and 
homeostatic function are less represented, just as harmful specificities are deleted.    
 
1.6.2  Natural antibodies and host defense against infection 
 
There are multiple lines of evidence supporting a role for natural antibodies in the very earliest 
aspects of host recognition and defense against pathogens.   Ochsenbein et al demonstrated that 
low titers of IgM are present in the serum of specific pathogen free mice against specific viruses 
such as LCMV, VSV, and Vaccinia, as well as the bacteria Listeria monocytogenes (191).   The 
IgM isotype against these pathogens significantly predominated in the serum relative to the IgG 
isotype and natural IgM against VSV was capable of neutralizing the virus, preventing against 
lytic infection of target cells.  Additionally, to assess the functional relevance of these IgM, they 
compared the ability of µMT, RAG (-/-), and wild type mice to handle dissemination of viral 
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infection.  They showed that wild type mice could restrict dissemination of infection with 
enhanced pathogen burden in the spleen relative to other tissue sites such as the kidney, blood, 
and liver where burden was enhanced in the µMT mice.   To prove that this phenomenon was 
mediated by preexisting specific components of the serum, natural antibodies, they observed that 
with transfer of high quantities serum from wildtype mice into µMT mice they could restrict viral 
dissemination and improve survival.   Of note, since these specificities were present in specific 
pathogen free mice and predominantly of the IgM isotype they were considered natural 
antibodies, however, it was not confirmed that their presence occurs in the absolute absence of 
exogenous stimulation, criteria proposed by other authors to characterize the natural antibody 
repertoire.     
Natural antibodies also appear to play a role in a murine model of burn injury and defense 
against bacterial infection.  Serum IgM antibodies decline after burn injury leading to impaired 
defense against Pseudomonas infection; this effect however can be reversed by treatment with 
IL-18 prior to infection, which significantly enhanced quantities of natural IgM leading to 
improved resistance to Pseudomonas upon exposure (192) .  Splenectomized mice are more 
susceptible to Streptococcus infection, and transfer of IgM from specific pathogen free mice or 
pretreatment of mice with IL-18 which increases baseline IgM, and enhances host defense 
against infection (193).  Serum from humans that are non-immune to Leishmania contain IgMs 
able to agglutinate promastigotes, enhance complement deposition, and increase macrophage 
ingestion by monocytes (194).   Interestingly, mice and humans not previously exposed to HIV 
gp120 possess IgM antibodies with the capacity to proteolytically cleave gp120 in vitro, 
suggesting that some natural IgM molecules may also have enzymatic effector function (195).      
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 As natural antibodies are predominantly of the IgM isotype, another model to assess the 
functions of innate secreted IgM in host defense is the sIgM (-/-) mouse.  The sIgM (-/-) mouse 
contains a deletion in the exon driving secretion of IgM but retains the capacity to make 
membrane bound IgM receptor allowing for positive selection of B cells in the periphery, and the 
production of antibodies of other isotypes.  These mice have significantly worsened survival in a 
model of septic peritonitis which can be corrected by prior treatment with purified IgM from 
specific pathogen free wild type mice (196).  Also noted in this model, proinflammatory 
cytokines TNF-α, IL-6, and neutrophils were decreased in the peritoneum relative to wild type 
controls, suggesting that lack of IgM impaired aspects of local antigen presentation.    Systemic 
quantities of LPS and chemokines were, however, enhanced relative to wild type controls, 
arguing that secreted IgM (sIgM) plays an important role in preventing dissemination of antigen.  
In a model of filarial infection, it was demonstrated that lack of IgM impaired clearance in 
primary and secondary challenges (197).     Another well described role for sIgM in host defense 
emerged in studies of the murine model of influenza virus.  Mice lacking in sIgM had impaired 
survival and reduced clearance of influenza virus (198).    Mice additionally had impaired 
kinetics of induced IgG responses against influenza, suggesting that natural and induced IgM 
antibodies are required for an optimal adaptive antibody response.  It was further demonstrated, 
using allotype chimeras, that IgM antibodies derived from both the B-1 subset and the traditional 
B-2 subset are each independently required for the optimal induction of adaptive IgG responses 
and are each needed for survival.  This data suggests that the natural antibodies of the IgM 
isotype derived from the B-1 and B-2 source have unique and required effector functions against 
influenza, and that the IgM isotype plays some functional role in antigen deposition or antigen 
presentation that is critical for B cells undergoing germinal center reactions, and further, that an 
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infection of the pulmonary mucosa relies on natural and induced IgM for specific host defenses.   
This observation is somewhat unexpected, as IgA is the predominant mucosal Ab, and the role of 
IgM in host defense against pulmonary infections is poorly explored.   
The relevance of natural antibodies and their potential mechanisms of action in host 
defense are just emerging.  From what is currently known, it is reasonable to assume that natural 
antibodies have a significant role in the very earliest aspects of host recognition and antigen 
presentation, and can influence infections to the point of host protection vs. host death.   
 
1.6.3 Natural antibodies and fungal disease 
 
Of note, the role of natural antibodies has been understudied in defense against fungal infections.   
It has been demonstrated that a monoclonal IgM that targets keratin has cross-reactivity with C. 
albicans germ tubes, and mice transgenically overexpressing this natural antibody can impair the 
growth of infection and inhibit the actual growth of C. albicans organisms.  Thus, it is suggested 
that at least a surface epitope on C. albicans has similar structure to keratin, and that natural 
antibodies targeting this structure have a function in host defense.    Additionally, using a looser 
definition of natural antibody, “natural” IgG antibodies targeting the fungal cell wall 
carbohydrate mannan have been described in healthy individuals (i.e. in the absence of any overt 
infection), with wide variation in titers when comparing individuals (199). In contrast, it was 
noted that anti-mannan IgG was not detected in rabbits unless directly infected with Candida.  In 
a separate study by Kozel and colleagues, IgG against mannan was observed to exist at higher 
titers than the mannan specific IgM in the general population.  Additionally, these authors 
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demonstrated that increased anti-mannan IgG levels correlated with
 
an increased rate of 
complement protein 3 (C3) binding to Candida (200).    
The potential contribution of the entire natural antibody repertoire and the IgM isotype, 
and the particular mechanisms of action of natural antibodies in influencing the evolving innate 
and adaptive response to fungal infection, have not been dissected for any fungal infection at the 
time of this writing.   
 In a disease such as Pneumocystis, it has been assumed that IgM is of very little 
importance in host defense.  As mice deficient in CD40 overproduce PC-specific IgM (96) and 
are still susceptible to infection, it is clear that natural IgM are not sufficient for host defense 
against infection.  However, it does not exclude their relevance in the very earliest aspects of 
recognition and innate defense and their contributions to an evolving adaptive immune response.      
 
1.6.4 Summary 
 
Natural antibodies are commonly defined as antibodies present in the serum in the absence of 
exogenous antigenic stimulation.  Traditionally of the IgM isotype, present at relatively low 
titers, and with a wide range in binding affinities for various antigens, they consist a broadly 
reactive repertoire.  Many natural antibodies are cross-reactive with host antigens, suggesting 
they may play some role in normal physiologic processes of the host, such as aiding in the 
identification and removal of apoptotic or dying cells.  However, natural antibodies also possess 
specificities against non-self antigens, including a variety of conserved pathogen associated 
molecular patterns, suggesting that the repertoire may be shaped by selection pressures that 
influence the host’s response to infection.  Indeed, natural antibodies have been demonstrated to 
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bind pathogens, neutralize pathogen, enhance complement deposition and enhance survival 
against infection.  They are able to restrict dissemination of infections.  Natural antibodies are 
further implicated in shaping aspects of the host’s adaptive immune response, as they participate 
in some of the earliest recognition events, and are likely very much involved in enhancing 
antigen deposition in secondary lymphoid organs, and hence antigen presentation.  Of note, the 
repertoire is restricted, as some natural antibody specificities are selected against.    Interestingly, 
natural IgM has been demonstrated to play a critical role in defense against mucosal infections of 
the lung, such as influenza.   
Studies in humans have utilized a broader definition of natural antibody, defining natural 
antibodies as those that are present in individuals in the absence of specific infection with 
pathogen.    It has been demonstrated that IgG antibodies targeting Candida mannan, found in 
healthy “uninfected” individuals, can enhance complement opsonization of Candida.  
Additionally, in fungal infection, it has been demonstrated that a natural IgM cross-reactive with 
keratin is also highly reactive with Candida, and that upon overexpression prevents infection by 
directly inhibiting germ tube growth (179).  The role of natural antibodies in shaping host 
defense responses against Pneumocystis remains to be studied, and could provide very useful 
information in the design of new therapies against infection.   
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1.7 ADAPTIVE ANTIBODY RESPONSES AGAINST CARBOHYDRATE ANTIGENS IN 
HOST DEFENSE 
 
1.7.1. Carbohydrate Antigens and the induction of antibody responses against mucosal 
infections: Implications for Pneumocystis 
  
The production of immunoglobulins targeting carbohydrate antigen are among the most 
protective immune responses generated in humans.   Additionally, some of the most essential 
vaccines in clinical use induce protective antibodies against carbohydrate antigens in the cell 
walls of bacteria such as Streptococcus pneumoniae, Hemophilus influenzae, or Neisseria 
meningitidis, preventing against human diseases ranging from pneumonia to meningitis (201).    
Despite the importance of these responses in host defense against infection, the actual 
mechanisms regulating the induction of antibody responses against carbohydrate antigens are 
poorly characterized.   
 Antigens are classified according to their requirement for T cell involvement in the 
production of antibodies.   Thymus-dependent, or T-D, antigens require MHC class II restricted 
T cell help for the induction of antibody, whereas Thymus-independent, or T-I antigens do not.   
T-I antigens are further subdivided based on the mechanism whereby they activate B cells.   TI-1 
antigens are polyclonal activators of B cells, such as LPS, which signal through receptors besides 
the B cell receptor in order to induce B cell activation and antibody production.  TI-2 antigens 
are described as repetitive carbohydrates, such as the capsular polysaccharide used in the 
Streptococcus vaccine, consisting of multiple repeating epitopes mediating significant cross-
linking of B cell antigen receptors.   TI-2 antigens are additionally characterized by their high 
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molecular weight given their polymeric nature, and their resistance to degradation.  With 
receptor stimulation by TI-2 antigen, the enzyme Btk is activated, which is the critically involved 
in the TI-2 signaling cascade (202).  Of note, xid mice, deficient in Btk and noted to lack B-1 B 
cells, have significant impairment of the TI-2 response, but relatively normal TI-1 responses 
(203).   TI-2 responses are impaired in splenectomized mice and humans (204, 205), suggesting 
that B cells producing these antibodies require this environment potentially for activities such as 
activation, antigen presentation, or differentiation into antibody secreting cells.   Collectively, 
given the specific localization requirement for some activities of B cells involved in TI-2 
responses, their specific signaling requirements, and the unique antigenic stimuli leading to the 
production of these antibody responses, it suggests that the rules driving these B cells differ from 
those of traditional B-2 cells.   
B-1 and the marginal zone (MZ) B cell subset of the spleen are implicated in responding 
to TI-2 antigens, as both subsets are implicated in the recognition of carbohydrate antigen, both 
subsets possess overlapping antibody idiotypes, for example reactivity against 
phosphorylcholine, as demonstrated by Martin et al (206), and both subsets can produce IgM 
antibody without  CD4+ T cells.  When the MZ B cell subset is absent, as seen in pyk-2 deficient 
mice, the early wave of antibody responses to TI-2 antigens to dextran and TNP-Ficoll is 
impaired (207), and as noted, xid mice are lacking in B-1 cells and have difficulty mounting TI-2 
antibody responses.   
 Of note, very few studies have been performed to assess antibody responses to 
carbohydrate antigens on intact pathogens.  As intact pathogens contain carbohydrates and 
proteins often covalently linked together, or in tight association, it is unclear whether antibody 
responses against carbohydrate antigens might be influenced or regulated by CD4+ T cells.   One 
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might hypothesize that proteins associated with carbohydrates might provide peptide that could 
be presented on MHC II proteins, allowing for CD4+ T cell help in the activation of B cells 
secreting antibodies against carbohydrates, operating much like a conjugate vaccine.  Studies 
from the laboratory of Snapper et al have demonstrated that antibody responses to 
phosphorylcholine, a component of the capsular polysaccharide of Streptococcus, in mice 
intraperitoneally challenged with Streptococcus pneumoniae, are indeed regulated by TCR- ß
+ 
T 
cells, CD40L, and B7-CD28/CTLA4 costimulation, in that IgG titers are significantly diminished 
in the absence of these molecules or when they were disrupted (208).  This group went on to 
show that capsular polysaccharide of Streptococcus, another TI-2 antigen, also requires CD4+ T 
cells for the IgG response, and even more specifically requires an intact T cell receptor in order 
to produce IgG, in contrast to the anti-phosphorylcholine IgG response which does not (209).   
These studies truly underscore the complexity of the nature of antibody responses against thymus 
independent antigens, and that while perhaps the IgM response against TI-2 antigen may not 
require CD4+ T cells, aspects of these responses may be influenced by CD4+ T cells, such as the 
process of isotype class-switch, the specific idiotypes generated, and the actual quantities of 
antibodies produced (210-212).    There may be further variation depending on the type of TI-2 
antigen.   
As Pneumocystis pneumonia is a disease most commonly seen in the setting of chronic 
CD4+ T cell deficiency, and antibodies have been identified to protect against infection, it is 
important to evaluate the role of CD4+ T cells in the production of antibodies targeting different 
protein and carbohydrate antigens.  Thus far, there are no studies on the induction of antibody 
responses against Pneumocystis carbohydrate antigens, and it is unclear how a deficiency in 
CD4+ T cells might influence the production antibodies targeting carbohydrates.  While there is 
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abundant evidence that antibodies sufficient for host defense against Pneumocystis are generated 
in a CD4+ T cell sufficient environment, it is unclear whether antibodies generated in a CD4+ T 
cell insufficient environment also have some protective efficacy, or modulate aspects of the host 
immune response.   
 Additionally, in the study of a mucosal disease such as Pneumocystis, where the a 
significant portion of the infection consists of trophozoites tightly adhering to the apical surface 
of epithelial cells, it is unclear what role CD4+ T cells have in guiding aspects of potential TI-2 
antibody responses in lungs.  The pulmonary compartment, for example, has significantly higher 
quantities of IgA than the serum, suggesting that aspects of immune responses at this distinct 
tissue site may influence host defense.  Indeed, mice unable to transport IgA and IgM across the 
epithelium have greater susceptibility to pulmonary challenges with Mycobacteria, and 
Streptococcus, and mice vaccinated against Vibrio cholerae are protected only if pIgR is intact 
(213).  Yet, in all of these studies, the specifities of these protective antibodies are unknown, as 
well as their reliance on CD4+ T cells for their production.  An evaluation of the antibody 
responses produced at the mucosa against Pneumocystis carbohydrate antigens, and the role of 
CD4+ T cells in these processes may inform on other epitopes identified by antibodies and the 
role of CD4+ T cells in the generation of these molecules.    Identification of antigens that 
produce antibodies in a CD4+ T cell independent manner, and additionally positively affect the 
immune response against Pneumocystis may allow for the design of new therapies against 
infection that enhance protective strategies already employed by the host.   
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1.7.2  B cell memory against carbohydrate antigens: Implications for Pneumocystis 
 
The ability of B cells to produce specific antibodies for many years after an exposure to a given 
antigen, and the significant enhancement of antibody responses after secondary exposure to 
antigen underscores the ability of the immune system to learn and to improve its functional 
utility over the course of an individual’s lifetime.    Traditionally, antibody-based immunologic 
memory has been considered in the context of the generation of at least two types of functional 
memory B cells (214).  The first of these effector memory B cells is the long-lived terminally 
differentiated antigen specific plasma cell, which localizes predominantly to the bone marrow in 
mouse and human after differentiation, where it receives growth factor support (215, 216).  The 
second effector memory B cell population, known as the quiescent memory B cells, do not 
secrete antibody at steady state, but upon reexposure to secondary antigen rapidly divide and 
differentiate into plasma cells, dramatically enhancing antibody responses within a short period 
of time.   Multiple lines of evidence suggest that quiescent memory B cells home to secondary 
lymphoid organs such as the spleen for their long-term survival (217, 218).  The production of B 
cell memory subsets secreting antibody against protein antigen requires CD4+ T cells, and the 
migration of antigen activated B cells to germinal centers, where, they undergo isotype class-
switching and affinity maturation (214).  While this model is well accepted for protein antigens, 
it is unclear if such memory responses against carbohydrate antigens are generated.  As 
individuals vaccinated with capsular polysaccharide make high quantities of specific antibodies, 
presumably via the generation of memory plasma cells, with the capacity to secrete antibody for 
many years, it is unclear if the quiescent memory B cell compartment forms against TI-2 
antigens.    A recent study by Obukhanych et al suggests that quiescent memory B cells are 
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generated in response to TI-2 antigen challenge, and that the regulation of antibody production 
by these quiescent memory B cells, upon rechallenge, is inhibited by high quantities of  antigen 
specific IgG in the serum (219).    
 In the setting of Pneumocystis susceptibility, where CD4+ T cell antibody-dependent 
responses are not reliable, it is important to understand if antibodies targeting carbohydrates 
antigens are generated, whether CD4+ T cells influence their production, as well as whether 
functional memory responses against carbohydrate antigens generated.   Also, it would be very 
informative to understand whether these responses can be reactivated in a CD4+ T cell 
insufficient environment, as this might be the manner in which one might rely on any 
carbohydrate vaccine to operate in the setting of HIV-AIDS.   
 
 
1.7.3 Summary 
 
The parameters guiding antibody responses against fungal cell wall carbohydrates in a model of 
mucosal infection are poorly characterized.  As Pneumocystis pneumonia is a disease whereby 
the most obvious cellular change results in a dramatic loss of CD4+ T cell numbers, it is 
important to characterize antibody responses that may be operative in a CD4+ T cell insufficient 
environment.  B-1 and MZ B cell subsets are implicated in the generation of TI-2 responses.   
The conserved fungal cell wall carbohydrates of Pneumocystis resemble TI-2 antigens, and there 
is some evidence that T cells influence aspects of these responses, such as quantity of antibody 
production and isotype switching.   While CD4+ T cells are required for the production of B cell 
memory, it is unclear whether they are required for functional B cell memory, elicited by either 
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plasma cells or antibody secreting cells.   A greater understanding of TI-2 and B cell reponses 
antigens in host defense against Pneumocystis may identify new targets in the design of vaccines 
against this infection.  
 
1.8 SPECIFIC AIMS 
 
Specific Aim I:  To evaluate whether a Dectin-1: IgG1 Fc fusion protein enhances host 
clearance of Pneumocystis.  We hypothesize that a molecule capable of recognizing the 
conserved inner cell wall carbohydrate, β-1,3 glucan, as well as FcγRs, will function as an 
antibody and promote host defense against Pneumocystis.    
 
Specific Aim II: To determine the presence, role, and regulation of Pneumocystis cellular 
wall carbohydrate directed antibodies, natural antibodies, and the IgM isotype in host 
defense against Pneumocystis.  We hypothesize that contributory antibodies in host defense 
against Pneumocystis involve CD4+ T cell independent natural antibodies targeting conserved 
fungal cell wall carbohydrates found in the cell wall of Pneumocystis.  We hypothesize that 
natural antibodies influence host defense against Pneumocystis, and influence aspects of antigen 
presentation, and that the IgM isotype, which is the primary isotype constituting the natural 
antibody repertoire, has an important role in host defense and in guiding adaptive immune 
responses.  Additionally, we hypothesize Pneumocystis challenge leads to the actual induction of 
antibody responses against these fungal cell wall carbohydrates, and may lead to functional 
immunologic memory responses against them.   
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2.0   ENHANCED DEFENSE AGAINST PNEUMOCYSTIS CARINII MEDIATED BY A 
NOVEL DECTIN-1 RECEPTOR: IGG1 FC FUSION PROTEIN 
 
2.1 INTRODUCTION 
 
Pneumocystis carinii (PC)
 
pneumonia is a major cause of illness
 
and death among the 
immunocompromised, most often observed in
 
individuals infected with HIV. Although incidence 
of PC pneumonia
 
has declined following the introduction of highly active antiretroviral
 
therapy 
(HAART), it remains the most prevalent of opportunistic
 
infections in industrialized countries 
(17). Further, the vast
 
majority of the world’s 45 million infected with HIV are
 
without access to 
HAART and at high risk for PC pneumonia (26, 220-223). Individuals receiving chronic 
immunosuppressive
 
therapy as a consequence of organ transplantation or autoimmune
 
disease 
represent another growing, at-risk population for this
 
opportunistic infection. The identification 
of dihydropteroate
 
synthase mutations in PC isolates from humans (224) suggests the
 
potential 
for resistance of PC organisms to existing chemotherapeutic
 
strategies and additionally 
underscores the need for alternate,
 
immune-based strategies against PC infection.
 
 
Murine models of PC infection, using the host specific pathogen
 
P. carinii f. sp. muris, 
have demonstrated the potential utility
 
of Ab-based immunity in host defense against PC. CD4
+
 
T cell
 
deficiency or blockade of CD40L renders mice susceptible to
 
PC and is coincident with 
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diminished IgG responses against PC
 
(42, 225). µMT knockout mice, deficient in B cells, are 
also
 
highly susceptible to PC pneumonia and signify the critical
 
nature of B cells and their 
effectors in PC resistance (91).
 
Adoptive transfer of serum from PC-vaccinated mice or mAbs 
directed
 
against PC Ags can prevent the establishment of infection upon
 
challenge (57, 93) or 
inhibit progression of existing PC pneumonia
 
in early through late stages of disease (167). 
Interestingly,
 
mice challenged with PC and thereafter depleted of CD4
+
 T cells
 
have persistent 
anti-PC IgG and are able to resist infection
 
given a subsequent exposure, suggesting that Ab-
based immunity
 
may be sufficient for preservation of anti-PC resistance in
 
the setting of CD4
+
 T 
cell deficiency (97). PC-directed Abs
 
likely function through multiple mechanisms to increase 
host
 
resistance to infection and have been shown to significantly
 
potentiate alveolar macrophage 
anti-PC effector function in
 
vitro (49, 92, 226). Though recent studies suggest that PC-specific
 
IgG is not absolutely required for host resistance, Fc R-deficient
 
mice clear PC organisms with 
delayed kinetics (96). These observations
 
suggest that PC-specific Abs may couple with Fc R-
bearing cells
 
to modulate aspects of host recognition and clearance of PC
 
and illustrate the 
potential of Ab-based strategies against
 
PC in the setting of immunodeficiency.
 
 
The specific Ags involved in Ab-based recognition and degradation
 
of PC, identifying 
either cystic and/or trophozoite forms of
 
the organism, are unclear. PC protein Ags under 
investigation
 
as vaccine targets, such as the major surface glycoprotein complex
 
and the surface-
associated protease Kexin, exhibit interspecies-
 
and intraspecies-specific variation (92, 118, 227), 
which may
 
complicate potential vaccination strategies. Conserved pathogen-associated
 
molecular 
patterns (PAMPs) of PC identified by innate immune
 
cells include the major carbohydrates of the 
fungal cellular
 
wall, -glucan, and mannan. It is unknown whether these carbohydrate
 
Ags could 
be effective targets of Ab-based responses. We have
 
previously shown that the -glucan receptor 
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Dectin-1 is involved
 
in alveolar macrophage recognition, nonopsonic phagocytosis,
 
and killing of 
PC in vitro (49). RAW 264.7 macrophages overexpressing
 
Dectin-1 bound PC organisms at 
higher levels than control cells,
 
suggesting a critical, and possibly independent, role of this
 
receptor in PC identification. In this study, we report on the
 
potential of a recombinant protein, 
consisting of the extracellular
 
domain of Dectin-1 fused to the murine IgG1 hinge through 
constant
 
heavy (CH)2 and CH3 domains, as a novel strategy for the identification,
 
specific  
targeting, and degradation of PC organisms.
 
 
 
2.2  MATERIALS AND METHODS 
 
2.2.1 Mice 
Male C57BL/6 mice, 6–8 wk of age, were purchased from
 
the National Cancer Institute, National 
Institutes of Health.
 
Male B6.scid mice, 6–8 wk of age, were purchased from
 
The Jackson 
Laboratory. All mice were maintained in a specific
 
pathogen-free environment in microisolator 
cages within an American
 
Association for Laboratory Animal Science-certified animal facility
 
in 
the Rangos Research Center at the Children’s Hospital
 
of Pittsburgh. Animal studies were 
reviewed and approved by
 
the Children’s Hospital of Pittsburgh Animal Research
 
and Care 
Committee.
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2.2.2 DNA constructs and adenoviral vectors 
The design of the Dectin-Fc recombinant gene construct was modeled
 
after the TNFR-IgG H 
chain, described by Peppel et al. (228).
 
A PCR 3.1 plasmid containing the full-length murine 
Dectin-1
 
receptor, provided by G. Brown (University of Cape Town, Cape
 
Town, South Africa), 
and the pACCKP2 plasmid containing the
 
TNFR extracellular domain linked to murine IgG1 H 
chain (229)
 
served as PCR templates. The cDNA encoding the extracellular
 
domain of the 
Dectin-1 receptor, consisting of amino acids 69–244
 
(139), was amplified by PCR with 
oligonucleotide primers ggtaccga
 
CGACACAATTCAGGG (corresponding to an engineered 
KpnI site, a
 
frame spacer, and the 5' end of the Dectin-1 receptor extracellular
 
domain) and 
ggatccacgcggaaccag CAGTTCCTTCTCACAG (corresponding
 
to the hexapeptide linker with 
thrombin cleavage site and the
 
3' end of the dectin-1 receptor). The cDNA-encoding CH2-CH3
 
was amplified with primers ctggttccgcgtggatcc GTGCCCAGGGATTGTGGT
 
(corresponding to 
the hexapeptide linker with thrombin cleavage
 
site and the 5' end of the IgG moiety) and gaattc 
TCATTTACCAGGAGAGTG
 
(corresponding to an engineered EcoRI site, an antisense stop
 
codon, and the 3' end of the IgG moiety). cDNA products were
 
isolated on an agarose gel and 
purified via extraction (Qiagen).
 
The products were combined at a 1:1 ratio and subjected to five
 
cycles of denaturation and reannealing to promote recombination
 
of homologous regions. The 5' 
primer for the dectin-1 receptor
 
extracellular domain and the 3' primer for the IgG moiety were
 
used to amplify the recombinant product Dectin-Fc. The chimeric
 
PCR product was isolated and 
purified via gel extraction and
 
subcloned into the TOPO-TA Vector (Invitrogen Life 
Technologies).
 
Using M13 primers, the Dectin-Fc DNA was amplified via PCR,
 
digested with 
KpnI and EcoRI, and inserted in-frame into the
 
multiple cloning site of pSecTag 2C mammalian 
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expression vector
 
(Invitrogen Life Technologies), containing the IgK leader sequence
 
facilitating 
protein secretion. To confirm the fusion gene product,
 
dideoxy sequencing was performed.
 
 
Ad-Dectin-Fc is an E1-E3 replication-deficient rAd5-based vector
 
containing the entire 
pSecTag 2C-Dectin-Fc expression cassette.
 
To generate Ad-Dectin-Fc, the Dectin-Fc expression 
cassette
 
was amplified and inserted into the Invitrogen Gateway entry
 
vector pENTR/D-TOPO, 
then shuttled in an exchange reaction using
 
LR Clonase into pAd/CMV/V5 DEST (Invitrogen 
Life Technologies).
 
The resultant plasmid was purified, digested with PacI to expose
 
adenoviral 
ITR sequences, and then transfected into 911 cells
 
supplying the E proteins required for 
adenovirus propagation.
 
Viruses were purified and concentrated by either CsCl density
 
gradient 
centrifugation or by membrane adsorption (Vivapure
 
Adenopack; Sartorius), and titered by a 
plaque assay on 911
 
cells, as previously described (89, 229). The control AdLuciferase
 
vector is 
identical but instead encodes the firefly luciferase
 
gene and was obtained from the Pittsburgh 
Pre-Clinical Vector
 
Core. The particle:PFU ratio was 100:1 and virus stocks contained
 
<0.01 
ng/ml endotoxin as determined by the QCL-1000 Limulus
 
lysate assay (BioWhittaker).
 
 
2.2.3 Production of Dectin-Fc and Western blot 
For Dectin-Fc protein generation, 293 cells cultured in DMEM
 
plus 10% FCS were transiently 
transfected with the pSecTag 2C-Dectin-Fc
 
vector with Lipofectamine 2000 (Invitrogen Life 
Technologies).
 
Supernatants were collected and cells were removed by centrifugation
 
and 
passage of supernatant over a 0.2 µM low protein-binding
 
filter. Supernatants were preserved at 
–80°C. For
 
some experiments, Dectin-Fc was affinity purified over a column
 
consisting of 
Sepharose beads conjugated to goat-anti-mouse
 
H chain IgG (Sigma-Aldrich), and SDS-PAGE 
followed by Coomassie
 
staining was used to confirm purity. Protein reactivity was
 
studied by 
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Western analysis. To evaluate protein structure,
 
Dectin-Fc-conditioned supernatant was 
pretreated with 2-ME.
 
Conditioned supernatant or purified protein was isolated on
 
SDS-PAGE, 
transferred to nitrocellulose membranes, and blocked
 
overnight with BSA (2% for tissue culture 
supernatant, 4–8%
 
for mouse BAL, serum, or lung homogenate). Rat anti- murine-Dectin-1
 
(R&D Systems) followed by goat anti-rat IgG-AP (Santa Cruz
 
Biotechnology), or goat anti-
mouse IgG-AP (Bio-Rad), all at
 
1:2000 in blocking buffer, were used for immunodetection, and
 
blots were developed with 5-bromo-4-chloro-3-indolyl phosphate/NBT
 
reagent (Bio-Rad).
  
 
2.2.4 β-glucan ELISA 
Laminarin and mannan (Sigma-Aldrich) were each dissolved in
 
PBS and seeded to a Nunc 
Polysorp-treated 96-well plates at
 
0.025 mg/ml at 4°C for 48 h. As a negative control, ,1–3-
glucan
 
linkages of laminarin were hydrolyzed by pretreatment with laminarinase
 
( -1,3 
endoglucosidase) isolated from Trichoderma sp. as per
 
manufacturer’s protocol (Sigma- Aldrich) 
and similarly
 
seeded at 0.025 mg/ml. The wells were washed, blocked for 2
 
h in PBS, 10% FBS, 
and 2.5% milk, then washed again. Dectin-Fc-conditioned
 
supernatant or purified Dectin-Fc was 
dissolved in blocking
 
buffer, serially diluted 1:2, and administered to wells in triplicate.
 
After 2 h 
of incubation, wells were washed, and a 1/1000 dilution
 
of goat-anti-mouse IgG-HRP was 
applied for 2 h. Wells were washed
 
and developed with tetramethylbenzidine (TMB; BD 
Biosciences-BD
 
Pharmingen) and the absorbance at 450 nm was measured and subtracted
 
from 
baseline absorbance. 
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2.2.5 BIAcore analysis 
Real-time surface plasmon resonance experiments were performed
 
on a BIAcore 3000 
Instrument with CM5 sensor chips (BIAcore)
 
and all interactions were studied at 25°C. N-
hydroxy succinimide/N,N-(3-dimethylaminopropyl)-N'-ethylcarbodimide
 
hydrochloride amine 
coupling was used to immobilize goat anti-mouse
 
Abs (Molecular Probes) diluted 1/50 in 10 mM 
sodium acetate
 
(pH 5) and empty reactive sites were quenched with 1 M ethanolamine.
 
Affinity 
purified Dectin-Fc (100 µg/ml) was captured by
 
injection at a flow rate of 5 µl/min (total 35 µl).
 
Laminarin was dissolved in PBS and diluted to 100, 2, or 0.2
 
µM in running buffer (10 mM 
HEPES (pH 8.0), 150 mM NaCl,
 
0.002% Tween 20), injected by KINJECT and allowed to reach 
equilibrium,
 
after which only running buffer was applied. Immobilized goat
 
anti-mouse Abs 
served as a control surface and nonspecific binding
 
of laminarin was subtracted from the surface 
plasmon resonance
 
signal in the active flow cell. The association rate constant
 
(ka) and 
dissociation rate constant (kd) were calculated and
 
the dissociation constant was determined (KD) 
using the BIAevaluation
 
3.1 software.
  
2.2.6 P. carinii f. sp. muris isolate 
The PC inoculum was prepared as previously described (42, 89).
 
Briefly, B6.scid mice with PC 
pneumonia were injected with a
 
lethal dose of pentobarbital and the lungs were aseptically
 
removed and frozen in 1 ml of PBS at –80°C. Lungs
 
were mechanically dissociated in sterile 
PBS, filtered through
 
sterile gauze, and pelleted at 500 x g for 10 min at 4°C. The pellet was 
resuspended in sterile PBS and a 1/5 dilution
 
was stained by a modified Giemsa stain (Diff-Quik; 
Baxter).
 
The number of PC cysts was quantified microscopically and the
 
inoculum concentration 
was adjusted to 2 x 106 cysts/ml. Gram stains were performed on the inoculum preparations to 
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exclude
 
contamination with bacteria. For in vitro studies, aliquots
 
of the inoculum were stored at 
concentrations of 10
6
 cysts/ml
 
at –80°C until use.
 
 
2.2.7 Peritoneal and alveolar macrophage isolation 
For peritoneal macrophage isolation, male C57BL/6 mice were
 
administered 3% sterile 
thioglycolate i.p. After 3–5 days,
 
mice were sacrificed and a peritoneal lavage was performed 
using
 
5 ml of PBS. The lavage fluid was centrifuged at 300 x g for 10 min, resuspended in RBC 
lysis buffer (Sigma-Aldrich) for
 
5 min, then washed, pelleted, and resuspended in RPMI 1640.
 
Cell pellets were studied and enumerated using a hemacytometer.
 
To isolate alveolar 
macrophages, male C57BL/6 mice were anesthetized
 
with isoflurane and sacrificed via terminal 
exsanguination.
 
With an intratracheal catheter, calcium and magnesium-free PBS
 
was used to 
lavage lungs. A total of 10 ml was used per mouse
 
in 0.5-ml increments with a 30 s dwell time. 
The lavage fluids
 
were pooled and centrifuged at 300 x g for 10 min, and the cells were collected 
for the coculture assay. Cell preparations were
 
generally >98% enriched for peritoneal or 
alveolar macrophages.
 
 
2.2.8 Zymosan association assay 
To assess macrophage surface association with zymosan, 10
5
 RAW
 
264.7 cells were suspended 
in RPMI 1640 plus 10% FCS in 5-ml
 
polystyrene tubes. Some groups were pretreated for 30 min 
with
 
5 µg of 2a11 (provided by G. Brown, as described in Ref.
 
(145)), a mAb with specific 
blocking activity against the murine
 
Dectin-1 receptor, and/or 2.5 µg of Fc RII/III blocking
 
Ab 
2.4G2 (eBioscience), and maintained at 37°C. FITC-zymosan
 
(Molecular Probes) was suspended 
in culture medium, sonicated,
 
enumerated, and preopsonized with conditioned supernatant 
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containing
 
Dectin-Fc, control medium consisting of DMEM plus 10% FCS, or
 
neat normal 
mouse serum, for 30 min at 4°C. Ten particles
 
of preopsonized zymosan were administered per 
macrophage and
 
allowed to incubate with macrophages at 37°C for 90 min.
 
A total of 10,000 
events were analyzed with a FACSAria flow
 
cytometer for relative FITC intensity (BD 
Biosciences). Macrophages
 
were distinguished from free zymosan by forward and side scatter
 
profiles. Mean fluorescence intensity (MFI) was calculated by
 
averaging all events across the 
macrophage live cell gate; fold
 
changes were calculated by normalizing the observed MFI to the
 
baseline MFI obtained from RAW cells incubated with zymosan
 
preopsonized with control 
medium.
 
 
2.2.9 Staining of Pneumocystis organisms with Dectin-Fc 
PC organisms were heat-fixed to glass slides and incubated with
 
Dectin-Fc-conditioned medium 
or control medium. After primary
 
incubation, organisms were extensively washed; bound Dectin-
Fc
 
was detected by incubating with Cy3-conjugated goat anti-mouse-IgG.
 
Following additional 
washes, ProLong-mounting medium and coverslips
 
were applied. Slides were examined under a 
Zeiss Axioplan 2
 
upright fluorescent deconvolution microscope and images were
 
captured using 
3I Slidebook version 4.0 software.
 
 
2.2.10 Pneumocystis viability assay 
Macrophages (10
6
/ml) suspended in a volume of 100 µl of
 
RPMI 1640 medium containing FCS 
were cocultured in round-bottom
 
96-well plates with PC (2 x 104 cysts/ml, 50 µl), yielding an 
effector to total PC organism ratio of 1:1 (estimated 1:10
 
cyst to trophozoite ratio). Before 
addition of PC, organisms
 
were preopsonized with 50 µl of Dectin-Fc-conditioned
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supernatant/purified Dectin-Fc or 50 µl of DMEM plus 10%
 
FCS. A viability control of PC 
incubated with control medium,
 
consisting of DMEM plus 10% FCS, was included. The plates 
were
 
spun at 2500 rpm to pellet PC organisms. The supernatants and
 
cell pellets were collected 
and total RNA was isolated using
 
TRIzol-LS reagent (Invitrogen Life Technologies). Viability
 
of 
PC was analyzed with real-time PCR measurement of PC large
 
subunit rRNA copy number 
(GenBank accession number AF257179)
 
and quantified against a standard curve of known copy 
number
 
of PC rRNA as previously described (49). This method detects
 
viable PC organisms as 
evidenced by loss of detectable PC rRNA
 
in heat-killed organisms or those exposed to 
trimethoprim/sulfamethoxazole. 
2.2.11 Adenoviral gene transfer and Pneumocystis challenge 
SCID mice (6–8 wk) received adenovirus at 1 x 109 PFU periorbitally (total volume 100 µl) 
under isoflurane analgesia.
 
Three days later, mice were anesthetized and challenged with
 
PC at 2 
x 105 cysts delivered intratracheally. At days 1, 5, 14, and 28 after PC challenge, mice were 
sacrificed by terminal
 
exsanguination under isoflurane analgesia; serum and bronchoalveolar
 
lavage fluid (BALF) was collected. Right lungs were preserved
 
for quantification of PC lung 
burden. A portion of the left
 
lung from individual mice was homogenized, normalized to a total
 
protein content of 1 mg/ml, and MIP-2 concentrations were determined
 
by ELISA (R&D 
Systems). 
2.2.12 Real-time PCR analysis of Pneumocystis infection 
Total RNA was isolated from the right lung of infected mice
 
by a single-step method using 
TRIzol reagent (Invitrogen Life
 
Technologies) as per manufacturer’s instructions. Thereafter,
 
 66 
RNA was transcribed to cDNA and real-time PCR was performed
 
as previously described; copy 
numbers were quantified against
 
a standard curve of known PC rRNA copy numbers (57). This
 
assay has a correlation coefficient of 0.98 with PC rRNA copy
 
number.
 
 
2.2.13 BALF analyses 
Fluid from the lower respiratory tract was obtained by bronchoalveolar
 
lavage of mice 
anesthetized with i.p. pentobarbital as described
 
previously (89). The first milliliter of BALF 
from SCID mice
 
infected with PC was collected at 5, 14, and 28 days was processed
 
at 500 x g 
and supernatant was stored at –80°C until
 
use. BALF samples were studied for Dectin-Fc 
expression or for
 
relative lactate dehydrogenase (LDH) activity as determined
 
with an LDH 
colorimetric assay kit (Sigma-Aldrich) detecting
 
the reduction of substrate NAD NADH. 
Absorbance was determined
 
at 530 nM. The remaining cell pellet and an additional 9 ml
 
of 
BALF was pooled and centrifuged at 800 x g for 10 min to collect cells and samples were 
cytospun onto slides, stained
 
by modified Giemsa, and analyzed for leukocyte differential.
 
 
2.2.14 Statistical analysis 
Data were analyzed using GraphPad statistical software. Comparisons
 
between groups when data 
were normally distributed were made
 
with the Student t test; comparisons among nonparametric 
data
 
were made with the Mann-Whitney U test. The Wilcoxon rank-sum
 
test was used when 
comparing experimental groups to a theoretical
 
value. Significance was accepted at a value of p 
< 0.05.
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2.3  RESULTS 
 
2.3.1 Characterization of Dectin-Fc protein reactivity and structure 
A recombinant fusion gene consisting of the extracellular domain
 
of the murine dectin-1 receptor 
(amino acids 69–244),
 
a thrombin sensitive hexapeptide linker, and the murine IgG1
 
hinge and 
CH2 through CH3 domains, was constructed and inserted
 
into the eukaryotic expression vector, 
pSecTag 2C, directing
 
protein secretion. The cloned portion of dectin-1
 
contains the entire, 
relatively compact, carbohydrate recognition
 
domain (CRD) of the receptor, which includes two 
putative N-glycosylation
 
sites. Western analysis of the supernatant generated from 293
 
transfectants revealed a 116-kDa product, reactive with both
 
goat-anti-mouse IgG Abs (Fig. 1A) 
and anti-murine dectin-1 Ab
 
(Fig. 1B). Under reducing conditions, the molecular mass of
 
the 
protein product was halved, demonstrating that the recombinant
 
protein adopts a disulfide-linked 
bivalent structure (Fig. 1B).
 
A schematic portrayal of the fusion protein itself is presented
 
in Fig. 
1C. As the murine hinge plus Fc domain is 60 kDa, the
 
extracellular domain of dectin-1 is 
roughly 28 kDa, in accordance
 
with a previous report describing the molecular structure of
 
the 
receptor (139).
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Figure 1. Analysis of Dectin-Fc protein reactivity and structure. 293 cells were transiently 
transfected with a pSecTag 2C vector containing the Dectin-Fc fusion gene cassette and 
culture supernatant was analyzed by Western blot. A, Reactivity of culture supernatant with 
goat-anti-mouse Abs. B, Culture supernatant reacted with mDectin-1 Abs followed by goat 
anti-rat IgG-HRP under nonreducing (lane 1) and strong reducing conditions (lane 2). C, 
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2.3.2 Analysis of Dectin-Fc Ag-binding site 
To define the properties of the carbohydrate recognition domain of Dectin-Fc, we assessed its 
ability to recognize laminarin,
 
a 7.7-kDa water soluble carbohydrate -glucan polymer isolated
 
from Laminaria digitata. Laminarin contains primarily -1,3 glucan
 
linkages with some -1,6 
glucan linkages, similar in ratio to
 
the -glucan linkages found in the cellular wall of 
Saccharomyces
 
cerevisiae and PC (110, 112, 230). In a study where dectin-1 was
 
expressed 
exogenously in the nonphagocytic NIH3T3 cell line,
 
laminarin was identified as the most potent 
competitive antagonist
 
of zymosan recognition among a panel of carbohydrates, underscoring
 
the 
molecular affinity of this carbohydrate for the dectin-1
 
receptor (144). By ELISA, we observed 
that Dectin-Fc bound laminarin in a dose-dependent manner (Fig.
 
2). This effect was entirely lost 
upon specific hydrolysis of
 
-1,3 linkages with laminarinase. Thus, the Ag recognition site
 
of 
Dectin-Fc displays high specificity toward the -1,3 linkages
 
of the -glucan laminarin.
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Figure 2.  The Dectin-Fc carbohydrate recognition domain identifies the -glucan 
laminarin. Laminarin, mannan, or β-1,3 endoglucanase laminarinase-treated laminarin 
were coated to individual ELISA plate at 25 µg/ml. Dectin-Fc supernatant was applied in 
a 2-fold dilution series, identified with HRP-conjugated goat anti-mouse IgG1 Abs, and 
developed with TMB. 
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We next determined the affinity of the Dectin-Fc carbohydrate recognition domain for -
glucan
 
linkages with real-time surface plasmon resonance measurements
 
(BIAcore). Affinity 
purified Dectin-Fc was captured with immobilized
 
goat-anti-mouse Abs; laminarin was applied 
at various doses
 
(0.2, 2, and 100 µM) and studied for interactions with
 
the Dectin-Fc Ag-binding 
site (Fig. 3). As expected, laminarin
 
bound Dectin-Fc and binding was dose dependent. The rate 
of
 
association (ka) was 5.6 x 10
3
 M
–1
s
–1
 and
 
the rate of dissociation (kd) was 1.14 x 10
–3
/s, 
signifying
 
that the stability of the complex slightly exceeds its capacity
 
to form. An overall 
equilibrium dissociation constant (KD) of
 
2.03 x 10–7 M was calculated, demonstrating high-
affinity
 
binding of Dectin-Fc to laminarin, similar in quality to various
 
carbohydrate directed Abs 
or lectin receptors for their ligands
 
(231-235). 
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Figure 3. Surface plasmon resonance analysis of the interaction of Dectin-Fc with 
the beta-1,3 linked glucan laminarin. Binding between Dectin-Fc and laminarin was 
studied in real-time using a BIAcore 3000 instrument. Goat anti-mouse Abs were 
chemically immobilized to CM5 chips and used as a capture surface for Dectin-Fc. 
Three doses of laminarin were injected at time –120 s (association) and replaced with 
buffer at time 0 s (dissociation). Nonspecific binding, which was minimal, was 
measured using a control flow cell consisting of immobilized goat anti-mouse Abs and 
was subtracted from each laminarin binding curve. The interaction between Dectin-Fc 
and laminarin is characterized by a KD of 2.03 x 10
–7
 M. 
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2.3.3 Dectin-Fc enhances macrophage recognition of zymosan 
 
To address the potential of Dectin-Fc to enhance macrophage
 
recognition of particulate -glucan, 
we evaluated whether Dectin-Fc
 
could enhance RAW264.7 macrophage recognition of fungal 
PAMP-containing
 
particulate zymosan. Zymosan is an insoluble cellular wall polysaccharide
 
derived from S. cerevisiae, composed mostly of -glucan and mannan
 
(236). FITC-labeled 
zymosan was preopsonized with either Dectin-Fc-conditioned
 
medium, control medium, or 
normal mouse serum and added to macrophages
 
for 90 min, and macrophage-associated FITC 
fluorescence was
 
determined by flow cytometry as a correlate of cellular association
 
with 
zymosan. As demonstrated in Fig. 4A, we observed enhanced
 
binding by macrophages of 
zymosan opsonized with normal mouse
 
serum, which increases baseline binding of zymosan 
predominantly
 
via CR3-based recognition (145). However, we observed even further
 
enhancement of macrophage recognition when zymosan was instead
 
preopsonized with Dectin-
Fc (Fig. 4A). Analysis of the average
 
macrophage MFI showed that recognition of zymosan by 
RAW cells
 
was significantly inhibited by Dectin-1 receptor blocking Ab
 
2a11, as previously 
reported (145), and that Ab-mediated blockade
 
of Fc RII and Fc RIII did not perturb FITC-
zymosan association
 
from baseline levels (Fig. 4B). Yet, Dectin-Fc enhanced the
 
average cellular 
MFI by 27% from baseline levels (Fig. 4B),
 
and the observed increased recognition of Dectin-Fc 
preopsonized
 
zymosan was entirely lost upon blockade of macrophage Fc RII
 
and Fc RIII (Fig. 
4B). As murine IgG1 immune complexes signal
 
primarily through Fc RII and Fc RIII (237), we 
conclude that Dectin-Fc-opsonized
 
zymosan was recognized through binding at these receptors. 
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Interestingly,
 
when the Dectin-1 receptor on macrophages was blocked, recognition
 
of Dectin-Fc 
preopsonized zymosan was further enhanced (Fig.
 
4B). Although the mechanism through which 
this occurs is unclear,
 
it raises the possibility that immune-complex associated, multimerized
 
FcRs generate stronger or more prolonged macrophage associations
 
with zymosan relative to that 
which occurs under competitive
 
binding with the Dectin-1 receptor. Thus, Dectin-Fc enhances
 
recognition of zymosan by macrophages, and in the absence of
 
cellular Dectin-1 receptor 
recognition, by promoting binding
 
through Fc RII and Fc RIII.
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Figure 4. Dectin-Fc enhances macrophage recognition of zymosan. FITC zymosan was 
preopsonized with either control medium, serum, or Dectin-Fc-conditioned culture medium and 
administered to RAW 264.7 macrophages for 90 min. 2a11 and anti-CD16/32 Abs were 
preadministered to macrophages to block the dectin-1 receptor or Fc II/Fc III, respectively. A 
total of 10,000 cells were collected and analyzed by flow cytometry for association with FITC 
particles. A, Histogram plot from zymosan association assay showing baseline fluorescence of 
macrophages (gray line), macrophages plus FITC-zymosan opsonized with control medium 
(dotted line), macrophages plus FITC-zymosan opsonized with serum (gray line, filled), and 
macrophages plus FITC-zymosan opsonized with Dectin-Fc (black line). B, Cumulative results 
from five separate experiments investigating the effects of Dectin-Fc on FITC-zymosan binding 
to RAW 264.7 macrophages, normalized to baseline MFI. For comparisons to the baseline 
condition, * represents a p < 0.05 and ** represents a p < 0.01 as calculated with the Wilcoxon 
rank-sum test after setting the baseline at a theoretical value of 1. For comparisons between 
Dectin-Fc and Dectin-Fc plus Fc block, ** represents a p < 0.05 by Student’s t test. 
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2.3.4 Dectin-Fc binds Pneumocystis organisms and enhances macrophage-dependent killing 
 
The cellular wall of the PC cyst consists of a thick electron-lucent
 
layer composed predominantly 
of -glucan, buried below a thin,
 
electron-dense surface layer consisting mainly of mannan and
 
glycoprotein (111, 112). Despite a seemingly shielded location,
 
it is believed that PC -glucan is 
sufficiently exposed to permit
 
recognition by the innate immune system via Dectin-1 (49) and
 
other pattern recognition receptors, such as the lactosylceramide-associated
 
-glucan receptor 
(63). Indeed, the specific interaction of PC
 
-glucan with these innate receptors has been 
demonstrated to
 
influence patterns of cytokine and chemokine expression, such
 
as the elicitation 
of the neutrophil chemoattractant MIP-2.
 
By fluorescent deconvolution microscopy, we observed 
that Dectin-Fc
 
bound to the surface of PC cysts (Fig. 5A). This observation
 
demonstrates the 
accessibility of Dectin-Fc to -glucan ligands
 
on PC organisms.
  
As we observed specific binding of Dectin-Fc to PC organisms,
 
we evaluated whether 
Dectin-Fc could enhance the recognition
 
and degradation of Pneumocystis organisms by Fc
RII/III-bearing
 
cells. We studied decreases in absolute quantities of PC large
 
rRNA copy 
numbers in the presence or absence of macrophages
 
as a correlate of in vitro PC killing, a 
methodology validated
 
by previous work (49, 87). PC organisms were isolated from infected
 
murine lung homogenates and were preopsonized with Dectin-Fc,
 
then administered to 
macrophages at a 1:1 PC organism to effector
 
cell ratio for 24 h. In studies with thioglycolate-
elicited
 
peritoneal macrophages, preopsonization of PC organisms with
 
Dectin-Fc diminished 
overall copy numbers by 3-fold relative
 
to organisms preopsonized with control medium (Fig. 
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5B). When
 
macrophages were pretreated with an Ab blocking activity at
 
the Dectin-1 receptor, 
killing of Dectin-Fc preopsonized PC
 
occurred to a similar degree. This observation suggested 
that
 
Dectin-Fc promoted PC killing independent of native Dectin-1
 
recognition. Additional 
blockade of Fc RII and Fc RIII abrogated
 
the killing effect, indicating that Dectin-Fc-dependent 
targeting
 
of PC toward Fc RII and Fc RIII was responsible for the diminished
 
PC rRNA signal. 
Resident alveolar macrophages appeared to have
 
a moderately higher level of effector activity 
against Dectin-Fc
 
preopsonized PC compared with recruited peritoneal macrophages,
 
decreasing 
PC rRNA copy numbers by nearly 10-fold relative to
 
medium opsonized PC (Fig. 5, C and D). 
We hypothesize that differences
 
between alveolar and elicited peritoneal macrophage 
populations
 
in responses such as phagocytosis, reactive oxide species generation,
 
and Ab-
dependent killing may be responsible for the enhanced
 
effector function against Dectin-Fc 
preopsonized PC by alveolar
 
macrophages. We conclude from these studies that primary murine
 
macrophages have enhanced recognition and killing of Dectin-Fc
 
preopsonized PC that is 
mediated via Fc RII and Fc RIII and this
 
occurs independently of dectin-1-based recognition. 
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Figure 5.  Dectin-Fc enhances 
macrophage killing of PC. A, 
Immunofluorescence patterns of 
Dectin-Fc-conditioned medium 
followed by goat anti-mouse 
Cy3 on heat-fixed preparations 
of PC cysts. No specific 
fluorescence was detected with 
control medium (data not 
shown). Original magnification, 
x630 oil emersion. B, PC was 
preopsonized with Dectin-Fc or 
control medium and added at a 
1:1 PC organism to effector cell 
target ratio to elicited peritoneal 
macrophages from male BL/6 
mice. PC alone (medium) and 
PC in the presence of Dectin-Fc 
(Dfc) was used as a control for 
PC viability. Total RNA was 
harvested, cDNA was 
synthesized, and viability was 
assessed through real-time PCR 
measurement of PC large 
subunit rRNA copy number. 
Data are expressed as mean 
copy number ± SEM from three 
experiments. *, A p value of 
<0.05; **, a p value of <0.01 by 
Student’s t test. C, A similar 
assay was performed with 
alveolar macrophages and 
affinity purified Dectin-Fc at 10 
µg. The figure shows 
representative data from three 
experiments. Data are expressed 
as PC large subunit rRNA copy 
number. D, Effect of Dectin-Fc 
on macrophage killing 
summarized as a percent of 
baseline macrophage effector 
function, calculated as 1 – 
(Dectin-Fc + macrophage 
killing/macrophage killing) x 
100%. 
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2.3.5 Dectin-Fc enhances clearance of Pneumocystis in SCID mice 
 
To study the effect of Dectin-Fc on PC infection in vivo, we
 
developed a replication incompetent 
type 5 adenovirus, Ad-Dectin-Fc,
 
containing the entire Dectin-Fc expression cassette, including
 
an Ig  leader sequence facilitating protein secretion upon cellular
 
transduction. As IgG protein 
administered directly into the
 
lungs is rapidly degraded (238), we considered adenoviral-based
 
transgene delivery of Dectin-Fc as a more appropriate system
 
to evaluate the effect of Dectin-Fc 
on this chronic, slow-growing
 
infection. Systemic administration of adenoviral vectors encoding
 
transgenes leads to high and prolonged levels of transgene protein
 
in the lungs in the absence of 
virus (239) and mice deficient
 
in CD4
+
 T cells do not mount significant neutralizing Ab 
responses
 
against adenoviruses (240), underscoring the suitability of gene
 
transfer as an effective 
means for long-term expression of Dectin-Fc
 
in the setting of immunodeficiency. SCID mice 
were treated with
 
either Ad-Dectin-Fc or an identical adenovirus expressing firefly
 
luciferase 
(Ad-luciferase), intravenously, at 1 x 109 PFU. Serum and lung homogenate were analyzed for 
Dectin-Fc protein expression
 
at various points after adenoviral treatment (Fig. 6A). The
 
fusion 
protein was detected in mice at high levels in both compartments
 
by 4 days after treatment 
through at least 31 days after treatment.
 
It is well-established that IgG crosses mucosal barriers, 
presumably
 
through transcytosis or interactions with FcRn (241), to function
 
in secretions. 
Dectin-Fc was also observed in the BALF, demonstrating
 
the presence of the fusion protein 
within the mucosal surfaces
 
and within compartments typical of murine IgG.
  
To assess the ability of Dectin-Fc to enhance host clearance
 
of PC, SCID mice were 
treated with Ad-Dectin-Fc or Ad-luciferase
 
i.v. and rested for 3 days, followed by intratracheal 
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challenge
 
with 2 x 105 PC cysts. Mice were then sacrificed at specific time points after challenge 
and studied for PC burden within
 
the lungs by assessment of total copy numbers of PC large 
rRNA
 
subunit (Fig. 6B). Despite equivalent cyst counts for the inoculum
 
between studies, PC 
rRNA counts were significantly different
 
and this may be due to the challenge of quantifying 
noncystic
 
PC forms. In a first experiment, 14 days after PC challenge,
 
an average of 25% of the 
original inoculum is present in the
 
Ad-luciferase-treated mice while the Ad-Dectin-Fc-treated 
mice
 
contained only an average of 6.9% of the original inoculum.
 
In a second experiment, 28 
days after PC infection, mice treated
 
with Ad-luciferase contained a substantially higher quantity
 
of PC in the lungs at an average of 549% of original inoculum
 
relative to the Ad-Dectin-Fc-
treated mice (averaging at 139%
 
of the inoculum). A third study, performed where a single 
inoculum
 
was administered and mice were analyzed at serial time points,
 
confirmed the 
inhibition of the growth kinetics of the PC organism
 
within the lungs of mice receiving a control 
vector compared
 
with mice receiving Dectin-Fc (Fig. 6C). Hence, treatment of
 
mice with Dectin-
Fc before PC infection considerably diminished
 
the growth of the organism within the lungs, 
contributing to
 
the ability of the SCID host to prevent PC multiplication within
 
the lung 
environment. The efficacy of Dectin-Fc to inhibit PC
 
growth is most apparent at later stages of 
PC infection, as
 
innate host clearance mechanisms lose their capacity to control
 
PC replication 
within the lungs. 
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Figure 6.  In vivo activity 
of Dectin-Fc in SCID 
mice challenged with PC. 
A, A replication 
incompetent Ad5 vector 
containing the entire 
pSecTag2 C Dectin-Fc 
expression cassette was 
generated. SCID mice 
were i.v. treated with 1 x 
10
9
 PFU Ad-Dectin-Fc or 
control vector Ad-
Luciferase; Dectin-Fc 
expression was assessed in 
various compartments at 
given time points after 
treatment. Individual 
mouse samples were 
studied for reactivity with 
mDectin-1 Abs at 116 
kDa. B, Three days post-
gene transfer (n = 
5/condition/time point), 
mice received 2 x 105 cysts 
i.t. and at specific time 
points thereafter, lungs 
were analyzed for total PC 
large rRNA subunit copy 
numbers. Days 14 (top) 
and 28 (middle) are 
displayed. Boxes represent 
the interquartile range of 
data between the 25th and 
75th percentiles and 
whiskers represent the 
upper and lower limits of 
the data.  The median is 
represented by the dividing line within the box. Bottom, Average copy numbers of PC organisms within the 
lungs of individual SCID mice normalized to the original inoculum per time point, plotted over time. C, To 
confirm inferences on kinetic growth a single inoculum was administered to mice (n = 5/condition/time 
point), lungs were harvested at various time points, and total PC large rRNA copy numbers are displayed. D, 
Data pooled from both SCID mice studies, day 28 after PC challenge (n = 10/time point/group), with 
individual PC lung burdens expressed as a percentage of total inoculum. In all frames, * represents a p value 
<0.05, and ** represents a p value of <0.01 between mice receiving Ad-Luciferase (control) and Ad-Dectin-
Fc (Dfc) by Mann-Whitney U test. 
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2.3.6 Effect of Dectin-Fc on correlative markers of lung injury in Pneumocystis infected  
 
SCID mice 
 
Although hyperinflammatory responses mediated by CD8
+
 T cells
 
generate significant lung 
damage and dysfunction in the murine
 
response to PC (242), SCID mice suffer lung damage at 
late stages
 
of pneumonia as a consequence of uncontrolled PC replication
 
and 
immunodysregulation (60, 243). We assessed the capacity of
 
Dectin-Fc to limit correlates of 
pulmonary damage associated
 
with PC infection by assessing the presence of intracellular
 
enzymes in the alveolar fluid. BALF collected from the study
 
described in Fig. 6C was analyzed 
over the time course of infection
 
for LDH activity. We observed significantly decreased levels
 
of 
BALF LDH in mice treated with Dectin-Fc, compared with control
 
mice, even as early as 5 days 
after PC challenge, when there
 
is low PC burden (Fig. 7A). As a significant portion of the
 
PC 
inoculum is cleared soon after intratracheal instillation,
 
as we (Fig. 6C) and others previously 
observed (97), it is possible
 
that targeting of PC to myeloid cells via Fc R-dependent host
 
recognition contributed to this phenotype. Twenty-eight days
 
after PC challenge, when there is a 
significantly higher PC
 
burden in the lungs of control mice relative to Dectin-Fc-treated
 
mice, 
BALF LDH was nearly twice as high in control mice relative
 
to mice receiving Dectin-Fc, 
suggesting that Dectin-Fc limited
 
both PC burden and cellular damage associated with infection.
 
Also by day 28 postchallenge, there were significant differences
 
in the quantities of neutrophils 
observed in the BALF, with
 
decreased levels in mice receiving Dectin-Fc (Fig. 7B). It has
 
been 
shown that SCID mice recruit high numbers of neutrophils
 
into the lungs at late stages of PC 
infection which is correlative
 
with lung damage (60) and in humans with PC pneumonia, 
increased
 
BALF neutrophil counts are associated with poor prognosis (27, 244). MIP-2, a 
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neutrophil chemoattractant secreted by alveolar
 
macrophages and airway epithelial cells in 
response to PC -glucan
 
(49, 63), and TNF- , a proinflammatory cytokine also secreted
 
by 
alveolar macrophages in response to PC -glucan (52), were
 
also measured in the lung 
homogenate. Though the differences
 
were not statistically significant, we observed a trend 
toward
 
higher levels of both cytokines in the lungs of control mice
 
relative to Dectin-Fc-treated 
mice (e.g., MIP-2 averaging 155
 
± 57 pg in the control group, 60 ± 21 pg in the
 
Dectin-Fc group; 
TNF-  levels were similar). Taken together,
 
these data suggest that correlates of pulmonary 
damage associated
 
with PC infection are limited by Dectin-Fc and this may be due
 
to enhanced 
clearance of PC and/or direction of PC organisms
 
toward Fc R-dependent recognition and 
degradation within the
 
lungs.
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Figure 7.  Correlates of PC-related lung damage after Dectin-Fc treatment. SCID mice 
were i.v. treated with 1 x 109 PFU Ad-Dectin-Fc or control vector Ad-Luciferase. Three 
days post-gene transfer, mice received 2 x 105 PC cysts i.t., and at specific time points 
thereafter, protein and cellular components of the BALF was studied. A, BALF from mice 
was analyzed for LDH activity over the time course of PC infection. Data are expressed as 
mean OD ± SEM from five mice in each group per time point. *, A p value <0.05 between 
mice receiving Ad-Luciferase (control) and Ad-Dectin-Fc (Dfc) by Student’s t test. B, 
Alveolar cells from BALF were analyzed on day 28 of PC infection for the percent of 
neutrophils by cytospins. Data are expressed as mean neutrophil percentage ± SEM from 
five mice in each group. *, A p value <0.05 between mice receiving Ad-Luciferase (control) 
and Ad-Dectin-Fc (Dfc) by Mann-Whitney U test. 
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2.4 DISCUSSION 
 
 
 
The -glucan receptor Dectin-1 is critically involved in innate
 
immune responses against PC 
(49), as well as Candida albicans
 
(245, 246) Aspergillus fumigatus (55, 247), and Coccidioides 
posadasii
 
(248). Two recent reports show that Dectin-1-deficient mice have
 
compromised 
clearance of PC (138) and C. albicans (249) as well
 
as attenuated macrophage responses to these 
fungal organisms.
 
In these fungal pathogens, -glucan is the major component of
 
the inner 
cellular wall, contributing to cellular rigidity and
 
structure, and eliciting host proinflammatory 
responses upon
 
exposure to the innate immune system (250). Notably, the PC cyst
 
contains high 
amounts of cellular wall -glucan while the trophozoite
 
form does not (112, 251, 252). Yet, the 
echinocandins, a class
 
of synthetically modified lipopeptides that inhibit the fungal-specific
 
enzyme -1,3-glucan synthase, rapidly diminish PC organisms in
 
rodent models of infection 
(114, 252). Given the abundance and
 
apparent accessibility of PC -glucan, as well as its 
potentially
 
critical role in the fungal life cycle, we considered immune-based
 
strategies targeting 
this defined cell wall component as a novel
 
therapy for PC pneumonia.
  
As macrophages overexpressing Dectin-1 have enhanced recognition
 
and uptake of PC 
organisms relative to normal macrophages, we
 
hypothesized that the CRD of Dectin-1 might be a 
sufficient
 
targeting structure for PC identification. Immunoprotective
 
Abs against PC enhance 
effector function at the level of the
 
myeloid cell and, as production of PC-specific IgG1 is most
 
perturbed by murine CD4
+
 T cell dysfunction (253), we chose to
 
couple the Dectin-1 CRD with 
the murine IgG1 Fc fragment to
 
promote recognition and signaling through Fc Rs. We expected
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that Dectin-Fc would function similarly to an Ab and would promote
 
host recognition and 
clearance of PC organisms by enhancing
 
the effector function of Fc R-bearing cells.
  
The recombinant protein, Dectin-Fc, demonstrated specific binding
 
to laminarin, a -
glucan-containing glycosidic linkages analogous
 
in stoichiometry to that observed in the PC cyst 
wall (112).
 
Hydrolysis of -1,3 linkages of laminarin entirely blocked Dectin-Fc
 
recognition, 
indicating its specificity for these glycosidic
 
bonds. Characterization of the Dectin-Fc CRD with 
surface plasmon
 
resonance measurements revealed a KD of 2.03 x 10
–7
 M
 
for laminarin, 
suggestive of high-affinity interaction. The
 
observed affinity of Dectin-Fc for -glucan is similar, 
if not
 
somewhat higher, than that observed for lectin receptors; this
 
may be attributable to the 
dimeric nature of the fusion protein.
 
For example, the interaction of SIGN-R, a major mannose 
receptor
 
on peritoneal macrophages, with terminal mannose epitopes is
 
characterized by a KD of 
9 x 10–6 M (231) while E-selectin, a receptor mediating tethering of granulocytes to the vascular 
membrane via recognition of E-selectin-ligand-1, possesses a
 
KD of 6.2 x 10
–5
 M (232). The Ag-
binding sites of anti-carbohydrate
 
Abs, such as those directed against either Chlamydia or 
Shigella
 
LPS O Ags, possess KD values ranging from 10
–5
 to 10
–6 
M (233) while murine anti-
carbohydrate Ab responses from
 
conjugate vaccines against meningococcemia yielded KD 
estimates
 
ranging from 10
–6
 to 10
–9
 for Ag (235) The affinity
 
of Dectin-Fc for -glucan, thus, 
falls within a range typical
 
for anti-carbohydrate Abs and lectin receptors for their ligands.
  
  
Preopsonization of zymosan with Dectin-Fc enhanced baseline
 
macrophage recognition 
of these particles and this phenotype
 
was lost upon blockade of the primary receptors for murine 
IgG1,
 
Fc RII, and Fc RIII. Our study demonstrates the sufficiency of
 
the Dectin-1 CRD as a 
targeting epitope for particulate -glucan
 
in vitro and is in accordance with evidence suggesting 
that
 
TLR2 and TLR6, receptors that cooperate with dectin-1 and regulate
 
MyD88- and NF- B-
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dependent signaling in response to zymosan,
 
are not required for the actual -glucan recognition 
event mediated
 
by Dectin-1 (254). As anticipated, Dectin-Fc bound to PC cysts,
 
demonstrating 
that the PC cell wall -glucan is accessible and
 
recognized by this fusion protein. Our 
observation is in line
 
with studies demonstrating an abundance of PC -glucan in the
 
inner cyst 
wall  (112) and previous observations that overexpression
 
of the Dectin-1 receptor in RAW 
macrophages enhanced binding
 
and recognition of PC cysts (49). We have previously shown that
 
Dectin-Fc binds A. fumigatus swollen conidia (55) and our current
 
study now extends the 
immunolocalization of Dectin-Fc to PC
 
cysts.
  
Dectin-Fc increased killing of PC by alveolar and elicited peritoneal
 
macrophages and 
such levels were sustained when macrophage Dectin-1
 
receptors and were blocked. Apparent 
efficacy was lost when
 
Fc RII and Fc RIII were additionally blocked, demonstrating that
 
Dectin-
Fc targets PC for degradation through these receptors.
 
The importance of alveolar macrophages 
in PC degradation and
 
clearance is well-documented (47, 55, 255), yet optimal macrophage-
dependent
 
clearance requires coordination with B and T cell-dependent
 
responses against PC, as 
macrophages and other innate cells
 
are ultimately insufficient in the control of infection. The
 
development of a fusion protein capable of recognizing PC -glucan
 
coupled with the capacity 
for Fc R-dependent targeting represents
 
a novel mechanism for the enhancement of baseline 
macrophage
 
effector function against PC, in the absence of B and T cell-dependent
 
immune 
responses against the pathogen.
  
Adenoviral delivery of Dectin-Fc in SCID mice significantly
 
reduced the kinetics of PC 
growth and overall PC burden within
 
the lungs by 28 days postchallenge and led to decreased 
pulmonary
 
LDH and BALF neutrophils, correlates of PC-related lung damage.
 
These findings 
demonstrate that Dectin-Fc promotes PC recognition
 
and clearance in vivo and increases the 
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specificity of the immune
 
response, presumably through enhancement of Fc R-dependent 
clearance
 
mechanisms directed by macrophages. Because the ability of Dectin-Fc
 
to inhibit PC 
growth is most apparent at late stages of PC infection,
 
as innate host clearance mechanisms lose 
their capacity to control
 
PC replication within the lungs, our studies suggest that Dectin-Fc
 
may 
improve the clearance of existing PC lung infections.
  
Though there was significantly altered growth and an overall
 
reduction of PC burden in 
SCID mice treated with Dectin-Fc,
 
the establishment of infection could not be prevented. This
 
observation may be a consequence of the expression pattern and
 
relative exposure of -glucan by 
PC in the context of the lung
 
environment. Although we have shown that PC -glucan can be 
targeted
 
in vitro by macrophages both in this study and in previous work
 
(49), -glucan may not 
be present or sufficiently exposed by
 
the as-yet uncharacterized infectious form(s) of the 
organism,
 
leading to early escape from Dectin-Fc-dependent recognition.
 
In the course of PC 
infection, soluble -glucan is shed into
 
the blood and BALF (256)and this may additionally 
contribute
 
to evasion mechanisms inhibiting -glucan-dependent recognition
 
of PC organisms. 
Further, pulmonary collectins target fungal
 
cellular wall carbohydrates and these may compete 
with Dectin-Fc
 
for binding to PC -glucan. In particular, surfactant protein
 
D (SP-D) targets -
1,6-linked glucan (257) and recognition of
 
these PC cell wall epitopes by SP-D may inhibit 
binding of Dectin-Fc
 
to its primary target, -1,3-linked glucan. Notably, SP-D-deficient
 
mice 
clear PC more rapidly than wild-type mice (74) and while
 
SP-D is capable of binding PC, it 
appears to inhibit macrophage
 
internalization (258), underscoring the advantages of harnessing
 
macrophage effector function in -glucan targeting strategies.
  
Abs and IgG Fc-based targeting molecules directed at fungal
 
cellular wall carbohydrates 
are emerging as important mediators
 
of host defense against a various fungal species. Natural 
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IgG
 
Abs directed against mannan have been shown to enhance complement
 
protein 3 binding to 
C. albicans, through both direct and alternative
 
pathways (259, 260). Others have demonstrated 
that a mannose receptor
 
human IgG1 fusion protein increased internalization of PC organisms
 
by 
human polymorphonuclear cells (261), underscoring the ability
 
of carbohydrate-directed Fc-
fusion proteins to enhance myeloid
 
cell function. In a recent study, a novel vaccine, consisting
 
of 
laminarin conjugated to a diphtheria toxoid carrier, generated
 
-glucan specific IgG that 
protected against vaginal candidiasis
 
as well as lethal hemogenous challenges of C. albicans and 
A.
 
fumigatus in mice (154). Interestingly, as -glucan-specific IgG
 
diminished growth of these 
fungal species in the absence of
 
effector cells in vitro, one mechanism through which these Abs
 
may function is via direct antimicrobial effects. This study
 
demonstrated that high-affinity -
glucan directed IgG, presumably
 
requiring CD4
+
 T cell-dependent B cell costimulation, targeted
 
antigenically conserved -glucan to enhance host clearance of
 
two very different fungal 
pathogens. Our studies demonstrate
 
that an additional fungal pathogen, PC, can be effectively 
targeted
 
via -glucan recognition with an IgG1 Fc-fusion protein, increasing
 
macrophage killing 
of PC organisms and significantly reducing
 
PC burden within the lungs of SCID mice.
  
Models of vaccination against PC have demonstrated that immunity
 
carried by Abs can 
protect CD4
+
 T cell-deficient hosts (97)
 
and strategies to develop Ab responses against PC within 
the
 
actual setting of CD4
+
 T cell deficiency are emerging (57, 92).
 
Targeting PC -glucan with 
Dectin-Fc by passive vaccination,
 
as demonstrated here through adenoviral delivery, may 
complement
 
these evolving approaches. By targeting PC specifically to FcRs
 
on myeloid cells 
such as dendritic cells, Dectin-Fc could potentially
 
improve aspects of PC Ag presentation to 
residual CD4
+
 T cells.
 
Also, as Dectin-Fc recognizes what is thought to be the most
 
inflammatory 
component of fungal cell wall (250) and recognition
 
of PC by dectin-1 leads to the elicitation of 
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neutrophil chemotactic
 
factors such as MIP-2 (49), this fusion protein could function
 
to limit 
potentially detrimental host responses to PC pneumonia,
 
such as excessive neutrophil recruitment 
into the lungs (244).
  
Our work supports the concept that Ab-dependent targeting of
 
-glucan may be a 
promising strategy against PC infection in
 
the immunocompromised host. Continued effort to 
understand the
 
potential of fungal carbohydrates as targets of protective immunity,
 
or as Ags in 
the generation of protective immunity, may inform
 
on optimal vaccination strategies against PC 
pneumonia. 
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3.0 IDENTIFICATION OF NATURAL IGM ANTIBODIES TARGETING CONSERVED 
FUNGAL CELL WALL CARBOHYDRATES AND FUNCTIONS OF NATURAL 
ANTIBODIES AND IGM IN HOST DEFENSE AGAINST PNEUMOCYSTIS 
 
 
 
3.1 INTRODUCTION 
 
Opportunisitic fungal pathogens, such as Pneumocystis jirovecii, cause severe, often fatal 
diseases among immunosuppressed individuals. As host defense against fungi is significantly 
influenced by the functions of CD4+ T cells, and susceptibility to fungal pathogens largely 
correlates with deficiencies in cell-mediated immunity, the functions of B cells and antibodies in 
host defense against fungi have been considered to be of less relevance.    However, host defense 
against Pneumocystis pneumonia requires the concerted function of CD4+ T cells and B cells in 
murine models of infection (43, 91).  While antibody production is not absolutely required for 
host defense against Pneumocystis pneumonia (96), antibodies produced in vaccinated murine 
hosts are capable of significantly inhibiting the growth of infection (82, 97, 167), notably without 
hyperinflammatory responses associated with CD4+ T cell-dependent clearance (82), and can 
enhance alveolar macrophage effector function against Pneumocystis organisms (49, 92).     
However, the specificites of protective antibodies, the relevance and function of particular 
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isotypes, and their mechanisms of enhancing Pneumocystis degradation or inhibiting 
Pneumocystis growth are not well characterized.  
Fungal pathogens contain conserved cell wall carbohydrates β-glucan, chitin, and mannan 
that
 
may be targets of multiple host defense pathways.  Pneumocystis sp., while atypical fungi in 
a number of structural and biochemical aspects, contain these conserved fungal cell wall 
carbohydrates within their cell walls as demonstrated by immunohistochemical and biochemical 
studies (111-113, 117, 137, 262).   Additionally, some of these carbohydrates have been 
investigated for their importance in innate recognition by pattern recognition receptors such as 
the mannose receptor (48), and the β-glucan receptors dectin-1 (49, 138) and lactosylceramide 
CDw17 (63).  The abundance of these antigens in fungi is underscored by evidence 
demonstrating that quantities of β-glucan in the serum are significantly elevated in patients 
infected with Pneumocystis jirovecii and other opportunistic fungal pathogens (256, 263, 264).  
However, the possibility that the fungal cell wall carbohydrates of Pneumocystis are targeted by 
antibodies has not been investigated.  
 Natural antibodies are predominantly of the IgM isotype, generated without the 
requirement for exogenous antigenic stimulation, and are primarily produced by the B-1 B cell 
subset.  Here, we present evidence for the existence of natural antibodies targeting fungal cell 
wall carbohydrates, and examine the role of natural antibodies and the IgM isotype in host 
defense against the pulmonary mucosal infection Pneumocystis.   
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3.2 MATERIALS AND METHODS 
3.2.1 Mice 
BALB/c mice, C57BL/6J mice, and BL/6.scid mice, 6-9 weeks in age, were purchased from 
Jackson Immunoresearch Laboratories, and BALB/c.scid mice 6-9 weeks of age were obtained 
from Taconic Farms.
 
  Mice with a deficiency in the ability to secrete IgM (sIgM (-/-)), but able 
to express the membrane bound form of IgM, on the C57/BL6J background were obtained from 
M. Diamond (Washington University, St. Louis) and were previously described (265). The 
parent strain was originally developed by Jianzhu Chen (MIT, Cambridge) and Michael Carroll 
(Harvard Medical School, Boston), and are described (196, 266).  Mice were age and sex 
matched within individual studies. All mice were maintained in a specific
 
pathogen-free 
environment in microisolator cages within
 
the animal care facilities of Children's Hospital of 
Pittsburgh
 
under protocols reviewed and approved by the Animal Research
 
and Care Committee. 
Mice were provided with water and food ad
 
libitum and received 12-h light/dark cycles.   
3.2.2 Serum Samples 
 
Serum samples from channel catfish, Ictalurus punctatus, were obtained from Eva Bengten 
(University of Mississippi).  Catfish (2kg) were obtained from the wild by angling (Ross Barnett 
reservoir, MS) or from USDA-ARS Stoneville, MS, and maintained in individual tanks until 
bleeding by caudal venipuncture.  Catfish, among the earliest evolved of jawed vertebrates and 
hence among the first animals with adaptive immune systems, are telosts (bony fish) and contain 
a tetrameric homolog of IgM as well as an IgD homolog in the serum.   
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Serum samples from C57BL/6 mice reared in germ-free conditions were obtained from 
Scott Plevy (University of North Carolina); and Daniel Peterson and Jeffrey Gordon 
(Washington University).    Mice reared in germ-free conditions were fed standard autoclavable 
chow and bled at 3-4 months of age.  For longitudinal studies with mice, small volumes of blood 
were collected from the periorbital sinus.   At terminal sacrifice of mice, blood was obtained 
from caudal venipuncture under anesthesia.   For all studies, serum was isolated from collected 
blood by use of serum separator tubes.   
Human cord blood serum was collected from full-term newborn patients after informed 
parental consent at Magee-Women’s Hospital, Pittsburgh, according to University of Pittsburgh 
Institutional Review Board guidelines.     
  Pooled serum for adoptive serum transfer studies was obtained from specific-pathogen 
free mice BALB/c or BALB/c.scid mice aged 6-8 weeks, via the caudal vena cava 
exsanguination, heated for 1 hr at 56 degrees C° to inactivate complement proteins, and stored at 
-80 until use.    
 
3.2.3 Detection of antibody responses against Beta-glucan, chitin/chitosan, mannan, and 
Pneumocystis 
 
Pneumocystis (PC) antigen was prepared as previously described (57) and derived from the lungs 
of infected BALB/c.scid and C57BL/6.scid mice by differential centrifugation to derive 
organisms, which were then sonicated.  PC antigen was normalized to protein concentration after 
sonication of organisms.  PC antigen was dissolved in carbonate buffer, pH 9.5, and seeded to 
Nunc-Polysorp 96 well plates at a concentration of 1 µg/mL.   Laminarin (Sigma), derived from 
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the brown algae Laminaria digitata, is composed primarily of β-1,3 linked glucan, the 
predominant β-glucan linkage found in fungal cell walls (102).  Medium molecular weight 
chitosan (Sigma), derived from crab shells, is polymer of chitin that is 75-85% deacetylated.  
Chitosan/chitin was dissolved in 2% acetic acid/PBS (v/v) at a concentration of 0.5-1mg/mL and 
thereafter diluted into PBS to final quantity of 25 µg/mL.   α-1,6 linked mannan (Sigma) derived 
from Saccharomyces cerevesiae was dissolved in PBS.  Carbohydrate antigens were seeded at a 
concentration of 25 µg/mL to Nunc-Polysorp 96 well plates and kept overnight at 4 degrees.  
Plates were blocked in 10% FBS and 5% Milk in PBS, and blocking buffer was used as a 
dilution buffer for serum and secondary antibodies.  Sera was applied in serial dilutions. BALF 
was run neat.  HRP-conjugated secondary antibodies against murine IgG, IgA, and IgM; and 
human IgM were obtained from Santa Cruz Biotechnology and Southern Biotech.  Catfish IgM 
was detected with the monoclonal antibody 9E1 (murine IgG1), a kind gift from Eva Bengten, 
and thereafter probed with anti-mouse IgG1-HRP.  Plates were developed with TMB and the 
reaction was quenched with 2N sulfuric acid.  Background for all ELISAs was typically less than 
.05 at an OD of 450 nM. Estimated endpoint titer was determined by assessing the lowest 
concentration at which signal was obtained that was 2 times higher than background.  If this 
value fell between 2 concentrations, then the titer was approximated relative to the numerical 
distance between the reading of the upper and lower concentration.   Optical density values were 
reported at 450 nM, absolute or with background subtracted, as indicated per graph.   
 
3.2.4 ELISPOT for detection of antibody-secreting cells specific for beta-glucan 
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96-well plate (Millipore, MSIPS4W10) nitrocellulose membranes were coated with laminarin 
dissolved in PBS (80 µg/mL) overnight.  Lung and splenic tissue were collected from naïve male 
BALB/c mice were crushed with a syringe plunger over a 70-µm pore size cell strainer to obtain
 
a single-cell suspension.  Additionally cells were collected from bone marrow and peritoneal 
lavage.  For all tissues, red blood cells were lysed with NH4Cl/Tris solution
 
for 5 min on ice and 
remaining cells were enumerated.  Plates were blocked with complete tissue culture media 
consisting of  RPMI 1640 medium, 10% fetal bovine serum, 2 mM L-glutamine,
 
100 mg/ml 
streptomycin, and 100 units/ml penicillin, and 2-ME at 5 x 10
-5
 M, and cells were seeded to 
plates in serial dilution.  After two days, cells were removed, and bound IgM reactive with beta-
glucan was identified with goat anti-mouse IgM-AP and detected with NBT/BCIP.   An 
ELISPOT reader was used to enumerate spots (Cellular Technology).   
 
3.2.5 P. carinii f. sp. muris isolate 
The Pneumocystis inoculum was prepared as previously described (42, 89).
 
Briefly, B6.scid and 
BALB/c.scid mice with Pneumocystis pneumonia were injected with a
 
lethal dose of 
ketamine/xylazine and the lungs were aseptically
 
removed and frozen in 1 ml of PBS at –80°C. 
Lungs
 
were mechanically dissociated in sterile PBS, filtered through
 
sterile gauze, and pelleted at 
500 x g for 10 min at 4°C. The pellet was resuspended in sterile PBS and a 1/5 dilution was 
stained by a modified Giemsa stain (Diff-Quik; Baxter).
 
The number of Pneumocystis cysts was 
quantified microscopically and the
 
inoculum concentration was adjusted to 2 x 106 cysts/ml. 
Gram
 
stains were performed on the inoculum preparations to exclude
 
contamination with 
bacteria.  
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3.2.6 Flow cytometric analyses of natural antibody binding to fungi 
Zymosan particles were obtained from Molecular Probes.  Aspergillus fumigatus isolate 13073 
was obtained from ATCC, was maintained on potato agar for 5 days, then harvested into 
PBS/.1% Tween 20 and passed over a 40-µm pore size cell strainer to remove hyphal fragments.   
Organisms were maintained as dormant resting conidia in PBS solution in an airtight conical at 
4°C until use.  Aspergillus fumigatus conidia were matured into growth phase by culture in 
RPMI at 37° C for 6 hours, where they were thereafter killed by incubation at 100° C for 15 
minutes to arrest growth.  Additionally a cyst enriched preparation was derived from the 
Pneumocystis inoculum via sucrose gradient centrifugation, as described by Lim et al ((267).   
400,000 Cells/particles were incubated with serum from BALB/c or BALB/c.scid mice for 3 
hours, at a 1:4 dilution in PBS.   After pelleting and washing, cells were incubated with goat anti-
mouse IgG or goat anti-mouse IgM antibodies conjugated to Cy3 (Invitrogen) diluted in 2% BSA 
solution.  Cell/particle fluorescence was assayed with FACSAria (BD Biosciences).  
3.2.7 Pneumocystis infection 
Mice were anesthetized and intratracheally challenged with the cyst enumerated preparation of 2 
x 10
5
 Pneumocystis cysts in 100 µL PBS.   At various timepoints after challenge, mice were 
sacrificed and right lung was homogenized in 1 mL TRIzol, and saved at   –80°C for later 
analysis of Pneumocystis organism burden via real-time PCR.  The left lung was homogenized in 
1 mL of PBS containing 0.05% Triton X and complete protease inhibitor (Roche).
  
Lung 
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homogenates were centrifuged at 13,000 x g for 10 min, and supernatant was stored at –80°C for 
later analysis of pulmonary cytokines and chemokines.   
3.2.8 Adoptive serum transfer  
BALB/c.scid mice were administered 400 µL of pooled serum from either specific pathogen free 
BALB/c mice or BALB/c.scid mice aged 7-9 weeks; serum was given 100µL intravenously and 
300 µL intraperitoneally.   One hour thereafter, mice were challenged with Pneumocystis 
intratracheally and infection was allowed to proceed until sacrifice.   
3.2.9 BALF analyses 
Fluid from the lower respiratory tract was obtained by bronchoalveolar
 
lavage of mice 
anesthetized with i.p. ketamine/xylazine as described
 
previously (89). Only 1 mL of BALF was 
collected from mice using sterile PBS.  Lavage fluids were centrifuged at 350 x g and 
supernatant was stored at –80°C until
 
use. The cell pellet derived from centrifugation was 
cytospun onto slides, stained
 
by modified Giemsa, and analyzed for leukocyte differential.
 
 
 
3.2.10 Real-time PCR analysis of Pneumocystis infection 
Total RNA was isolated from the right lung of infected mice
 
by a single-step method using 
TRIzol reagent (Invitrogen Life
 
Technologies) as per manufacturer’s instructions. Thereafter,
 
RNA was transcribed to cDNA and real-time PCR was performed
 
as previously described; copy 
numbers were quantified against
 
a standard curve of known PC rRNA copy numbers (57). This
 
assay has a correlation coefficient of 0.98 with PC rRNA copy
 
numbers.  
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3.2.11 Cytokine analysis 
Lung homogenate samples were analyzed for protein
 
levels of 22 cytokines, including IL-1α, IL-
1β, KC, MCP-1, TNF-α, G-CSF, IL-2, IL-6, IL-17, IFN-γ, IL-9, IL-5, MIP-1α, IL-10 using a 
Luminex multiplex suspension cytokine array according to the manufacturer’s
 
instructions 
(Linco/Millipore). The data were analyzed using Bio-Plex Manager
 
software.   
3.2.12 Intratracheal Zymosan challenge and trafficking experiment 
sIgM (-/-) or C57/BL/6 mice were intratracheally challenged with 500 µg zymosan covalently 
linked to FITC, in a volume of 50 µL (Molecular Probes).  18 hours after challenge, mice were 
sacrificed, and mediastinal lymph nodes were collected and dissociated into single cell 
suspensions by dispersing through a 70-µm pore size cell strainer.  Additionally, lungs were 
collected, digested with 25 U/ml DNase and 1 mg/ml collagenase A for 30 minutes at 37° C.   
Cells were then passed through 70-µm pore size cell strainer, and RBC’s were lysed with 
NH4Cl/Tris solution
 
for 5 min on ice.  Lymph nodes and lungs were studied individually. Cells 
were stained with CD11c-APC (BD-Pharmingen) to identify antigen presenting cells in the 
lymph node and lungs.   Cells were studied with FACSAria (BD Biosciences).  
3.2.13 In Vitro Lymph Node Restimulation  
Fourteen days after Pneumocystis challenge, individual mediastinal lymph nodes from sIgM (-/-) 
mice and control C57BL/6 mice were dissected from the lungs, teased apart, and placed into 96 
well plate containing 200 µL of complete media.  Lymph node cells were restimulated with an 
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enumerated 40,000 cysts from the Pneumocystis inoculum.  Three days after seeding, lymph 
node cells were pelleted, and supernatants were collected and stored at -80° C until later luminex 
analysis.   
3.2.14 IL-5, IL-17, and IFN-γ ELISPOT 
Fourteen days after Pneumocystis challenge, individual mediastinal lymph nodes from sIgM (-/-) 
mice and control C57BL/6 mice were dissected, teased apart, and strained into single cell 
suspensions by pressing over a 70 -µm pore size cell strainer and enumerated, and placed into 96 
well nitrocellulose membrane plate containing 100 µL complete media for 2 days.   Additionally 
28 days after infection, lungs from mice sIgM (-/-) and wt mice were collected, and digested with 
25 U/ml DNase and 1 mg/ml collagenase A for 30 minutes at 37° C.   Cells were then passed 
through 70-µm pore size cell strainer, RBC’s were lysed, and cells enumerated and placed into 
culture under the same conditions for lymph node cells.    IL-5 (eBiosciences), IFN-γ (R&D), 
and IL-17 (R&D) ELISPOT kits were utilized and the assays were performed according to the 
manufacturer’s instructions.  To assess intrinsic numbers of Pneumocystis primed cells secreting 
IL-5, IL-17, and IFN-γ in the draining lymph node, without potentially expanding the population, 
cells were not restimulated with antigen.  An ELISPOT reader was used to determine spot 
forming units (Cellular Technology).    
3.2.15 Statistical Analysis 
Data were analyzed using GraphPad statistical software. Comparisons
 
between groups were 
made
 
with the Student t test or Mann-Whitney U test. Significance was accepted at a value of p < 
0.05. 
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3.3 RESULTS 
 
3.3.1 High quantities of IgM antibodies targeting fungal cell wall carbohydrates observed 
in mice prior to fungal pathogen challenge 
To assess antibody responses against fungal cell wall carbohydrates induced as a consequence of 
Pneumocystis exposure, BALB/c mice were challenged with Pneumocystis intratracheally, and 
immunoglobulin responses were monitored prior to challenge and followed over time.   
Unexpectedly, we noticed high quantities of IgM, reactive with laminarin, a primarily β-1,3 
linked glucan, and chitosan/chitin, a polymer of 75-85% deacetylated chitin, prior to 
Pneumocystis challenge (Figure 8a).   Of note, IgM in the serum was not reactive with α-1,6 
linked mannan.  Titers of IgM against β-glucan and chitosan/chitin rapidly enhanced through two 
days after challenge, and subsided to approach baseline levels one week after exposure to 
Pneumocystis.  These observations demonstrate that a resident population of B cells is 
continually, spontaneously secreting IgM reactive with beta-glucan and chitosan/chitin.   
 
3.3.2 IgM targeting β-glucan and chitosan/chitin are found in diverse species and do not 
require microbial stimulation for their production 
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As IgM specificities targeting β-glucan and chitosan/chitin are present in the serum of mice 
reared in specific pathogen free conditions, we questioned whether adventitious exposure to 
environmental pathogens, or colonization of the gut by bacteria or fungal organisms, for 
example, might be inducing the differentiation of B cells producing these antibodies.  Serum 
from age-matched C57BL/6 mice reared in germ-free conditions was compared to serum from 
mice reared in specific pathogen free conditions for quantities of IgM targeting beta-glucan and 
chitosan/chitin (Figure 8b).   The particular specificities were present at essentially equivalent 
concentrations in the germ-free and specific pathogen free mice, suggesting that these antibodies 
might be natural antibodies, produced in the absence of exogenous microbial stimulation.    Since 
natural antibodies have been demonstrated to play a critical role in host defense against infection, 
likely acting at the very earliest moments after pathogen exposure (191), it is hypothesized that 
natural antibody specificities may have been selected over evolutionary time partially as a 
function of their ability to defend against infection.  Hence, we investigated whether these 
antibody specificities might be present in some of the earliest evolved animals with adaptive 
immune systems.   We probed the serum of channel catfish, Ictalurus punctatus, which contains 
a tetrameric homolog of IgM, for IgM reactivity against beta-glucan and chitosan/chitin.    
Antibodies with these reactivities were also present in catfish serum, with quantities of β-glucan 
specific IgM higher than chitosan/chitin specific IgM (Figure 8c).    Finally, to explore whether 
these IgM specificities are present in the human preimmune repertoire we assessed human cord 
blood for reactivity against these carbohydrates.  Since IgM does not cross the placenta, IgM 
present in human cord blood represents specificities generated in the preimmune repertoire by 
the fetus.  We observed IgM targeting β-glucan in three of four patients, and IgM targeting 
chitosan/chitin in four of four patients; none of the patients had IgM antibodies reactive with 
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mannan (data not shown).    Of responders, IgM against β-glucan and chitosan/chitin was present 
though at relatively low concentrations, with β-glucan specific IgM demonstrating greater 
average reactivity than chitosan specific IgM (Figure 8d).  Hence, IgM specifities exist that 
target important structural carbohydrates present in most all fungal cell walls, and these 
specificities are conserved across multiple species, and apparently do not require exogenous 
microbial stimulation for their production.   
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Figure 8:  IgM antibodies targeting conserved carbohydrates of fungal cell walls among diverse species, and in the 
absence of exogenous microbial stimulation.  Serum samples were used in an ELISA against laminarin (a primarily β-1,3 
linked glucan) and chitosan/chitin seeded at 25 µg/mL.  Detection antibodies were HRP conjugates and plates were 
developed with TMB and reactions quenched with 2N H2SO4.    Error bars represent standard error of the mean.  (A) 
Specific pathogen free BALB/c mice were challenged with Pneumocystis intratracheally and serum was assessed by ELISA 
for quantities of IgM reactive with beta-glucan and chitosan/chitin over time.  Bound antibody was detected with anti-
mouse IgM-HRP. Estimated endpoint titers are presented.  (B)  Serum from age-matched C57BL/6 mice reared in germ-free 
conditions or specific pathogen free (SPF, control) conditions was assessed for ELISA reactivity against beta-glucan and 
chitosan/chitin.  Serum was diluted 1:30 and bound IgM was detected with anti-mouse IgM-HRP.  Optical densities were 
determined at 450 nM, after subtraction of background.  (C)  Serum from channel catfish (Ictalurus punctatus) was studied 
for ELISA reactivity against beta-glucan and chitosan/chitin.  Bound IgM was detected with a mouse anti-catifish IgM, 
which was then identified with anti-mouse IgG1-HRP.  Optical densities were determined at 450 nM, after subtraction of 
background.   (D) Among responders, human cord blood IgM was studied for reactivity against beta-glucan.  Bound IgM 
was detected with anti-human IgM HRP and average OD is presented.  Background OD at 450 nM was .049.  (E) 
Estimated endpoint titer of concentrations of human cord blood IgM targeting conserved carbohydrates of fungal cell walls 
among responders.  
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3.3.3  B cells spontaneously producing IgM targeting β-glucan predominate in the spleen 
 
Given the observation of natural IgMs targeting conserved fungal cell wall carbohydrates in the 
serum of specific pathogen free mice, we assessed the localization of B cells spontaneously 
producing IgM targeting β-glucan.    B-1 B cells are considered the predominant B cell subset 
involved in the production of natural IgM antibodies (169), and in mice are present in peritoneal 
and pleural spaces.   Hence, using specific pathogen free BALB/c mice, we compared cells 
derived from peritoneal lavage, to cells from the spleen, bone marrow and the lung, for the 
ability to produce IgM reactive with β-glucan by ELISPOT.  We observed that the highest 
quantities of cells producing IgM reactive with β-glucan are present in the spleen, followed 
thereafter by the bone marrow (Figure 9).      It has been identified that peritoneal B-1 cells do 
not spontaneously secrete natural antibodies directly from the peritoneum (184), but rather 
migrate into the spleen and secondary lymphoid organs upon stimulation by antigen or TLR 
ligands, (188, 189, 268), where they differentiate into antibody secreting cells.   Our data support 
studies suggesting that the spleen is a common site for natural antibody secreting cells, such as 
the natural antibodies targeting conserved fungal cell wall carbohydrates.   
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Figure 9: Site of antibody secreting cells spontaneously producing IgM specific 
for β-glucan.   ELISPOT was performed to detect individual IgM secreting cells 
secreting antibody reactive with β-glucan in various tissues of individual mice.  3 mice 
per were evaluated per tissue.  The results are representative of two similar 
experiments.  Mean +/- SEM are presented.   
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3.3.4 Natural antibodies bind fungal cell walls 
 
Given the observation that natural IgM antibodies exist in the serum of multiple host species 
with specificity for beta-glucan and chitosan/chitin, we investigated whether natural antibodies, 
present in specific pathogen free mice, are reactive with diverse fungal species cell walls.  We 
incubated Pneumocystis organisms, derived from a cyst enriched preparation, with diluted serum 
from either BALB/c.scid mice or SPF naïve BALB/c mice, and assessed for binding of natural 
IgM.  We observed high quantities of natural IgM binding to Pneumocystis (Figure 10a) relative 
to natural IgG binding (Figure 11a).   We then compared binding affinity of natural IgM for 
zymosan, a particulate derived from the cell wall of Saccharomyces cervesiae, primarly 
consisting of polysaccharides, of which β-1,3 glucan predominates.   Zymosan was also highly 
reactive with IgM present in specific pathogen free mice (Figure 10b).  Finally, we compared the 
ability of natural IgM to bind another opportunistic pulmonary fungal pathogen, Aspergillus 
fumigatus.  Resting conidia were notably poorly reactive with natural IgM, while conidia that 
were matured to a swollen, prehyphal state by incubation at 37° C for 6h, bound significant 
quantities of IgM (Figure 10c).  Additionally, swollen conidia had significantly higher reactivity 
with natural IgM compared to natural IgG (Figure 11b).  These data suggest natural IgM 
antibodies are a common opsonin for diverse species of fungi.  As TLR2, TLR4, and dectin-1 
mediate non-opsonic recognition of zymosan by macrophages, natural IgM are also reactive with 
zymosan, natural IgM may recognize ligands similar to those recognized by pattern recognition 
receptors.  Additionally, specific ligands targeted by natural antibodies may be more abundant or 
accessible during different stages of the fungal life cycle.    
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Figure 10: Assessment of natural IgM binding to fungal cell walls.  (A) Pneumocystis 
organisms from a cyst enriched preparation, (B) Zymosan particles, (C) and Aspergillus 
fumigatus resting (solid lines) and swollen conidia (dotted lines) were incubated with serum 
from naïve BALB/c.scid or BALB/c mice (Dilution 1:4).   Cells/particles were washed, and 
incubated with anti mouse-IgM Cy3 and analyzed by flow cytometry.  Red lines denote 
incubation with BALB/c serum, black lines denote incubation with BALB/c.scid serum.   
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Figure 11: Assessment of natural Ig isotype specificity in fungal cell wall 
recognition.  Pneumocystis organisms from a cyst enriched preparation (A) and 
Aspergillus fumigatus swollen conidia (B) were incubated with serum from naïve 
BALB.scid or BALB/c mice (Dilution 1:4).   Cells/particles were washed, and incubated 
with anti-mouse IgG or anti mouse-IgM Cy3 and analyzed by flow cytometry.  Red 
lines denote IgM reactivity, green lines denote IgG reactivity.  
B A 
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3.3.5 Impaired growth of Pneumocystis infection in the lung, and enhancement of 
pulmonary IL-1a and IL-6 as a consequence of natural antibodies 
 
To assess the relevance of natural antibodies in host defense against infection, we compared 
serum derived from wt naïve BALB/c mice, containing innate IgM  reactive with fungi such as 
Pneumocystis, to immunoglobulin-free serum from BALB/c.scid mice, in the ability to affect the 
growth of Pneumocystis organisms in the lungs of susceptible mice.     BALB/c.scid mice were 
transferred with complement-inactivated serum from host source, administered in a combination 
of intravenous and intraperitoneal routes, and one hour later challenged with Pneumocystis 
intratracheally.    Both intravenous and intraperitoneal routes were utilized for administration of 
high quantities of serum, as such a combination was observed to be efficiacious in enhancing 
survival in murine VSV infection by Ochsenbein et al (190).   We observed that serum 
containing natural antibodies suppressed the growth of Pneumocystis infection, as observed at 5 
and 14 days after infection (Figure 12a, Figure 12b).   But rather than simply neutralizing 
pathogen to facilitate clearance, as one might expect as a primary effector function of IgM, the 
presence of wt naïve serum enhanced inflammatory responses in the lungs of infected mice, 
suggesting that immune complex formation led to enhancement of antigen presentation.   
Quantities of IL-1α, IL-6, G-CSF, and IL-2 were elevated in the lung homogenates of mice 
receiving wt naïve serum compared to mice receiving SCID serum (Figure 13).   IL-6 and IL-1α, 
in particular, had impaired kinetics of production in mice receiving SCID serum.  Of note, 
signaling at the IL-1 receptor has been demonstrated to be required for host defense against 
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Pneumocystis pneumonia (85)  and IL-6 is implicated in diminishing numbers of neutrophils and 
CD8+ T cells recruited into the lungs after Pneumocystis challenge (269), hence natural antibody 
containing serum enhanced the production of these cytokines important in the evolving host 
response to infection.  We hypothesize that natural antibodies enhance antigen presentation, 
leading to increased clearance and increased production of host defense related cytokines.  We 
demonstrate that host defense against a mucosal fungal infection is significantly influenced by 
the presence of naïve serum containing natural antibodies.   
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Figure 12:  Pathogen burden in the lungs of SCID mice transferred with naïve serum 
and challenged with Pneumocystis.   Cohorts of 4-5 SCID mice received a total of 400 µL 
serum (100µL of serum intravenously and 300µL of serum intraperitoneally), from either 
specific pathogen free wt mice or SCID mice. Mice were then challenged with Pneumocystis 
intratracheally.  (A) Pathogen burden was determined at 5 and (B) 14 days thereafter, by 
assessing lungs for total PC mtLSU subunit copy numbers. Boxes represent the interquartile 
range of data between the 25th and 75th percentiles and whiskers represent the upper and 
lower limits of the data.  The median is represented by the dividing line within the box.  * 
denotes p<. 05, ** denotes p<.01.  Day 5 study was independently repeated 3 times with 
similar results.   
A 
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Figure 13:  Inflammatory responses in the lungs of SCID mice transferred with specific pathogen free 
serum and challenged with Pneumocystis.  4-5 mice per group were evaluated per timepoint.  Lung 
homogenates from mice described in FIGURE 5 were evaluated for quantities of (A) IL-6 , (B) IL-1a (C) G-CSF 
and (D) IL-2 as determined by luminex assay.   (E) Kinetics of IL-1a induction  (F) Kinetics of IL-6 induction.  
Error bars represent SEM.  * indicates P<.05 
A B 
C D 
F E 
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3.3.6 Natural antibodies limit pulmonary neutrophil recruitment in the setting of acute 
Pneumocystis challenge 
 
Our group and others have demonstrated that intratracheal challenge of SCID or wild type mice 
with Pneumocystis leads to rapid clearance of the inoculum (47, 97, 270), thereafter followed by 
growth of infection, which wild type mice ultimately clear but SCID mice ultimately succumb to.   
We sought to assess whether natural antibodies influence the process of rapid clearance of the 
majority of the inoculum in the host response to acute Pneumocystis challenge.   SCID mice 
were transferred with either naïve wt or SCID sera, then challenged with Pneumocystis 
intratracheally, and assessed for pathogen burden, neutrophil recruitment into the airspaces, and 
the production of inflammatory cytokines and chemokines in the lungs.   We observed no 
difference in pathogen burden 20 hours after challenge, yet by 3 days mice receiving wt naïve 
serum begin to show some level of protection against Pneumocystis, and by 5 days the growth of 
the infection in the lungs is impaired (Figure 14a), which continues into 14 days (Figure 12b).   
Interestingly, while there was no difference in pathogen burden at 20 hours, there was a 
significant decrease in the frequencies of neutrophils recruited into the lungs at 20 hours and 3 
days, in mice receiving naïve wt serum (Figure 14b).  In relation to the diminished frequencies of 
neutrophils observed in the mice receiving wt sera, levels of IL-1β (Figure 14c), TNF-α (Figure 
14d), KC/CXCL1 (Figure 14e), and MCP-1/CCL2 (Figure 14f) in lung homogenates were 
decreased.    The presence of high quantities of neutrophils recruited into the airways does not 
positively influence the rapid clearance of Pneumocystis, underscoring the observation that this 
function is primarily driven by alveolar macrophages (47).  We conclude that while naïve serum 
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containing natural antibodies does not appear to enhance the rapid clearance of Pneumocystis 
organisms after acute intratracheal challenge, it significantly diminishes relative neutrophil 
recruitment into the airways, hence acts at the very earliest timepoints after Pneumocystis 
challenge.  We hypothesize that binding of natural antibodies to the surface of Pneumocystis 
organisms limits inflammation guided by the resident innate effector cells in the lung, alveolar 
macrophages and the alveolar epithelium, which produce chemokines and cytokines driving 
neutrophil recruitment.  As natural antibody specificities target β-glucan, and isolated β-glucan is 
inflammatory in the lungs (137), natural antibodies may also bind shed β-glucan from degraded 
organisms, shielding it from recognition by innate inflammatory cells.  Thus, it appears that in 
the setting of acute challenge, natural antibodies act at the very earliest aspects of antigen 
presentation, thereby limiting neutrophil recruitment into the lungs, while at intermediate stages 
of infection enhance Pneumocystis clearance and promote the production of cytokines involved 
in host defense processes.   
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Figure 14: Influence of serum containing natural antibodies on early clearance of Pneumocystis and early 
inflammatory responses.  SCID mice were transferred with naïve specific pathogen free BALB/c or SCID serum, 
then challenged with Pneumocystis intratracheally.  4-5 mice per group were evaluated per timepoint.  (A) The 
presence of Pneumocystis organisms during stages of early clearance was determined by assessing PC mtLSU copy 
numbers over time. p value or NS indicated.  (B)  Percent neutrophils in cells obtained from BALF  (C) Quantities of 
TNF-a, (D) Quantities of IL-1b, (E) Quantities of MCP-1, (F) Quantities of KC observed in lung homogenate as 
determined by luminex assay.   Error bars represent SEM.  
D 
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3.3.7  Mice with a deficiency in the ability to secrete IgM have increased burden of 
Pneumocystis in the lungs and diminished IL-1a and IL-6 levels in the lungs 
 
As we have demonstrated the presence of natural IgM antibodies targeting conserved 
carbohydrates of fungal cell walls, and as natural antibodies, which are predominantly of the IgM 
isotype, inhibit the growth of Pneumocystis in the lungs, we sought to assess aspects of host 
defense against Pneumocystis in mice unable to secrete IgM.   Mutant mice that are unable to 
secrete IgM but normally express B cell surface IgM and IgD, and isotype class switch normally 
to secrete other immunoglobulin isotypes, have been previously reported and characterized (196, 
265, 266).    Using C57/BL6 mice with this mutation, sIgM (-/-), we compared their relative 
ability to clear Pneumocystis infection to wt mice at an intermediate timepoint, fourteen days 
after intratracheal challenge.  We observed that sIgM (-/-) mice have impaired clearance of 
Pneumocystis relative to wt mice (Figure 15).   Additionally, these mice have diminished 
production of IL-1a and IL-6 (Figure 16) in the lungs, cytokines that were notably enhanced by 
the transfer of naïve serum containing natural antibodies (Figure 13) in SCID mice challenged 
with Pneumocystis.  Interestingly, the sIgM (-/-) mice additionally promoted production of IL-10 
in the lungs, a cytokine which inhibits the kinetics of Pneumocystis clearance (271).  Hence, we 
conclude that IgM antibodies have an important role in host defense at early stages of 
Pneumocystis infection, presumably in the formation of immune complexes that influence 
antigen presentation, and that the natural IgM antibodies are important for early IL-1a and IL-6 
responses from innate cells against this opportunistic fungal pathogen in vivo.    
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Figure 15:  Impaired clearance of Pneumocystis from the lungs of C57/BL6J sIgM 
(-/-) mice.   wt or sIgM (-/-) mice were challenged with Pneumocystis intratracheally 
and assessed for pathogen burden 14 days after infection by real-time PCR assessment 
of PC mtLSU copy numbers.    Individual mice are represented by the symbols, 4-5 
mice per group were evaluated per timepoint, and data are pooled from two independent 
experiments.  ** indicates P<.01 
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Figure 16:  Importance of the IgM isotype for the production of pulmonary 
proinflammatory cytokines after Pneumocystis challenge.  Studying mice as presented in 
Figure 15, lung homogenates were assessed for quantities of (A)IL-1α, (B) IL-6 and (C) IL-10  by 
luminex assay.  Individual mice are represented by symbols. * indicates P<.05.   
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3.3.8 sIgM (-/-) mice have impaired trafficking of CD11c+ cells carrying zymosan to 
lymph nodes, but normal recognition in the lungs by CD11c+ cells 
 
We have demonstrated that serum containing natural IgM antibodies bind fungi and inhibit the 
growth of Pneumocystis infection in the lungs of susceptible mice, and that mice lacking secreted 
IgM, the primary isotype for natural antibodies, have impaired clearance of Pneumocystis in the 
lungs as observed at intermediate timepoints after infection.  Additionally, natural antibodies 
regulate inflammatory responses against Pneumocystis, inhibiting early pulmonary chemokine 
induction, while later enhancing the production of IL-1α and IL-6 in the lungs.   As natural IgM 
appears to alter the manner in which Pneumocystis antigen presentation is occurring, we sought 
to assess whether mice deficient in secreted IgM have impaired presentation of fungal cell wall 
antigen to CD11c+ APCs in vivo.  Wt or sIgM (-/-) mice were intratracheally challenged with 
FITC-zymosan and 16 hours later assessed for quantities of CD11c+ cells that were FITC 
positive as a function of zymosan endocytosis, in the lungs and in draining lymph nodes.  In the 
lungs, we observed that almost all CD11c+ cells were FITC positive after FITC-zymosan 
challenge, and equivalent quantities of FITC+ CD11c+ cells were observed in wild type 
compared to sIgM (-/-) mice (Figure 17), suggesting that secreted IgM is not important for 
CD11c+ cell recognition of zymosan in the lungs.   Additionally observed, mice lacking sIgM 
had greater quantities of FITC-zymosan in CD11c- cell populations in the lungs.  However, 
when we compared quantities of CD11c+ cells in the mediastinal draining lymph node, we 
observed that the presence of FITC+ CD11c+ cells was somewhat diminished in sIgM (-/-) mice, 
suggesting that the migration of CD11c+ antigen presenting cells to the lymph nodes is impaired 
in the absence of secreted IgM (Figure 18).  These data suggest that IgM coated zymosan guides 
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the recognition of antigen through pathways that do not as readily mature dendritic cells for 
migration to lymph nodes, and that natural IgMs are involved in the very earliest aspects of 
fungal carbohydrate antigen recognition in the host, influencing CD11c+ cell trafficking to 
lymph nodes.    
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Figure 17:  FITC-zymosan internalization by CD11c+ cells in the lungs of wt vs sIgM (-/-) mice.   Wt or sIgM 
(-/-) mice were challenged with 500µg of FITC-zymosan or unlabelled zymosan intratracheally.  16 hours after 
challenge, mice were sacrificed, and lung cells were stained with CD11c, and analyzed for CD11c+/FITC+ cells by 
flow cytometry.  Individual flow cytometry plots/mouse are presented.  A) wt and C) sIgM (-/-) mice that received 
unlabelled zymosan.  B) wt and D) sIgM (-/-) mice that received FITC-zymosan.   
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Figure 18:  Evaluation of trafficking of zymosan loaded 
CD11c+ cells to mediastinal lymph nodes in sIgM (-/-) 
vs. wt mice.   Wt and sIgM (-/-) mice were challenged 
with 500 µg of FITC-zymosan intratracheally.  16 hours 
later, individual mediastinal lymph nodes were collected, 
dispersed into single cell suspensions, stained with CD11c-
APC, and analyzed by flow cytometry.   After gating on 
CD11c cells, percent of cells which were FITC high was 
quantified and expressed as a fraction of CD11c cells.  A) 
and B) Representative plots from individual wt mice as 
gated on CD11c+ cells C) and D) Representative plots 
from individual sIgM (-/-) mice as gated on CD11c+ cells. 
E) Summary of average frequency of CD11c+/FITC hi+ 
cells from n=5 or more individual lymph nodes/mouse per 
group, error bars represent the SEM.  * indicates P<.05 by 
Mann Whitney test.  
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3.3.9 sIgM (-/-) mice have impaired IL-5 and IL-17 production in draining lymph nodes 
after Pneumocystis challenge 
 
As mice unable to produce sIgM have diminished fungal cell wall carbohydrate antigen 
presentation by CD11c+ cells in draining lymph nodes, and delayed clearance of Pneumocystis 
from the lungs at 14 days, coupled with altered inflammatory responses in the lungs such as 
diminished IL-6 and enhanced IL-10, we hypothesized that perhaps the environment influencing 
Th priming in the lymph nodes might be affected by the absence of sIgM.  As sIgM may have 
the function of affecting Pneumocystis antigen presentation by CD11c+ cells in lymph nodes as 
demonstrated with zymosan, and absence of sIgM results in the decrease in potent Th2 skewing 
cytokines such as IL-6 in the lungs, we hypothesized that perhaps Th2 and Th17 polarization in 
the lymph nodes might be affected by the absence of sIgM. Mice were challenged with 
Pneumocystis intratracheally, and 14 days after challenge, cells isolated from individual 
mediastinal lymph nodes were compared for their relative production of three different cytokines 
associated with CD4+ Th polarization, IFN-γ (Th1), IL-5 (Th2), and IL-17 (the recently 
described Th17 subset (272, 273).   To determine frequencies without expanding the population 
ex vivo, lymph node cells were not re-stimulated with antigen.  We observed that lymph node 
cells from sIgM mice challenged with Pneumocystis had significantly lower frequencies of IL-5 
and IL-17 producing cells relative to wt mice (Figure 19 a, b).  However, frequencies of IFN-γ 
producing lymph node cells from sIgM (-/-) and wt mice while trending lower in sIgM mice, 
were similar (Figure 19 c).   Hence we conclude that at this timepoint, sIgM is involved in the 
 125 
optimal production of IL-5 and IL-17 from lymph node cells as seen in wild type mice.   Thus, 
we believe that sIgM, which likely partially involves natural antibodies targeting fungal cell wall 
carbohydrate antigens, are capable of shaping responses in lymph nodes guiding the adaptive 
immune response to Pneumocystis.   
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Figure 19: Influence of sIgM on 
the production of cells producing 
cytokines associated with CD4 Th 
lineages in the lymph node 14 
days after Pneumocystis 
challenge.   Wt or sIgM (-/-) mice 
were challenged with Pneumocystis 
intratracheally.   14 days thereafter, 
mice were sacrificed and the 
draining mediastinal lymph node 
was collected, individually 
dissociated into single cell 
suspensions, and studied for 
frequencies of single cells 
producing IL-5 (A), IL-17 (B), and 
IFN-γ (C) by ELISPOT assay.  4 
mice were evaluated per group and 
average (+/-) SEM is presented.  * 
indicates P<.05 and ** indicates 
P<.01 by Mann-Whitney test.   
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3.3.10 sIgM (-/-) mice have impaired serum IgG1 anti-Pneumocystis antibody responses, 
and enhanced anti-PC IgG2a antibody responses 
 
The IgM isotype has been demonstrated to influence the kinetics of the evolving adaptive IgG 
antibody response to mucosal pulmonary pathogens such as influenza virus.  Baumgarth et al 
observed that sIgM (-/-) mice have delayed serum kinetics of specific influenza IgG2a, and to a 
lesser extent delayed kinetics of specific IgG1 production , however the respective quantities 
observed in sIgM (-/-) mice reach equivalent levels to wt mice by 22 days after infection (198).  
As the role of IgM has not been assessed in the evolving antibody response against any fungal 
organism, we explored the kinetics and isotype production of antibodies from sIgM (-/-) mice.   
Unexpectedly, we observed that the production of anti-Pneumocystis IgG1 was significantly 
impaired in sIgM (-/-) mice, with the trend emerging as early as 10 days after challenge but 
notably continuing through 28 days after infection, with total quantities of IgG1 significantly 
lower (Figure 20a).  Of note, IgG1 is the predominant anti-Pneumocystis isotype produced after 
infection (98) and is an antibody isotype associated with Th2 immunity.    In comparision, serum 
anti-Pneumocystis IgG2a, which is an isotype associated with Th1 immunity, was significantly 
increased in the sIgM (-/-) mice, with the trend emerging as early as 10 days and observed 
through 28 days after infection (Figure 20b).   
These data suggest that sIgM guides the adaptive immune response to Pneumocystis by 
influencing the isotype of anti-Pneumocystis IgG antibodies produced in the blood.  As B cell 
isotype class-switching is influenced by many factors, including Th cells, we hypothesize that 
sIgM, by influencing aspects of antigen presentation, promotes Th2 responses after challenge 
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with fungi within lymph nodes, leading to the promotion of an adaptive anti-Pneumocystis 
immunoglobulin response promoting the production of IgG1 over IgG2a.  As we observed 
heightened numbers of IL-5 producing cells in the mediastinal lymph nodes, at 14 days after 
Pneumocystis challenge,  in wt mice relative to sIgM (-/-) mice (Figure 19), and we demonstrate 
that whole lymph nodes isolated from sIgM (-/-) mice upon Pneumocystis Ag restimulation 
produced diminished quantities of IL-5 and IL-9, (Figure 23a) we believe that a Th2 dominant 
response in the lymph nodes in wild type mice influences the B cell germinal center reaction 
leading to enhanced class-switch recombination towards the IgG1 isotype, while impaired class-
switch recombination towards the IgG2a isotype.   Additionally, IL-21 has been demonstrated to 
significantly influence the production of IgG1, and synergizes with Th2 cytokine IL-4 in mice 
(274) to promote this class-switch, and IL-21 production is associated with Th17 cells (275).  As 
we observed 14 days after Pneumocystis challenge diminished quantities of IL-17 producing 
cells in the lymph nodes isolated from sIgM (-/-) mice (Figure 19), and impaired production of 
IL-17 from whole lymph nodes isolated from sIgM mice (-/-)restimulated with Pneumocystis 
antigen (Figure 23a), it is possible that impaired generation of Th17 cells via IL-21 production 
may also contribute to impaired anti-PC IgG1 production.   
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Figure 20:  Influence of sIgM on adaptive serum antibody responses against 
Pneumocystis.   Wt or sIgM (-/-) mice were challenged with Pneumocystis 
intratracheally.  Mice were bled at the indicated timepoints, and serum was assessed for 
IgG1(A) or IgG2a (B) reactivity against Pneumocystis (PC) antigen by ELISA.  Average 
responses from 4-5 mice per group per timepoint are presented.  Error bars represent 
SEM.  * indicates p<.05, ** indicates p<.01   
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3.3.11 Mucosal antibody responses against Pneumocystis protein and carbohydrate 
antigens are impaired in sIgM (-/-) mice 
 
The respiratory mucosa is in continual contact with environmental antigens, hence local immune 
responses at these sites are among the most important in host defense against pulmonary 
infections.   The most abundant antibody isotype in the body is IgA, with the vast majority 
localized to mucosal surfaces, and produced by local B cells, though IgG and IgM are also 
significant components of mucosal secretions.  We questioned whether the production of 
Pneumocystis specific immunoglobulins at the mucosa was affected by the absence of sIgM, 
given that sIgM influenced production of systemic immunoglobulins against Pneumocystis.   Wt 
and sIgM (-/-) mice were challenged with Pneumocystis intratracheally, and 28 days after 
infection bronchoalveolar lavage fluid was collected and assessed for the presence of specific 
IgG and IgA responses against the fungal pathogen.  Notably, we observed that quantities of 
anti-Pneumocystis specific IgG and IgA at the pulmonary mucosa were significantly decreased 
in mice lacking sIgM 28 days after infection (Figure 21a).  As IgA induction in the serum against 
Pneumocystis Ag is essentially absent, these data suggest that sIgM is involved in optimizing 
local adaptive mucosal B cell responses against Pneumocystis protein antigens.   Additionally, 
mucosal, induced IgG responses against the conserved fungal cell wall carbohydrate β-1,3 glucan 
also trended towards lower quantities in the absence of IgM, hence induced antibody responses 
targeting fungal carbohydrate antigens may also be influenced by sIgM (Figure 21b).    
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As the IgM isotype is not as abundant an isotype relative to IgA at mucosal surfaces, its 
importance in host defense, and in particular in guiding adaptive mucosal responses has not been 
deciphered.  We demonstrate that mucosal IgG and IgA responses are enhanced by the presence 
of IgM, and we believe this to be a function of enhancing immune-complex generation, and 
increasing Th2 responses, which promote antibody-based immunity.    
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Figure 21:  Influence of sIgM on induced mucosal antibody responses against 
Pneumocystis and β-glucan.   Wt or sIgM (-/-) mice were challenged with 
Pneumocystis intratracheally and at 28 days were sacrificed and BALF analyzed.  A) 
BALF was assessed for IgG and IgA reactivity against Pneumocystis (PC) antigen by 
ELISA.  B) BALF was assessed for IgG reactivity against the β-1,3 linked glucan 
laminarin.  Average responses from 4-5 mice per group are presented.  Error bars 
represent SEM.  * indicates p<.05, ** indicates p<.01, otherwise p value is presented 
above graph.    
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3.4 DISCUSSION 
 
Immunity against fungal infections involves numerous host defense mechanisms, of varied 
importance, operating simultaneously or within temporal proximity and often with the capacity 
to influence one another.  Some of these immune responses are required for effective host 
defense against fungi, others are contributory, while still others are detrimental.  Here, we report 
on the significant contributory functions of natural antibodies and particularly the IgM isotype in 
host defense against the pulmonary mucosal opportunistic fungal pathogen Pneumocystis carinii.    
While adaptive immune defense mechanisms involving CD4+ T cells and B cells are central to 
host defense against Pneumocystis pneumonia, we have identified a significant function for 
secreted IgM (sIgM) in host defense against fungi, and demonstrate that natural, innate 
antibodies and sIgM are involved in immunologic responses at the earliest stages of infection, 
enhance clearance of infection, and shape the evolving adaptive immune response mounted by 
the host.   
Almost all fungi possess a cell wall with conserved composition, consisting of a core of 
β-1,3 linked glucan interlinked with chitin (102).  These polysaccharides, which notably cannot 
be synthesized by vertebrates, provide important structural function to fungal cell walls, and 
when studied in isolation are highly immunogenic in mammals (122, 123, 132).    While the 
manner in which these carbohydrates initiate and enhance immune responses likely involves 
recognition by membrane associated pattern recognition receptors, such as CD11b (123, 276), 
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dectin-1 (145), toll-like receptors, and cellular enzymes such as chitinases (132, 277), the role of 
innate antibodies in the identification of these structures has not been evaluated.   We demonstate 
that high quantities of IgM targeting β-glucan and chitosan/chitin are present in the serum of 
naïve wt mice, and that mice reared in germ-free conditions also contain these specificities.  
These data suggested to us that microbial stimulation is not required for the production of IgM 
targeting β-glucan and chitosan/chitin, and that these specificities are part of the innate, 
preexisting natural antibody repertoire.   
Natural antibodies are molecules primarily of the IgM isotype, often with the capacity to 
bind more than one antigen, and usually encoded by a limited set of germ-line genes without N-
region additions (169).   Given their presence in the steady state, many groups have observed 
their importance in immediate immunologic responses such as delayed type hypersensitivity, 
(278)  and in defense against infections (191, 196).  The repertoire, while broad, is nonetheless 
highly restricted (279), as for example, mice produce natural antibodies targeting the 
carbohydrate antigen Galα1-3Gal (Gal) only after genetic deletion of an enzyme required for the 
production of this carbohydrate (185), and in our studies, we note that natural IgM is not reactive 
with mannan.    As the natural antibody repertoire is likely to be the first representation of B cell 
immunity in evolution, we questioned whether more primitive organisms produce these 
specificities targeting conserved fungal cell wall carbohydrates.  Catfish, among the earliest 
species containing immunoglobulins, and containing a tetrameric homolog of IgM, possessed 
serum IgM reactivity against β-glucan and chitosan/chitin, though notably reactivity with β-
glucan was higher.   While these catfish IgM may be innate or induced by antigenic stimulation, 
these data suggest that the capacity to make these specificities is conserved between species, 
likely due to important functions in host defense and/or homeostasis.  Finally, we detected 
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natural IgM antibodies targeting β-glucan and chitosan/chitin in human umbilical cord blood, 
demonstrating that these specificities are conserved and also present in the absence of exogenous 
antigenic stimulation in humans.    While these IgM specificities might be further enhanced by 
microbial exposure, we believe their production is partially represented in the innate IgM 
repertoire, which is predominantly produced by B-1 cells.   We argue that these IgM represent 
soluble pattern recognition receptors for conserved fungal cell wall carbohydrates and may play 
a role in the observed immunogenicity of chitin and β-glucan.    
As B-1 cells are the predominant B cell subset involved in the production of natural 
antibodies, we determined the localization of cells responsible for the secretion of IgM targeting 
β-glucan.    We observed that production of these antibodies predominates in the spleen, and that 
cells isolated from the peritoneum had negligible frequencies of IgM secreting B cells specific 
for β-glucan.  Our observations support studies demonstrating that B-1 cells, while primarily 
associated with the body cavitites such as the pleural and peritoneal space, migrate into 
secondary lymphoid organs after stimulation, where they differentiate into antibody secreting 
cells (184, 188) producing natural IgM, and it is perhaps this mechanism that leads to the 
substantial presence of β-glucan specific IgM in the serum.   While it has been demonstrated that 
TLR ligand stimulation, particularly LPS or peptidoglycan stimulation, leads to B-1 cell CD11b 
downregulation and migration from the body cavities (189), as well as differentiation, it is 
unclear whether antigen specific signaling through the B cell receptor or through non-TLR 
pattern recognition receptors could potentially initiate this process.  However, this mechanism, 
while likely having a steady state function, and hence involved in maintaining IgM within the 
narrow physiologic range observed in humans, demonstrates a pathway whereby natural IgM 
could be rapidly enhanced in settings of infection.  Additionally, it underscores the presence of 
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B-1 derived IgM in secondary lymphoid organs, where adaptive immune responses are being 
initiated.   
Natural IgM antibodies are opsonins in host defense against bacteria and viruses (191, 
280), hence we sought to evaluate their capacity to bind fungal cell walls.   We observed that 
serum IgM binds cell walls such as zymosan, suggesting that the carbohydrate components of 
fungal cell walls are specific targets of natural IgM.  Additionally, natural IgM binds 
Pneumocystis organisms and growing Aspergillus conidia, suggesting that certain antigens 
targeted by natural antibodies may be more accessible at certain stages of fungal cell growth, for 
particular pathogens.  As it has been observed that dectin-1 is accessible to Aspergillus β-glucan 
particularly as conidia mature, it suggests that the natural antibody repertoire may be targeting 
these same antigens.  Of note, IgG present in specific pathogen free mouse serum has much 
lower affinity for fungal cell walls than IgM.  Hence, we argue that specificities targeting fungal 
cell wall carbohydrates predominate in the IgM isotype in naïve, specific pathogen free mice.  
We used naïve specific pathogen free serum, from either wt or SCID mice, to assess the 
effects of the natural antibody repertoire on host defense against Pneumocystis in susceptible 
SCID mice, a similar strategy to that employed by Ocshenbein et al in first defining functions of 
natural antibodies in restricting viral and bacterial dissemination (191).  Wt serum significantly 
limited the growth of infection in SCID mice challenged with Pneumocystis, with the effect 
observed at intermediate timepoints after infection, 5 and 14 days thereafter.   Additionally, 
naïve wt serum enhanced production in SCID mice infected with Pneumocystis of IL-1α and IL-
6 in the lungs, cytokines important in host defense mechanisms against this infection.  However, 
at earlier timepoints, in the immediate response to the inoculum, natural antibody containing 
serum limited the quantities of neutrophils as well as pulmonary chemokines associated with 
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neutrophil chemotaxis, while not detectably influencing rates of Pneumocystis clearance.    
Collectively, these data suggest that natural antibodies alter the routes of antigen presentation, 
perhaps partially inhibiting recognition of Pneumocystis directly through membrane bound 
pattern recognition receptors such as dectin-1, TLR2 or lactosylceramide, and perhaps 
neutralizing inflammatory components such as shed β-glucan resulting from Pneumocystis 
degradation, leading to the inhibiton of the production of signals for neutrophil chemotaxis into 
the lungs.  Simultaneously, the rerouting of antigen through other recognition pathways leads to 
enhanced inflammation at later stages of infection, coupled with diminished pathogen burden.  
The hypothesized contribution of the IgM isotype in these responses was confirmed with studies 
in the sIgM (-/-) mouse, which also demonstrated impaired clearance of Pneumocystis at 
intermediate stages of infection and impaired production of IL-1α and IL-6 in the lungs.    These 
models together demonstrate that natural antibodies, particularly IgM, are significant 
contributory effector molecules in host defense against Pneumocystis.   Our data confirm reports 
from other groups demonstrating a value for natural antibodies and the IgM isotype in host 
defense against systemic and mucosal infections.   
As the earliest aspects of Pneumocystis recognition were altered in the absence of natural 
antibodies, we hypothesized that the absence of sIgM may potentially have consequences in the 
production of adaptive immune responses.  We studied the interaction of zymosan with 
pulmonary CD11c+ cells, as it is these cells which are hypothesized to rapidly migrate into the T 
cell zones of draining lymph nodes after instillation of antigen into the lungs  (281).  By 
assessing how the trafficking of the fungal cell wall carbohydrate antigen particle zymosan 
occurs in the lungs in the absence of sIgM, we observed that pulmonary CD11c+ cells were 
equivalently capable of internalizing the particulate.    However, analysis of CD11c+ cells in the 
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mediastinal draining lymph node, dendritic cells (DC’s) that have migrated secondary to 
activation and maturation, demonstrated that the presence of these cells containing zymosan in 
inductive sites was impaired in the absence of sIgM.   As dendritic cell migration is dependent on 
the process of cellular maturation and the expression of specific chemokine receptors mediating 
lymph node homing, which in turn is guided by the signaling pathways initiated by pathogen 
associated molecular patterns, we believe that fungal cell wall carbohydrate antigen coated in 
IgM are processed through pattern recognition receptors which enhance the process of DC 
maturation.   Not understood however, is how sIgM coated zymosan specifically mediates 
interactions with CD11c+ cells leading to the promotion of migration.  It is possible that sIgM 
modulates zymosan recognition by DC through some pattern recognition receptors over others in 
the lung, and as sIgM is an excellent promoter of the classical complement pathway, it may be 
that sIgM enhances complement deposition on fungi leading to recognition and DC activation 
through signaling at complement receptors.   Additionally, receptors that specifically identify 
IgM-antigen complexes, such as the more recently described Fcα/µ receptor identified in mice 
and humans on hematopoeitic and other cells (282, 283), could be preferentially involved in the 
recognition of IgM coated zymosan by DCs, shaping the cell maturation program upon 
activation.   Recognition of sIgM coated Pneumocystis, for example, could lead to differential 
production of activation molecules on airway DCs such as OX40L(284), chitinases (285), or 
leukotriene receptors (286) which could significantly alter DC priming towards Th2 adaptive 
immune responses.  Of note, we also observed diminished quantities of chemokines MCP-1 and 
MIP-1α, and chemokine regulating cytokine IL-1β from whole lymph nodes isolated from sIgM 
(-/-) mice 14 days after challenge with Pneumocystis and restimulated with Ag in vitro 
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(Supplemental Figure 23b), and this phenotype may contribute to aspects of DC homing over the 
course of infection.    
 The inflammatory environment of the airway is widely considered to be Th2 inclined, 
though host responses to pulmonary fungal infections involve the production of Th1, Th2 and 
Th17 type inflammatory responses (287-293).   While there is evidence that a Th2 type immune 
response is detrimental in host defense against various fungi, this has not been demonstrated to 
be the case in host defense against Pneumocystis, and notably the Th2 response dominates in 
response to this infection (98, 294, 295).   We demonstrate that sIgM plays an important role in 
the production of the Th environment in the draining pulmonary lymph nodes, as absence of this 
antibody isotype markedly impaired the production of cells producing IL-17 and IL-5, while not 
significantly influencing the generation of IFN-γ producing cells in the lymph node.  As we 
observed heightened quantities of IL-6 in the lungs of wt relative to sIgM mice after 
Pneumocystis challenge, it may be that this potent cytokine promoting Th-2 responses influences 
this process.  Our studies suggest that DC modulation of Th priming is influenced by the 
presence of sIgM, and an important component of sIgM at this early stage are natural antibodies 
targeting conserved fungal cell wall carbohydrates.    While we cannot distinguish whether 
antigen dose in draining lymph nodes or aspects of antigen presentation guides this phenotype, 
we hypothesize that IgM antibodies play a significant role in the Th2 bias of the respiratory 
mucosa.     
Given that sIgM deficient mice produce less IL-5 and IL-17 in draining lymph nodes, at a 
timepoint as the adaptive immune response is shaping, and have diminished trafficking of 
zymosan to inductive sites at early timepoints, we hypothesized that the production of adaptive B 
cell responses against Pneumocystis might be diminished, and the antibody isotype profile 
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skewed towards a Th1 type response, as Th derived cytokines play a critical role in B cell 
differentiation and isotype class-switch recombination (296, 297). We observed that the 
generation of Pneumocystis specific IgG1 antibodies was significantly diminished in the absence 
of sIgM, while IgG2a was enhanced.  The dramatic alteration in isotype prevalance against 
Pneumocystis is similar to what is observed in IL-4 (-/-) mice challenged with Pneumocystis 
(98), with strong inhibition of IgG1 production and enhanced production of IgG2a.  Our data 
support the concept that IgM present at early stages of infection promote Th2 effector functions 
while diminishing Th1 effector functions, as manifested in selective Th help promoting class-
switch recombination towards IgG1.   As these trends emerge as early as 10 days after infection, 
we believe that the natural antibody repertoire, combined with early induced sIgM contributes to 
this phenotype.    Additionally, we observed a net decrease in anti-Pneumocystis antibodies of 
the IgG and IgA isotype at the mucosa in the absence of sIgM.  The observed decrease in 
mucosal IgA suggests that local B cell responses influencing the presence of antibodies at the 
mucosa require sIgM for optimal production, and this outcome may have implications in 
memory responses against Pneumocystis.    Hence, sIgM influences both specific isotype 
production as well as overall presence of antibodies against Pneumocystis in the mucosa, and we 
believe this is initiated by sIgM dependent antigen presentation at the very earliest stages of 
infection.   
As individuals with X-linked hyper-IgM syndrome possess CD40L mutations, yet 
produce abundant IgM and are susceptible to Pneumocystis, it has been argued that the IgM 
antibody isotype is unimportant in host defense mechanisms against this infection.  These studies 
demonstrate that functions of IgM are significant in host defense against Pneumocystis, and in 
the evolving adaptive response to fungi.  Additionally, individuals with HIV-AIDS, who are 
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susceptible to Pneumocystis with progressing infection, suffer from polyclonal B cell activation 
and polyclonal gammopathy, with poor antibody responses to specific antigens (298).  
Dysregulation of natural and adaptive IgM could potentially play a major role in aspects of 
fungal antigen presentation, Th priming, adaptive antibody responses, and overall host defense, 
influencing the phenotype of Pneumocystis pneumonia susceptibility.   
In summary, we report on the presence of conserved natural IgM targeting the abundant 
and conserved carbohydrate antigens present in fungal cell walls.  We demonstrate that natural 
antibodies and sIgM are involved in the earliest stages of fungal recognition and host defense, 
and identify the critical importance of sIgM in promoting adaptive Th2 type immune responses 
locally and systemically in response to Pneumocystis fungal infection of the lungs.   
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3.5 SUPPLEMENTAL DATA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 22:  Supplemental Data.  Confirmation of absence of secreted IgM in 
sIgM (-/-) mice on the C57BL/6J background.  Serum from naïve wt and sIgM 
mice were compared for the production of total serum IgM.    Average data from 2 
mice/group/dilution are presented.   
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Figure 23a:  Supplemental Data.  Cytokine profiles of mediastinal lymph nodes from 
sIgM and wt mice challenged with Pneumocystis and restimulated with 
Pneumocystis Ag in vitro.  Whole lymph nodes were isolated from wt of sIgM (-/-) mice 
14 days after intratracheal Pneumocystis challenge.  Single lymph nodes were teased 
apart, and restimulated with Pneumocystis antigen in vitro and cultured for 3 days. 
Cytokine responses from individual lymph nodes are represented by the symbols.   
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Figure 23b:  Supplemental Data.  Chemokine/Cytokine profiles of mediastinal lymph 
nodes from sIgM and wt mice challenged with Pneumocystis and restimulated with 
Pneumocystis Ag in vitro.  Whole lymph nodes were isolated from wt or sIgM (-/-) mice 
14 days after intratracheal Pneumocystis challenge.  Single lymph nodes were teased 
apart, and restimulated with Pneumocystis antigen in vitro and cultured for 3 days. 
Cytokine responses from individual lymph nodes are represented by the symbols.   
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Figure 24:  Supplemental Data.  
Quantitative ELISPOT analysis of single 
cells in the lung producing cytokines 
associated with Th1, Th2, and Th17 
lineages 28 days after Pneumocystis 
challenge in wt vs sIgM (-/-) mice.  Wt of 
sIgM (-/-) mice were challenged with 
Pneumocystis intratracheally.  28 days 
thereafter, lungs were digested, dispersed into 
single cells suspensions, enumerated, and 
analyzed for production of IL-5, IFN-γ, and 
IL-17 by ELISPOT assay.  Average of 
responses from 5 individual mice/group, and 
error bars represent SEM.  Mann-Whitney test 
P values presented above respective graphs. 
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4.0 ADAPTIVE ANTIBODY RESPONSES AGAINST PNEUMOCYSTIS 
CONSERVED FUNGAL CELL WALL CARBOHYDRATES AND REGULATION 
OF RESPONSES BY CD4+ T CELLS 
 
 
 
4.1 INTRODUCTION 
 
 
Host defense against the opportunisitic pulmonary fungal pathogen Pneumocystis jirovecii 
involves the interplay between innate and adaptive immune responses, which are ultimately 
initiated through the detection of specific Pneumocystis antigens.  Currently, very few protein 
antigens from this complex pathogen have been identified as capable of initiating adaptive host 
defense responses with some protective benefit (92, 299-301), and many of these Pneumocystis 
proteins are generated from multi-copy gene families or demonstrate significant diversity 
between Pneumocystis species, impairing the assessment of potential vaccine candidates (302-
304).   The evaluation of potential antigens in adaptive immune responses, with greater 
conservation, and perhaps a less critical requirement for CD4+ T cells in the development of 
responses, may be provide an alternate approach for the development of therapies in settings of 
disease susceptibility.    
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The fungal cell wall of Pneumocystis consists of the conserved carbohydrates, mannan, β-
glucan, and chitin, found in most all fungi (111, 116, 305).  The carbohydrate components of the 
Pneumocystis cell wall have been studied as targets of various soluble and membrane-bound 
pattern recognition receptors (48, 49, 72, 138), but the potential role of these carbohydrates as 
targets of adaptive humoral responses in Pneumocystis infection has not been explored.   
Structurally, these fungal cell wall carbohydrates are comparable to typical thymus-independent 
type II (TI-2) antigens, given their large size, highly repetitive structures, and non-protein nature.  
In these studies, we assessed whether adaptive antibody responses are generated against these 
conserved carbohydrates antigens, and we sought to define the role of CD4+ T cells in the 
generation of these responses.  Additionally, in the study of a mucosal disease such as 
Pneumocystis, where the a significant portion of the infection consists of trophozoites tightly 
adhering to the apical surface of epithelial cells, we sought to specifically understand mucosal 
antibody production against these carbohydrates, as it is unclear what role CD4+ T cells have in 
guiding aspects of potential TI-2 antibody responses in lungs.   Further, as the contribution of 
CD4+ T cells may be restricted to various stages of B cell function, we assessed whether 
memory B cells require a CD4+ T cell sufficient environment for the production of antibodies 
targeting Pneumocystis fungal cell wall carbohydrates.   
While there is abundant evidence that antibodies sufficient for host defense against 
Pneumocystis are generated in a CD4+ T cell sufficient environment (82, 97, 167), it is unclear 
whether antibodies generated in a CD4+ T cell deficient environment also have some protective 
efficacy, or modulate aspects of the host immune response.    Here we demonstrate that 
chitosan/chitin, and β-glucan are targets of adaptive antibody responses against Pneumocystis, 
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and we dissect the requirements for CD4+ T cells in isotype class-switching, mucosal antibody 
production, and functional B cell memory against these antigens. 
  
 
4.2 MATERIALS AND METHODS 
 
4.2.1 Mice 
Male BALB/c mice, 6-8 weeks in age, were purchased from Jackson Immunoresearch 
Laboratories, and Male BALB/c.scid mice 6-8 weeks of age were obtained from Taconic Farms.
 
  
All mice were maintained in a specific
 
pathogen-free environment in microisolator cages within
 
the animal care facilities of Children's Hospital of Pittsburgh
 
under protocols reviewed and 
approved by the Animal Research
 
and Care Committee. Mice were provided with water and food 
ad
 
libitum and received 12-h light/dark cycles 
4.2.2 Chronic In vivo CD4+ T cell depletion 
BALB/c mice were chronically depleted of CD4+ T cells using the rat mAb GK1.5 obtained 
from National Cell Culture Center.  Mice received 200 µg GK1.5/weekly, intraperitoneally, for 
two weeks prior to Pneumocystis challenge, and weekly treatments of GK1.5 were continued 
through the course of the infection.  This dose of mAb was confirmed to be sufficient for the 
depletion of CD4+ T cells to less than 0.5% of the original quantity of CD4+ T cells in the 
spleen, as measured with staining of CD4 with RM4-4 (BD Pharmingen).  Additionally, this 
dose leads to sustained depression of CD4+ T cells in the spleen through at least 7 days (at which 
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point GK1.5 is again administered), and Pneumocystis susceptibility.  Control mice received 
weekly treatments of Rat IgG at the same dose and administered in the same schedule (Sigma).   
Both antibodies were dissolved in sterile PBS.  GK1.5 and control antibody were kept at -80°C 
until needed.  
4.2.3 P. carinii f. sp. muris isolate 
The Pneumocystis inoculum was prepared as previously described (42, 89).
 
Briefly, B6.scid and 
BALB/c.scid mice with Pneumocystis pneumonia were injected with a
 
lethal dose of 
ketamine/xylazine and the lungs were aseptically
 
removed and frozen in 1 ml of PBS at –80°C. 
Lungs
 
were mechanically dissociated in sterile PBS, filtered through
 
sterile gauze, and pelleted at 
500 x g for 10 min at 4°C. The pellet was resuspended in sterile PBS and a 1/5 dilution was 
stained by a modified Giemsa stain (Diff-Quik; Baxter).
 
The number of Pneumocystis cysts was 
quantified microscopically and the
 
inoculum concentration was adjusted to 2 x 106 cysts/ml. 
Gram
 
stains were performed on the inoculum preparations to exclude
 
contamination with 
bacteria.  
4.2.4 Pneumocystis infection 
Mice were anesthetized and intratracheally challenged with the cyst enumerated preparation of 2 
x 10
5
 Pneumocystis cysts in 100 µL PBS.    
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4.2.5 Serum and BALF collection 
 
Fluid from the lower respiratory tract was obtained by bronchoalveolar
 
lavage of mice 
anesthetized with i.p. ketamine/xylazine as described
 
previously (89). 1 mL of BALF was 
collected from mice using sterile PBS.  Lavage fluids were centrifuged at 350 x g and 
supernatant was stored at –80°C until
 
use. 
For serum collection in longitudinal studies with mice, small volumes of blood were 
collected from the periorbital sinus.   At terminal sacrifice of mice, blood was obtained by caudal 
venipuncture under anesthesia.   Serum was isolated from collected blood by use of serum 
separator tubes, as per protocol.  Serum was stored at –80°C until
 
use.  Additionally, in various 
timecourse studies as noted, after Pneumocystis challenge mice were sacrificed and serum was 
pooled per timepoint.   
 
4.2.6 Detection of antibody responses against Pneumocystis, beta-glucan, mannan,  
and chitosan/chitin 
 
Pneumocystis (PC) antigen was prepared as previously described (57) and derived from the lungs 
of infected BALB/c.scid and C57BL/6.scid mice by differential centrifugation to derive 
organisms, which were then sonicated.  PC antigen was normalized to protein concentration after 
sonication of organisms.  PC antigen was dissolved in carbonate buffer, pH 9.5, and seeded to 
Nunc-Polysorp 96 well plates at a concentration of 1 µg/mL.   Laminarin (Sigma), derived from 
the brown algae Laminaria digitata, is composed primarily of β-1,3 linked glucan, the 
predominant β-glucan linkage found in fungal cell walls (102).  Medium molecular weight 
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chitosan (Sigma), derived from crab shells, is polymer of chitin that is 75-85% deacetylated.  
Chitosan/chitin was dissolved in 2% acetic acid/PBS (v/v) at a concentration of 0.5-1mg/mL and 
thereafter diluted into PBS to final quantity of 25 µg/mL.   α-1,6 linked mannan (Sigma) derived 
from Saccharomyces cerevesiae was dissolved in PBS.  Carbohydrate antigens were seeded at a 
concentration of 25 µg/mL to Nunc-Polysorp 96 well plates and kept overnight at 4 degrees.  
Plates were blocked in 10% FBS and 5% Milk in PBS, and blocking buffer was used as a 
dilution buffer for serum and secondary antibodies.  Sera was applied in serial dilutions. BALF 
was run neat.  HRP-conjugated secondary antibodies against murine IgG, IgA, and IgM were 
obtained from Santa Cruz Biotechnology and Southern Biotech.  Plates were developed with 
TMB, and the reaction was quenched with 2N sulfuric acid.  Background for all ELISAs was 
typically less than .05 at an OD of 450 nM. Estimated endpoint titer was determined by assessing 
the lowest concentration at which signal was obtained that was 2 times higher than background.  
If this value fell between 2 concentrations, then the titer was approximated relative to the 
numerical distance between the reading of the upper and lower concentration.   Optical density 
values were reported at 450 nM, absolute or with background subtracted, as indicated per graph.   
 
4.2.7 Measurement of BAFF/BlyS and active TGF-β 
 
BAFF levels in serum, lung homogenates, and BALF were measured by ELISA (R&D Systems).   
Active TGF-  levels in serum and lung homogenates were measured by
 
ELISA using a TGF- 1 
DuoSet (R&D Systems). 
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4.2.8 Adoptive transfer studies in SCID mice 
 
Wild type BALB/c mice were challenged with Pneumocystis intratracheally and rested for 3.5 
months (PC memory mice).  Spleens were collected from PC memory mice or age-matched 
naïve mice, pushed through 70-µm pore size cell strainer, and RBC’s lysed with sterile 
NH4Cl/Tris solution
 
for 5 min on ice.  Thereafter, cells were simultaneously stained with 
fluorochrome conjugated antibodies against B220 and CD4, and typically a combination of 
APC-anti-B220 and PE-anti-CD4 was used.  B220+/CD4- and CD4+ /B220- populations were 
each collected by FACS and typically the purity of B220+ cells was ~98% and ~92% for CD4+ 
T cells.   Cells were suspended in sterile PBS.  Depending on the group, 10
6
 B cells +/- 500,000 
CD4+ T cells were administered to SCID mice intravenously.  Three days after cell transfer, 
SCID mice were challenged with Pneumocystis intratracheally.  50 days after challenge, mice 
were harvested for analysis of systemic and mucosal antibody responses.  
 
4.2.9  Statistical Analysis 
Data were analyzed using GraphPad statistical software. Comparisons
 
between groups were 
made
 
with the Student t test or Mann-Whitney U test. Significance was accepted at a value of p < 
0.05. 
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4.3 RESULTS 
 
4.3.1  Induction of IgG responses against beta-glucan and chitosan/chitin in the blood and 
enrichment of mucosal of IgA, IgG, and IgM isotypes targeting fungal cell wall  
carbohydrates after Pneumocystis challenge 
 
To assess whether adaptive antibody responses are generated against the conserved fungal cell 
wall carbohydrates β-glucan, chitosan/chitin, and mannan, Balb/c wt mice were challenged with 
Pneumocystis intratracheally.  At serial timepoints, 2-3 mice were sacrificed, and serum was 
pooled and assessed for Ag reactivity in various ELISAs.  First, we observed that naïve mice 
possess low levels of IgM reactive with Pneumocystis Ag (PC) prior to challenge at a titer of 
1:150, whereas anti-PC IgG is entirely absent (Figure 25 a).  However, both the IgG and IgM 
response rapidly enhance after challenge, with the IgM preceding the IgG response, plateauing at 
22 and 36 days respectively.   When we probed this same serum for IgG reactivity against β-
glucan and chitosan/chitin, we noted that the IgG responses against these antigens occurred as 
well, plateauing somewhat later, at 42 days after infection (Figure 25 b).  There were no IgG 
responses against mannan (data not shown).   Specific IgG induced against β-glucan and 
chitosan/chitin after PC challenge is of significantly lower quantities than polyclonal responses 
against IgG produced against PC protein antigen.  However, we demonstrate that IgG responses 
targeting conserved fungal cell wall carbohydrates are induced as a consequence of 
Pneumocystis challenge.   
To assess how these serum responses might translate into changes in mucosal Abs lining 
the lung epithelium, we compared the IgG, IgA, and IgM responses to β-glucan and 
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chitosan/chitin in the BALF of naïve mice and mice that had been challenged with Pneumocystis 
28 days earlier.  We observed that Pneumocytis challenge significantly enhanced quantities of 
these antibodies targeting fungal cell wall carbohydrates in the lung (Figure 25c,d).   Of note, 
these dynamics differ from studies of BALF reactivity against PC sonicate, where no reactivity 
of any isotype is observed at baseline (data not shown), hence Pneumocystis exposure is not 
required for the production of the IgG, IgA, and IgM against β-glucan and chitosan/chitin at 
baseline.  These data suggest that Pneumocystis exposure leads to the increased presence of 
mucosal antibodies targeting Pneumocystis fungal cell wall carbohydrates.    
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Figure 25:  Systemic and mucosal immunoglobulins targeting beta-glucan and chitosan/chitin are 
enhanced after Pneumocystis challenge.   BALB/c wt mice were challenged with Pneumocystis 
intratracheally.  Pooled serum from n=2-3 sacrificed mice per timepoint was A) probed for IgG and IgM 
reactivity against Pneumocystis sonicate (PC) or B)  IgG reactivity against beta-glucan or chitosan/chitin.  C 
& D) Mice were sacrificed 28 days after challenge and BALF was compared to naïve age-matched mice for 
IgG, IgA, and IgM reactivity against chitosan chitin (C) or beta-glucan (D).  4-5 mice per group.  Average 
values presented, error bars represent SEM.  
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4.3.2 CD4+ T cell depletion impairs production of serum isotypes targeting Pneumocystis 
protein Ag but does not impair serum responses against fungal cell wall carbohydrate 
antigen: Beta-glucan and chitosan/chitin are TI-2 Ags 
 
We sought to assess the role of CD4+ T cells in the production of antibodies targeting fungal cell 
wall carbohydrates after Pneumocystis challenge.  Utilizing a monoclonal Ab that specifically 
targets CD4, GK1.5, we chronically depleted wt mice of CD4+ T cells in secondary lymphoid 
organs, leading to a phenotype of significant Pneumocystis growth in the lungs after intratracheal 
challenge, as previously described (42).   Mice were treated mice with 200 µg of GK1.5, or Rat 
IgG as a control, weekly.  After two weeks of treatment, mice were challenged with 
Pneumocystis intratracheally.   Weekly GK1.5 and Rat IgG treatments were continued through 
the duration of the experiment to maintain chronic CD4+ T cell depletion.  Mice were sacrificed 
28 days after challenge, and blood and BALF were analyzed for antibody reactivity against 
Pneumocystis Ag (PC) as well as β-glucan and chitosan/chitin.  In the serum, we observed that 
chronic CD4+ T cell depletion significantly impairs the production of anti-PC IgG isotypes, of 
which the IgG1 isotype is most dramatically affected, while not influencing quantities of anti-PC 
IgM (Figure 26a).  These data support studies by other groups on the effect of CD4+ T cell 
depletion on the production of Abs targeting Pneumocystis Ag (97, 98), and suggest that the 
majority of the polyclonal response against PC Ag is directed against CD4+ T cell dependent 
antigens, likely of protein nature.  Yet, when we probed the serum for anti-beta glucan and anti-
chitosan/chitin IgG responses, we noticed that CD4+ T cell depletion had no effect on its 
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production, and additionally did not influence quantities IgM (Figure 26b,c), which in Chapter 
Three, we argued were likely innate Abs.   Hence we conclude that the induced IgG response 
occurs in the absence of specific requirement for CD4+ T cells, and given the structural nature of 
these carbohydrates, we conclude that these are thymus-indpendent type II antigens.   
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Figure 26:  Effect of CD4+ T cells on the presence of antibodies targeting PC or 
fungal cell wall carbohydrates in the serum.  Mice were challenged with 
Pneumocystis intratracheally.  28 days thereafter, mice were sacrificed and serum 
collected and probed for reactivity against A) PC sonicate, with specific analysis of 
isotype reactivity, or B) Beta-glucan, for IgG or IgM reactivity, or C) Chitsan/chitin, 
for IgG or IgM reactivity. 4-5 mice/group.    Average responses are presented, with 
error bars representing the SEM.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Anti-PC sonicate, serum reactivity
0
0.2
0.4
0.6
0.8
1
IgG1 IgG2a IgG2b IgG3 IgM
O
D
 4
5
0
 n
M
 (
1
:3
0
 d
ilu
ti
o
n
, 
b
a
c
k
g
ro
u
n
d
 s
u
b
tr
a
c
te
d
) Control CD4+ cell depleted
Serum beta-glucan reactivity
0
0.2
0.4
0.6
0.8
1
1.2
IgG IgM
(1
:3
0
 d
ilu
ti
o
n
) 
O
D
 4
5
0
 n
M
b
a
c
k
g
ro
u
n
d
 s
u
b
tr
a
c
te
d
Control
CD4+  Cell
Depleted
Serum chitosan/chitin reactivity
0
0.2
0.4
0.6
0.8
1
1.2
IgG IgM
(1
:3
0
 d
ilu
ti
o
n
) 
O
D
 4
5
0
 n
M
b
a
c
k
g
ro
u
n
d
 s
u
b
tr
a
c
te
d Control
CD4+  Cell
Depleted
A 
B C 
 159 
4.3.3 Absence of CD4+ T cells significantly influences mucosal Ab responses against fungal 
cell wall carbohydrate antigen 
 
We next sought to assess how antibody responses targeting fungal cell wall carbohydrates might 
be generated at the mucosa, in the absence of CD4+ T cells.  We analysed BALF collected from 
mice described in Figure 26.  First in our analyses, we assessed reactivity against PC Ag, and 
observed that significant quantities of induced IgG and IgA against PC Ag are present in the 
mucosa, and that these responses are highly impaired in the setting of CD4+ T cell deficiency 
(Figure 27a), while the anti-PC IgM response is unaffected.   
At the mucosa, CD4+ T cell depletion notably affected the presence of various isotypes 
targeting the fungal cell wall conserved carbohydrates, but in a different manner than which anti-
PC antibodies were affected.    While CD4+ T cell depletion did not reduce quantites of IgG 
targeting β-glucan and chitosan/chitin at the mucosa, quantities of IgA were significantly 
impaired (Figure 27 b, 27c).    These data suggest that the production of specific IgA targeting 
conserved fungal cell wall carbohydrates at the mucosa crtically involves CD4+ T cells, 
suggesting perhaps that Th cells are critically involved in IgA class-switching at the mucosa in 
the production of these antibodies.    Alternatively, CD4+ T cells might influence survival or 
homing signals to IgA antibody secreting cells of the lung.   
Additionally, we observed specific enhancement of quantities of IgM targeting fungal 
cell wall carbohydrates in the mucosa, and of note, we did not observe enhanced production of 
these carbohydrates in the serum, suggesting that the phenotype is manifested by local IgM 
producing cells in the mucosa (Figure 27 b, 27c).      These data suggest that in the setting of 
impaired host defense against Pneumocystis and consequently enhanced PC Ag in the lungs, as 
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occurs in the absence of CD4+ T cells which possess required effector function in host defense 
(96), antibody secreting cells producing IgM targeting fungal cell wall carbohydrates 
preferentially home to the lung, where they influence mucosal IgM responses against 
Pneumocystis.   This finding is striking in light of the observation that anti-PC IgM is not 
affected by CD4+ T cell depletion in the serum or in the lung mucosa.    It suggests to us that 
perhaps different B cells are responsible for the production of IgM targeting fungal cell wall 
carbohydrates vs IgM targeting PC antigen, accounting for their differences in regulation.  We 
hypothesize that the enhanced IgM production against fungal cell wall carbohydrates at the 
mucosa may represent a primitive host defense pathway, which is activated in the setting of 
impaired pulmonary defense against Pneumocystis and increased pulmonary burden in the lungs 
. 
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Figure 27:  Effect of CD4+ T cells on the presence of antibodies targeting PC or fungal cell 
wall carbohydrates in the BALF.   BALF was collected from mice as described in Figure 26, 28 
days after infection.  BALF was probed for reactivity, by isotype, against A) PC sonicate, B) Beta-
glucan, and C) Chitosan/chitin.  All data are pooled from two independent experiments, n=8-10 
mice/group.  Mean value with SEM are presented.  p values were calculated with Students t test.   
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4.3.4 Assessment of the regulation of potential IgA class-switch factors in mice challenged 
with Pneumocystis in the setting of CD4+ T cell deficiency 
 
We sought to understand factors that might be responsible for the perturbation of IgA       
responses in the lung against fungal cell wall carbohydrates.   As class-switching towards IgG 
occurred normally, we questioned whether specific IgA isotype-class switch signals might be 
impaired in the setting of CD4+ T cell deficiency.  Mucosal IgA class switch factors include 
TGF-β, which is considered a CD4+ T cell related isotype class-switch factor, and the cytokines 
BAFF/Blys and APRIL, which have recently been demonstrated to be released by the mucosal 
epithelium in a CD4+ T cell-independent, TLR-dependent manner (306, 307).  We hypothesized 
that factors promoting CD4+ T cell-dependent and CD4+ T cell-independent class-switching 
towards IgA would both be diminished, leading to the diminished quantities of IgA targeting 
beta-glucan and chitosan/chitin that we observed.   We found that while TGF-β levels were 
decreased in the serum and lung homogenate, quantities of BAFF/BlyS were very high, 
significantly enhanced in the setting of CD4+ T cell depletion (Figure 28).  Hence, impaired 
release of BAFF/BlyS likely does not account for the impaired IgA response against these 
carbohydrate Ags, but perhaps decreased TGF-β accounts may play a role in these differences.   
Additionally, other IgA class-switch recombination factors such as IL-5 (308) or iNOS (309) 
may be relevant.   
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Figure 28:  Presence of IgA class-switch recombination factors in tissues of mice 
challenged with Pneumocystis in the setting chronic CD4+ T cell depletion. BAFF/BlyS 
measured from A) lung homogenate, B) serum, and C) BALF.  Active TGF-β measured from 
D) lung homogenate, and E) serum.  Quantities of active TGF-β were negligible in BALF. 4-5 
mice were studied/group.  Mean with SEM are presented 
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4.3.5  Memory B cells targeting fungal cell wall carbohydrates are produced as a 
consequence of Pneumocystis challenge, and do not require CD4+ T cells for reactivation 
 
Our studies thus far have indicated that while the conserved fungal cell wall carbohydrates β-
glucan and chitosan are TI-2 antigens, the production of antibodies at mucosal sites is regulated 
by CD4+ T cells.  Hence, we sought to understand the importance of CD4+ T cells in potential 
memory B cell responses against these carbohydrates as a consequence of Pneumocystis 
challenge.  wt mice develop Pneumocystis infection in the lungs and ultimately clear it while 
generating protective adaptive immune responses within 4-5 weeks (96, 310), hence we 
challenged BALB/c mice with Pneumocystis intratracheally, and allowed rodents to rest 110 
days thereafter in order to provide sufficient time for resolution of the infection, and we hereafter 
refer to these rodents “PC memory mice”.   As memory B cells have been described to be 
localized primarily in secondary lymphoid organs in mice (214, 218), we took splenocytes from 
the Pneumocystis memory mice, or from age-matched naïve mice “PC naïve mice”, and selected 
either B220+ cells or CD4+ cells by FACS.    Mice received combinations of CD4+ T cells and 
B cells from either group, or B cells alone.  Three days later, BALB/c.scid mice were challenged 
with Pneumocystis intratracheally.  50 days after challenge, tissues were collected and analyzed 
for the production of Abs targeting fungal cell wall carbohydrates.  In a first analysis, we 
compared the ability of SCID mice receiving B cells from PC memory mice or PC naïve mice to 
produce antibody responses targeting fungal cell wall carbohydrates in the serum and blood.  We 
found that mice receiving B cells from PC memory mice have higher quantities of IgG 
antibodies targeting β-glucan and chitosan/chitin than mice receiving B cells from PC naïve mice 
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in the serum and at mucosal sites.   Interestingly, chitosan/chitin responses dominate in SCID 
mice relative to the β-glucan response, which dominate in the wt mouse, suggesting that even the 
factors guiding B cell function between these two specificities may differ, as well as the 
manifestation of responses as evaluated over different timecourses, with this study evaluating 
presence at day 50 after challenge, in SCID mice.  These data suggested to us that Pneumocystis 
challenge in wt mice enriches the spleen for B cells capable of producing antibody responses 
against fungal cell wall carbohydrates.  We argue that this constitutes a functional immunologic 
memory, as IgG responses against fungal cell wall carbohydrates are induced, and Pneumocystis 
challenge led to the alteration of the rodent’s B cell population such that it possessed a greater 
ability to produce antibody against these carbohydrate specificities when transferred into SCID 
hosts and challenged with Pneumocystis.  As we also demonstrate that B cells from 
Pneumocystis naïve mice are capable of producing a de novo IgG responses to fungal cell wall 
carbohydrates, in the absence of CD4+ T cells, it underscores the capacity of these B cells to 
produce IgG in a CD4+ T cell independent manner in a primary response.    Hence, the primary 
and memory anti-beta glucan and chitosan/chitin IgG responses do not require CD4+ T cells, and 
Pneumocystis challenge enriches the spleen for cells capable of producing IgG against these 
carbohydrates.   
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Figure 29:   Functional memory IgG responses as a consequence of PC challenge against 
conserved carbohydrates, and operativity in the absence of CD4+ T cells.  Wt mice were 
challenged with Pneumocystis intratracheally and rested for 110 days.  1 million B220+ cells 
sorted from pooled splenocytes from either PC memory mice (B cell, PC memory) or PC naïve, 
unchallenged mice (B cell, PC naïve) were transferred into individual SCID mice and 3 days later 
mice were challenged with Pneumocystis intratracheally.   Mice were sacrificed 50 days 
thereafter, and BALF and serum analyzed by ELISA to detect IgG responses against fungal cell 
wall carbohydrates.   Average +/- SEM for n=2 (B cell, PC memory) and n=3 (B cell, PC naïve) 
individual mice per reactivity assessed per graph.   
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4.3.6 Optimal IgA production against fungal cell wall carbohydrates requires CD4+ T cells 
in an adoptive transfer model 
 
Given the observation that the absence of CD4+ T cells impairs the production of specific IgA 
against fungal cell wall carbohydrates, we sought to confirm this requirement by assessing 
whether IgA production against fungal cell wall carbohydrates occurs in the BALF of SCID mice 
transferred with B cells but in the absence of CD4+ T cells.  Cells from PC memory and PC 
naïve splenocytes are those collected in section 4.3.5.   Comparisions were made between mice 
receiving 1 million B cells from either PC memory or PC naïve mice; mice receiving 1 million B 
cells from PC memory mice supplemented with 500,000 CD4+ T cells from PC naïve mice; and 
mice receiving 1 miilion PC naïve B cells supplemented with 500,000 CD4+ T cells from PC 
memory mice.   We found that neither group where B cells were transferred alone was capable of 
producing significant quantities of mucosal IgA targeting fungal cell wall carbohydrates, while 
both groups receiving B cells and CD4+ T cells were capable of producing an IgA response 
against these antigens (Figure 30).   We conclude that the IgA responses observed were the result 
of de novo B cell priming and homing to the lung mucosa, requiring CD4+ T cells as helper 
cells, as there was no significant difference between the mice receiving naïve B cells or PC B 
cells in mucosal IgA responses if simultaneously provided CD4+ T cells.   
As patients with HIV have diminished quantities and functions of CD4+ T cells , and our 
studies demonstrate that CD4+ T cell deficiency leads to impaired production of mucosal IgA 
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targeting fungal cell wall carbohydrates, we hypothesize that this response may be an important 
pathway that is perturbed in the setting of CD4+ T cell deficiency.  IgA may have unique 
effector functions.  Additionally, the quantities of IgA that occur at baseline targeting these 
carbohydrates could be perturbed in the setting of HIV, leading to impaired defense in the setting 
of acute exposure, allowing for escape of Pneumocystis organisms from humoral host defenses.    
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Figure 30:   Mucosal IgA production in the BALF of SCID mice transferred with B cells,  and 
requirement for CD4+ T cells for optimal IgA production against targeting fungal cell wall 
carbohydrate antigen.   Wt mice were challenged with Pneumocystis intratracheally and rested for 
110 days.  SCID mice were transferred with 1 million B220+ cells sorted from pooled splenocytes 
from either PC memory mice (B cell, PC memory) or PC naïve, unchallenged mice (B cell, PC naïve).  
Additionally cohorts containing an additional 500,000 CD4+ T cells from either source PC memory or 
PC naïve were generated: (B cell, PC memory/CD4 T cell, PC naïve) and (B cell, PC naïve/ CD4 T 
cell, PC memory).  Cells were transferred into individual SCID mice and 3 days later mice were 
challenged with Pneumocystis intratracheally.   Mice were sacrificed 50 days thereafter, and BALF 
analyzed by ELISA to detect IgA responses against fungal cell wall carbohydrates.   Average +/- SEM 
for n=2 mice (B cell, PC memory) and n=3 mice for all other groups, per reactivity, per graph.   
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4.4 DISCUSSION 
 
 
The generation of immunoglobulins targeting carbohydrate antigen are among the most 
important protective immune responses generated in humans.   Some of the most essential 
vaccines in clinical use induce protective antibodies against carbohydrate antigens in the cell 
walls of bacteria such as Streptococcus pneumoniae, Hemophilus influenzae, or Neisseria 
meningitidis, preventing against human diseases ranging from pneumonia to meningitis (201).    
Despite the importance of these responses in host defense against infection, the mechanisms 
regulating the induction of antibodies against carbohydrate antigens in the setting of an actual 
infection are poorly characterized.   With recent studies in murine models demonstrating that a β-
glucan-diphtheria toxoid conjugate vaccine enhanced host defense against systemic and/or 
mucosal Aspergillus and Candida infection (154), and that a fusion protein with the ability to 
recognize β-glucan as well as bind FcγR’s could enhance host defense against Pneumocystis 
(270), we sought to understand whether antibody responses targeting the conserved fungal cell 
wall carbohydrates of Pneumocystis are induced in the setting of actual pathogen infection.  
Further, as Pneumocystis pneumonia susceptibility correlates with major defects in adaptive 
immune responses, and most clearly with diseases that specifically perturb CD4 + T cell 
function, we questioned how such antibody responses might be affected by absence of these 
cells.  Finally, to design any vaccine in the setting of such immunodeficiency, we must 
understand the factors influencing memory responses, and how CD4+ T cells factor into the 
maintenance phase of responses.  Hence, these studies sought to make initial characterizations of 
the antibody responses generated against the conserved fungal cell wall carbohydrates, and their 
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regulation, after Pneumocystis challenge, with implications relevant for host defense against 
Pneumocystis and potentially other fungal pathogens.   
 We observed that intratracheal Pneumocystis challenge led to the slow induction of 
specific IgG targeting β-glucan and chitosan/chitin in the serum, and additionally, 28 days after 
infection, quantities of IgG, IgA, and IgM against these antigens were enhanced at the mucosal 
surface of the lung.  These data demonstrate, first, that specific anti-carbohydrate antibodies 
targeting Pneumocystis carbohydrates are synthesized by the host after challenge with intact 
pathogen.  Additionally, as IgA responses were absent in the serum against these carbohydrates, 
it demonstrates that the induction of local B cell immune responses occurs against β-glucan and 
chitosan/chitin, with enrichment of specific IgG and IgM as well at the mucosa, either through 
systemic or local processes.  As these carbohydrates are conserved between most all fungal 
species, we hypothesize that production of these antibodies may occur after exposure to other 
pathogenic fungi, and that in mucosal infections, these responses may particularly accumulate at 
mucosal sites.   
 Second, we demonstrate that β-glucan and chitosan/chitin are TI-2 independent antigens. 
CD4+ T cells are not required for the production of antibodies targeting these antigens, and there 
is no perturbation of quantities of IgG or IgM against these antigens in the blood, while IgG 
isotype responses are significantly impaired againt PC sonicate, likely representing protein 
antigens that generate strong, high-affinity antibody responses.  Hence, antibody responses 
targeting conserved fungal cell wall carbohydrates may occur in settings of CD4+ T cell 
insufficiency.   
We observed heightened mucosal IgM targeting fungal cell wall carbohydrates in the 
setting of CD4+ T cell deficiency and Pneumocystis challenge.  Taken with the observation that 
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there was no enhancement of IgM responses against PC sonicate at the mucosa, and no 
difference between control mice and CD4+ T cell depleted mice in quantities of β-glucan and 
chitosan/chitin IgM in the serum, we argue that perhaps the enhanced IgM mucosal response 
specific to carbohydrates in the setting of persisting antigen is a primitive host defense 
mechanism.  To reconcile the observation of enhanced quantities of carbohydrate-specific IgM 
secreting cells in the mucosa, but not in the serum, we argue that this response requires specific 
trafficking of IgM antibody-secreting cells to the mucosa.   
Our studies suggest that CD4+ T cells are required for the production of fungal cell wall 
carbohydrate directed IgA, while not IgG, at the mucosal surfaces of the lung. We observed 
significantly diminished quantitites of IgA in the BALF of β-glucan and chitosan/chitin specific 
antibodies after Pnuemocystis challenge in the models of chronic CD4+ T cell depletion and 
after adoptive transfer of B cells without CD4+ T cells into SCID mice.  IgA responses are local 
responses, presumably generated as a consequence of regional priming, and we observed no 
appreciable IgA in the serum against these carbohydrates, thus, we did not consider CD4+ T cell 
derived migration of IgA antibody secreting cells to play a major role in this process.   Hence, we 
hypothesized that CD4+ T cells may make signals that are required for local IgA class-switch 
recombination.  We evaluated whether class-switching factors might impair the production of 
IgA, and evaluated quantities of TGF-β, which is involved in the CD4+ T cell dependent IgA 
class-switching and BAFF/BlyS/Tnfsf13b, a B cell survival factor which is involved in CD4+ T 
cell independent IgA class-switch recombination at the mucosa (309).  We demonstrate that in 
mice depleted of CD4+ T cells and challenged with Pneumocystis, that active TGF-β is 
decreased, suggesting that CD4+ T cell depletion itself may reduce production of TGF-β.   On 
the other hand, while we anticipated that factors guiding non-CD4+ T cell dependent IgA class 
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switch recombination would be reduced, these BAFF quantities are significantly enhanced in 
CD4+ T cell depleted mice challenged with Pneumocystis.   Hence, we believe that CD4+ T cell 
dependent IgA class-switch recombination is perturbed in this model, and that IgA class-switch 
recombination factors that are considered CD4+ T cell independent, are unable to compensate for 
the deficiency of CD4+ T cell derived factors.  While the majority of mucosal IgA is produced in 
a CD4+ T cell independent manner, our data suggests that some antigen induced carbohydrate-
directed mucosal IgA is produced in a CD4+ T cell dependent manner.   
Finally, we provide evidence that functional B cell memory responses are generated after 
Pneumocystis challenge against fungal cell wall carbohydrates.  Splenic B cells from mice 
previously challenged with Pneumocystis, when transferred into SCID mice and challenged with 
the fungal organism, produce significantly more specific IgG against β-glucan and 
chitosan/chitin in the serum and at the lung mucosa, compared to SCID mice receiving B cells 
from mice that had not been challenged with Pneumocystis.   Importantly, SCID mice receiving 
B cells from mice not previously challenged with Pneumocystis, produced significant quantities 
of IgG against β-glucan and chitosan/chitin in SCID mice after Pneumocystis challenge, 
underscoring our observation that the production of these antibodies does not require CD4+ T 
cells.  These data suggest that CD4+ T cells are not required for the induction of IgG targeting 
fungal cell wall carbohydrates, and additionally, that memory B cells producing antibodies that 
target β-glucan and chitosan/chitin do not require a CD4+ T cells for activation and functions 
after their generation.   
These data describe
 
novel roles for fungal cell wall carbohydrates as targets of adaptive
 
antibody responses and underscore the complexity of T cell involvement
 
on the production of 
antibody targeting carbohydrates antigens at mucosal sites.   
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5.0 SUMMARY 
 
 
The core conclusions from these investigations are summarized below:  
1) A molecule with the capacity to recognize β-1,3 linked glucan, and bind to FcγRII and 
FcγRIII receptors on antigen presenting cells, was able to enhance recognition of fungal 
cell wall carbohydrates by macrophages, enhance macrophage effector function against 
Pneumocystis, and impair the growth of Pneumocystis infection in the lungs of SCID 
mice.  We hypothesized that the host may recapitulate this effective strategy to limit 
growth of fungal organisms by the production of antibodies targeting fungal cell wall 
carbohydrates.  
2) We observed that natural IgM antibodies target the conserved fungal cell wall 
carbohydrates β-glucan and chitosan/chitin.   Probing for these IgM specificities in germ-
free mice, and in human cord blood, we determined that microbial stimulation is not 
required for the production of these specificities.    Underscoring their conservation, these 
IgM specificities were observed in catfish, which contain a primitive immune system and 
a tetrameric homolog of IgM.   In mice, natural antibody containing serum limits rapid 
recruitment of neutrophils as observed in the acute challenge, and at intermediate 
timepoints after infection, limits the growth of Pneumocystis organisms in the lungs and 
leads to enhanced IL-1α and IL-6 in the lungs.   Mice unable to secrete IgM, sIgM (-/-), 
and hence lacking the major isotype normally consisting the bulk of natural antibodies, 
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have impaired clearance of Pneumocystis at intermediate timepoints and impaired IL-1α, 
IL-6 in the lungs.  As IgM appears to influence the earliest host responses against 
Pneumocystis, we assessed aspects of fungal cell wall carbohydrate antigen trafficking in 
sIgM (-/-) mice.  We observed that sIgM (-/-) mice have normal uptake of zymosan in the 
lungs by CD11c+ cells, but impaired trafficking of CD11c+ cells containing the particle 
to the mediastinal lymph nodes.   Fourteen days after infection, sIgM (-/-) mice have 
decreased quantities of IL-5 and IL-17 producing cells in the lymph node, while 
comparable quantities of IFN-γ producing cells.  The apparent involvement of IgM in 
producing a dominant Th2 response was additionally manifested in the adaptive humoral 
response, as the production of serum anti-Pneumocystis IgG1 was significantly impaired 
while IgG2a much enhanced.  Additionally quantities of anti-Pneumocystis IgG and IgA 
at the mucosa were impaired.  Hence, we conclude that natural and early induced IgM 
play a significant role in host defense against Pneumocystis and in the types of adaptive 
immune responses mounted by the host.  
3) Pneumocystis challenge results in induced/adaptive antibody responses that target 
conserved fungal cell wall carbohydrates β-glucan and chitosan/chitin.   Particularly, 
serum levels of IgG against these carbohydrates increase, and quantities of specific IgG, 
IgA, and IgM increase in the lung after Pneumocystis challenge.  CD4+ T cells are 
required for mucosal IgA production, but are not required for mucosal IgG production 
against fungal cell wall carbohydrates.  Additionally IgM responses against these 
carbohydrates are significantly enhanced at the mucosa in the absence of CD4+ T cells, 
but not in the blood, suggesting that these cells are recruited into the lungs as a potential 
host defense mechanism to deal with increased Ag load in the setting of CD4+ T cell 
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deficiency.  Lastly, we observe functional memory B cell responses against these 
carbohydrates, as a long term consequence of PC challenge, and provide evidence that 
these responses do not require CD4+ T cells for functions in the memory phase.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 177 
 
APPENDIX: PUBLICATIONS 
 
 
 
 Zheng, M., A. J. Ramsay, M. B. Robichaux, K. A. Norris, C. Kliment, C. Crowe, R. R. 
Rapaka, C. Steele, F. McAllister, J. E. Shellito, L. Marrero, P. Schwarzenberger, Q. 
Zhong, and J. K. Kolls. 2005. CD4+ T cell-independent DNA vaccination against 
opportunistic infections. J Clin Invest 115:3536-3544. 
 
 Steele, C., R. R. Rapaka, A. Metz, S. M. Pop, D. L. Williams, S. Gordon, J. K. Kolls, and 
G. D. Brown. 2005. The Beta-Glucan Receptor Dectin-1 Recognizes Specific 
Morphologies of Aspergillus fumigatus. PLoS Pathog 1:e42. 
 
Rapaka, R. R., E. S. Goetzman, M. Zheng, J. Vockley, L. McKinley, J. K. Kolls, and C. 
Steele. 2007. Enhanced defense against Pneumocystis carinii mediated by a novel dectin-
1 receptor Fc fusion protein. J Immunol 178:3702-3712. 
 
 Mattila, P. E., A. E. Metz, R. R. Rapaka, L. D. Bauer, and C. Steele. 2008. Dectin-1 Fc 
targeting of aspergillus fumigatus beta-glucans augments innate defense against invasive 
pulmonary aspergillosis. Antimicrob Agents Chemother 52:1171-1172. 
 
Rapaka, R. R., and J. K. Kolls. 2008. Pathogenesis of Allergic Bronchopulmonary 
Aspergillosis in Cystic Fibrosis: Current Understanding and Future Directions. Med 
Mycol:1-7. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 178 
REFERENCES 
 
 
 
1. Hocker, B., C. Wendt, A. Nahimana, B. Tonshoff, and P. M. Hauser. 2005. Molecular 
evidence of Pneumocystis transmission in pediatric transplant unit. Emerg Infect Dis 
11:330-332. 
2. Cheung, Y. F., C. F. Chan, C. W. Lee, and Y. L. Lau. 1994. An outbreak of 
Pneumocystis carinii pneumonia in children with malignancy. Journal of paediatrics and 
child health 30:173-175. 
3. Gigliotti, F., A. G. Harmsen, and T. W. Wright. 2003. Characterization of transmission of 
Pneumocystis carinii f. sp. muris through immunocompetent BALB/c mice. Infect Immun 
71:3852-3856. 
4. Wakefield, A. E. 1996. DNA sequences identical to Pneumocystis carinii f. sp. carinii 
and Pneumocystis carinii f. sp. hominis in samples of air spora. Journal of clinical 
microbiology 34:1754-1759. 
5. Wakefield, A. E. 1994. Detection of DNA sequences identical to Pneumocystis carinii in 
samples of ambient air. J Eukaryot Microbiol 41:116S. 
6. Peglow, S. L., A. G. Smulian, M. J. Linke, C. L. Pogue, S. Nurre, J. Crisler, J. Phair, J. 
W. Gold, D. Armstrong, and P. D. Walzer. 1990. Serologic responses to Pneumocystis 
carinii antigens in health and disease. The Journal of infectious diseases 161:296-306. 
7. 1981. Pneumocystis pneumonia--Los Angeles. Mmwr 30:250-252. 
8. Malaspina, A., S. Moir, S. Kottilil, C. W. Hallahan, L. A. Ehler, S. Liu, M. A. Planta, T. 
W. Chun, and A. S. Fauci. 2003. Deleterious effect of HIV-1 plasma viremia on B cell 
costimulatory function. J Immunol 170:5965-5972. 
9. Moir, S., K. M. Ogwaro, A. Malaspina, J. Vasquez, E. T. Donoghue, C. W. Hallahan, S. 
Liu, L. A. Ehler, M. A. Planta, S. Kottilil, T. W. Chun, and A. S. Fauci. 2003. 
Perturbations in B cell responsiveness to CD4+ T cell help in HIV-infected individuals. 
Proc Natl Acad Sci U S A 100:6057-6062. 
10. Moir, S., A. Malaspina, K. M. Ogwaro, E. T. Donoghue, C. W. Hallahan, L. A. Ehler, S. 
Liu, J. Adelsberger, R. Lapointe, P. Hwu, M. Baseler, J. M. Orenstein, T. W. Chun, J. A. 
Mican, and A. S. Fauci. 2001. HIV-1 induces phenotypic and functional perturbations of 
B cells in chronically infected individuals. Proc Natl Acad Sci U S A 98:10362-10367. 
11. Malaspina, A., S. Moir, S. M. Orsega, J. Vasquez, N. J. Miller, E. T. Donoghue, S. 
Kottilil, M. Gezmu, D. Follmann, G. M. Vodeiko, R. A. Levandowski, J. M. Mican, and 
A. S. Fauci. 2005. Compromised B cell responses to influenza vaccination in HIV-
infected individuals. J Infect Dis 191:1442-1450. 
 179 
12. Malaspina, A., S. Moir, J. Ho, W. Wang, M. L. Howell, M. A. O'Shea, G. A. Roby, C. A. 
Rehm, J. M. Mican, T. W. Chun, and A. S. Fauci. 2006. Appearance of 
immature/transitional B cells in HIV-infected individuals with advanced disease: 
correlation with increased IL-7. Proc Natl Acad Sci U S A 103:2262-2267. 
13. Noursadeghi, M., D. R. Katz, and R. F. Miller. 2006. HIV-1 infection of mononuclear 
phagocytic cells: the case for bacterial innate immune deficiency in AIDS. The Lancet 
infectious diseases 6:794-804. 
14. Streeck, H., Z. L. Brumme, M. Anastario, K. W. Cohen, J. S. Jolin, A. Meier, C. J. 
Brumme, E. S. Rosenberg, G. Alter, T. M. Allen, B. D. Walker, and M. Altfeld. 2008. 
Antigen Load and Viral Sequence Diversification Determine the Functional Profile of 
HIV-1-Specific CD8(+) T Cells. PLoS medicine 5:e100. 
15. Donaghy, H., A. Pozniak, B. Gazzard, N. Qazi, J. Gilmour, F. Gotch, and S. Patterson. 
2001. Loss of blood CD11c(+) myeloid and CD11c(-) plasmacytoid dendritic cells in 
patients with HIV-1 infection correlates with HIV-1 RNA virus load. Blood 98:2574-
2576. 
16. Phair, J., A. Munoz, R. Detels, R. Kaslow, C. Rinaldo, and A. Saah. 1990. The risk of 
Pneumocystis carinii pneumonia among men infected with human immunodeficiency 
virus type 1. Multicenter AIDS Cohort Study Group. N Engl J Med 322:161-165. 
17. Morris, A., J. D. Lundgren, H. Masur, P. D. Walzer, D. L. Hanson, T. Frederick, L. 
Huang, C. B. Beard, and J. E. Kaplan. 2004. Current epidemiology of Pneumocystis 
pneumonia. Emerg Infect Dis 10:1713-1720. 
18. Tellez, I., M. Barragan, C. Franco-Paredes, P. Petraro, K. Nelson, and C. Del Rio. 2008. 
Pneumocystis jiroveci pneumonia in patients with AIDS in the inner city: a persistent and 
deadly opportunistic infection. The American journal of the medical sciences 335:192-
197. 
19. Jaillon, S., G. Peri, Y. Delneste, I. Fremaux, A. Doni, F. Moalli, C. Garlanda, L. Romani, 
H. Gascan, S. Bellocchio, S. Bozza, M. A. Cassatella, P. Jeannin, and A. Mantovani. 
2007. The humoral pattern recognition receptor PTX3 is stored in neutrophil granules and 
localizes in extracellular traps. J Exp Med 204:793-804. 
20. Atochina, E. N., J. M. Beck, A. M. Preston, A. Haczku, Y. Tomer, S. T. Scanlon, T. 
Fusaro, J. Casey, S. Hawgood, A. J. Gow, and M. F. Beers. 2004. Enhanced lung injury 
and delayed clearance of Pneumocystis carinii in surfactant protein A-deficient mice: 
attenuation of cytokine responses and reactive oxygen-nitrogen species. Infect Immun 
72:6002-6011. 
21. Wannamethee, S. G., S. Sirivichayakul, A. N. Phillips, S. Ubolyam, K. Ruxrungtham, M. 
Hanvanich, and P. Phanuphak. 1998. Clinical and immunological features of human 
immunodeficiency virus infection in patients from Bangkok, Thailand. International 
journal of epidemiology 27:289-295. 
 180 
22. Leelayoova, S., S. Siripattanapipong, P. Tan-Ariya, J. Worapong, and M. Mungthin. 
2005. Genetic diversity of Pneumocystis jirovecii in Thailand. Journal of the Medical 
Association of Thailand = Chotmaihet thangphaet 88 Suppl 3:S330-338. 
23. Siika, A. M., J. M. Chakaya, G. Revathi, S. S. Mohamed, and K. M. Bhatt. 2006. 
Bronchoscopic study on aetiology of chronic cough in HIV-infected adults with negative 
sputum smears for Mycobacterium tuberculosis at Kenyatta National Hospital, Nairobi. 
East African medical journal 83:295-305. 
24. Thea, D. M., G. Lambert, J. Weedon, P. B. Matheson, E. J. Abrams, M. Bamji, W. L. 
Straus, P. A. Thomas, K. Krasinski, and M. Heagarty. 1996. Benefit of primary 
prophylaxis before 18 months of age in reducing the incidence of Pneumocystis carinii 
pneumonia and early death in a cohort of 112 human immunodeficiency virus-infected 
infants. New York City Perinatal HIV Transmission Collaborative Study Group. 
Pediatrics 97:59-64. 
25. Rabie, H., A. de Boer, S. van den Bos, M. F. Cotton, S. Kling, and P. Goussard. 2007. 
Children with human immunodeficiency virus infection admitted to a paediatric intensive 
care unit in South Africa. Journal of tropical pediatrics 53:270-273. 
26. Bakeera-Kitaka, S., P. Musoke, R. Downing, and J. K. Tumwine. 2004. Pneumocystis 
carinii in children with severe pneumonia at Mulago Hospital, Uganda. Annals of tropical 
paediatrics 24:227-235. 
27. Thomas, C. F., Jr., and A. H. Limper. 2004. Pneumocystis pneumonia. N Engl J Med 
350:2487-2498. 
28. Thomas, C. F., Jr., and A. H. Limper. 1998. Pneumocystis pneumonia: clinical 
presentation and diagnosis in patients with and without acquired immune deficiency 
syndrome. Seminars in respiratory infections 13:289-295. 
29. Yale, S. H., and A. H. Limper. 1996. Pneumocystis carinii pneumonia in patients without 
acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy. 
Mayo Clinic proceedings 71:5-13. 
30. Mori, S., F. Imamura, C. Kiyofuji, K. Ito, Y. Koga, I. Honda, and M. Sugimoto. 2006. 
Pneumocystis jiroveci pneumonia in a patient with rheumatoid arthritis as a complication 
of treatment with infliximab, anti-tumor necrosis factor alpha neutralizing antibody. 
Modern rheumatology / the Japan Rheumatism Association 16:58-62. 
31. Gerrard, J. G. 1995. Pneumocystis carinii pneumonia in HIV-negative 
immunocompromised adults. The Medical journal of Australia 162:233-235. 
32. Russian, D. A., and S. J. Levine. 2001. Pneumocystis carinii pneumonia in patients 
without HIV infection. The American journal of the medical sciences 321:56-65. 
 181 
33. Bollee, G., C. Sarfati, G. Thiery, A. Bergeron, S. de Miranda, J. Menotti, N. de Castro, A. 
Tazi, B. Schlemmer, and E. Azoulay. 2007. Clinical picture of Pneumocystis jiroveci 
pneumonia in cancer patients. Chest 132:1305-1310. 
34. Nahimana, A., M. Rabodonirina, P. Francioli, J. Bille, and P. M. Hauser. 2003. 
Pneumocystis jirovecii dihydrofolate reductase polymorphisms associated with failure of 
prophylaxis. J Eukaryot Microbiol 50 Suppl:656-657. 
35. Huang, L., K. Crothers, C. Atzori, T. Benfield, R. Miller, M. Rabodonirina, and J. 
Helweg-Larsen. 2004. Dihydropteroate synthase gene mutations in Pneumocystis and 
sulfa resistance. Emerg Infect Dis 10:1721-1728. 
36. Takahashi, T., N. Hosoya, T. Endo, T. Nakamura, H. Sakashita, K. Kimura, K. Ohnishi, 
Y. Nakamura, and A. Iwamoto. 2000. Relationship between mutations in dihydropteroate 
synthase of Pneumocystis carinii f. sp. hominis isolates in Japan and resistance to 
sulfonamide therapy. Journal of clinical microbiology 38:3161-3164. 
37. Gigliotti, F., A. G. Harmsen, C. G. Haidaris, and P. J. Haidaris. 1993. Pneumocystis 
carinii is not universally transmissible between mammalian species. Infect Immun 
61:2886-2890. 
38. Durand-Joly, I., M. Aliouat el, C. Recourt, K. Guyot, N. Francois, M. Wauquier, D. 
Camus, and E. Dei-Cas. 2002. Pneumocystis carinii f. sp. hominis is not infectious for 
SCID mice. Journal of clinical microbiology 40:1862-1865. 
39. Gigliotti, F., and A. G. Harmsen. 1997. Pneumocystis carinii host origin defines the 
antibody specificity and protective response induced by immunization. The Journal of 
infectious diseases 176:1322-1326. 
40. Mazars, E., K. Guyot, I. Durand, E. Dei-Cas, S. Boucher, S. B. Abderrazak, A. L. Banuls, 
M. Tibayrenc, and D. Camus. 1997. Isoenzyme diversity in Pneumocystis carinii from 
rats, mice, and rabbits. J Infect Dis 175:655-660. 
41. Smulian, A. G. 2001. Pneumocystis carinii: genetic diversity and cell biology. Fungal 
Genet Biol 34:145-154. 
42. Shellito, J., V. V. Suzara, W. Blumenfeld, J. M. Beck, H. J. Steger, and T. H. Ermak. 
1990. A new model of Pneumocystis carinii infection in mice selectively depleted of 
helper T lymphocytes. J Clin Invest 85:1686-1693. 
43. Harmsen, A. G., and M. Stankiewicz. 1990. Requirement for CD4+ cells in resistance to 
Pneumocystis carinii pneumonia in mice. J Exp Med 172:937-945. 
44. McFadden, D. C., M. A. Powles, J. G. Smith, A. M. Flattery, K. Bartizal, and D. M. 
Schmatz. 1994. Use of anti-CD4+ hybridoma cells to induce Pneumocystis carinii in 
mice. Infect Immun 62:4887-4892. 
 182 
45. Roths, J. B., J. D. Marshall, R. D. Allen, G. A. Carlson, and C. L. Sidman. 1990. 
Spontaneous Pneumocystis carinii pneumonia in immunodeficient mutant scid mice. 
Natural history and pathobiology. Am J Pathol 136:1173-1186. 
46. Board, K. F., S. Patil, I. Lebedeva, S. Capuano, 3rd, A. M. Trichel, M. Murphey-Corb, P. 
A. Rajakumar, J. L. Flynn, C. G. Haidaris, and K. A. Norris. 2003. Experimental 
Pneumocystis carinii pneumonia in simian immunodeficiency virus-infected rhesus 
macaques. J Infect Dis 187:576-588. 
47. Limper, A. H., J. S. Hoyte, and J. E. Standing. 1997. The role of alveolar macrophages in 
Pneumocystis carinii degradation and clearance from the lung. J Clin Invest 99:2110-
2117. 
48. Ezekowitz, R. A., D. J. Williams, H. Koziel, M. Y. Armstrong, A. Warner, F. F. 
Richards, and R. M. Rose. 1991. Uptake of Pneumocystis carinii mediated by the 
macrophage mannose receptor. Nature 351:155-158. 
49. Steele, C., L. Marrero, S. Swain, A. G. Harmsen, M. Zheng, G. D. Brown, S. Gordon, J. 
E. Shellito, and J. K. Kolls. 2003. Alveolar macrophage-mediated killing of 
Pneumocystis carinii f. sp. muris involves molecular recognition by the Dectin-1 beta-
glucan receptor. J Exp Med 198:1677-1688. 
50. Hollifield, M., E. Bou Ghanem, W. J. de Villiers, and B. A. Garvy. 2007. Scavenger 
receptor A dampens induction of inflammation in response to the fungal pathogen 
Pneumocystis carinii. Infect Immun 75:3999-4005. 
51. Wang, S. H., C. Zhang, M. E. Lasbury, C. P. Liao, P. J. Durant, D. Tschang, and C. H. 
Lee. 2008. Decreased inflammatory response in Toll-like receptor 2 knockout mice is 
associated with exacerbated Pneumocystis pneumonia. Microbes Infect 10:334-341. 
52. Hoffman, O. A., J. E. Standing, and A. H. Limper. 1993. Pneumocystis carinii stimulates 
tumor necrosis factor-alpha release from alveolar macrophages through a beta-glucan-
mediated mechanism. J Immunol 150:3932-3940. 
53. Zhang, J., J. Zhu, A. Imrich, M. Cushion, T. B. Kinane, and H. Koziel. 2004. 
Pneumocystis activates human alveolar macrophage NF-kappaB signaling through 
mannose receptors. Infect Immun 72:3147-3160. 
54. Ding, K., A. Shibui, Y. Wang, M. Takamoto, T. Matsuguchi, and K. Sugane. 2005. 
Impaired recognition by Toll-like receptor 4 is responsible for exacerbated murine 
Pneumocystis pneumonia. Microbes Infect 7:195-203. 
55. Steele, C., R. R. Rapaka, A. Metz, S. M. Pop, D. L. Williams, S. Gordon, J. K. Kolls, and 
G. D. Brown. 2005. The Beta-Glucan Receptor Dectin-1 Recognizes Specific 
Morphologies of Aspergillus fumigatus. PLoS Pathog 1:e42. 
 183 
56. Holt, P. G., D. H. Strickland, M. E. Wikstrom, and F. L. Jahnsen. 2008. Regulation of 
immunological homeostasis in the respiratory tract. Nat Rev Immunol 8:142-152. 
57. Zheng, M., J. E. Shellito, L. Marrero, Q. Zhong, S. Julian, P. Ye, V. Wallace, P. 
Schwarzenberger, and J. K. Kolls. 2001. CD4+ T cell-independent vaccination against 
Pneumocystis carinii in mice. J Clin Invest 108:1469-1474. 
58. Kobayashi, H., S. Worgall, T. P. O'Connor, and R. G. Crystal. 2007. Interaction of 
Pneumocystis carinii with dendritic cells and resulting host responses to P. carinii. J 
Immunother 30:54-63. 
59. Azoulay, E., A. Parrot, A. Flahault, D. Cesari, I. Lecomte, P. Roux, F. Saidi, M. 
Fartoukh, J. F. Bernaudin, J. Cadranel, and C. Mayaud. 1999. AIDS-related 
Pneumocystis carinii pneumonia in the era of adjunctive steroids: implication of BAL 
neutrophilia. Am J Respir Crit Care Med 160:493-499. 
60. Wright, T. W., F. Gigliotti, J. N. Finkelstein, J. T. McBride, C. L. An, and A. G. 
Harmsen. 1999. Immune-mediated inflammation directly impairs pulmonary function, 
contributing to the pathogenesis of Pneumocystis carinii pneumonia. J Clin Invest 
104:1307-1317. 
61. Smith, R. L., W. M. el-Sadr, and M. L. Lewis. 1988. Correlation of bronchoalveolar 
lavage cell populations with clinical severity of Pneumocystis carinii pneumonia. Chest 
93:60-64. 
62. Swain, S. D., T. W. Wright, P. M. Degel, F. Gigliotti, and A. G. Harmsen. 2004. Neither 
neutrophils nor reactive oxygen species contribute to tissue damage during Pneumocystis 
pneumonia in mice. Infect Immun 72:5722-5732. 
63. Hahn, P. Y., S. E. Evans, T. J. Kottom, J. E. Standing, R. E. Pagano, and A. H. Limper. 
2003. Pneumocystis carinii cell wall beta-glucan induces release of macrophage 
inflammatory protein-2 from alveolar epithelial cells via a lactosylceramide-mediated 
mechanism. J Biol Chem 278:2043-2050. 
64. Wang, J., F. Gigliotti, S. P. Bhagwat, S. B. Maggirwar, and T. W. Wright. 2007. 
Pneumocystis stimulates MCP-1 production by alveolar epithelial cells through a JNK-
dependent mechanism. Am J Physiol Lung Cell Mol Physiol 292:L1495-1505. 
65. Pottratz, S. T., and W. J. Martin, 2nd. 1990. Mechanism of Pneumocystis carinii 
attachment to cultured rat alveolar macrophages. J Clin Invest 86:1678-1683. 
66. Pottratz, S. T., J. Paulsrud, J. S. Smith, and W. J. Martin, 2nd. 1991. Pneumocystis carinii 
attachment to cultured lung cells by pneumocystis gp 120, a fibronectin binding protein. J 
Clin Invest 88:403-407. 
 184 
67. Limper, A. H., J. E. Standing, O. A. Hoffman, M. Castro, and L. W. Neese. 1993. 
Vitronectin binds to Pneumocystis carinii and mediates organism attachment to cultured 
lung epithelial cells. Infect Immun 61:4302-4309. 
68. Neese, L. W., J. E. Standing, E. J. Olson, M. Castro, and A. H. Limper. 1994. 
Vitronectin, fibronectin, and gp120 antibody enhance macrophage release of TNF-alpha 
in response to Pneumocystis carinii. J Immunol 152:4549-4556. 
69. Vassallo, R., T. J. Kottom, J. E. Standing, and A. H. Limper. 2001. Vitronectin and 
fibronectin function as glucan binding proteins augmenting macrophage responses to 
Pneumocystis carinii. Am J Respir Cell Mol Biol 25:203-211. 
70. Linke, M., A. Ashbaugh, J. Koch, R. Tanaka, and P. Walzer. 2005. Surfactant protein A 
limits Pneumocystis murina infection in immunosuppressed C3H/HeN mice and 
modulates host response during infection. Microbes Infect 7:748-759. 
71. Vuk-Pavlovic, Z., E. K. Mo, C. R. Icenhour, J. E. Standing, J. H. Fisher, and A. H. 
Limper. 2006. Surfactant protein D enhances Pneumocystis infection in immune-
suppressed mice. Am J Physiol Lung Cell Mol Physiol 290:L442-449. 
72. Vuk-Pavlovic, Z., J. E. Standing, E. C. Crouch, and A. H. Limper. 2001. Carbohydrate 
recognition domain of surfactant protein D mediates interactions with Pneumocystis 
carinii glycoprotein A. Am J Respir Cell Mol Biol 24:475-484. 
73. McCormack, F. X., A. L. Festa, R. P. Andrews, M. Linke, and P. D. Walzer. 1997. The 
carbohydrate recognition domain of surfactant protein A mediates binding to the major 
surface glycoprotein of Pneumocystis carinii. Biochemistry 36:8092-8099. 
74. Yong, S. J., Z. Vuk-Pavlovic, J. E. Standing, E. C. Crouch, and A. H. Limper. 2003. 
Surfactant protein D-mediated aggregation of Pneumocystis carinii impairs phagocytosis 
by alveolar macrophages. Infect Immun 71:1662-1671. 
75. Koziel, H., D. S. Phelps, J. A. Fishman, M. Y. Armstrong, F. F. Richards, and R. M. 
Rose. 1998. Surfactant protein-A reduces binding and phagocytosis of pneumocystis 
carinii by human alveolar macrophages in vitro. Am J Respir Cell Mol Biol 18:834-843. 
76. Abgrall, S., I. Charreau, V. Joly, J. Bloch, and J. Reynes. 2001. Risk factors for 
esophageal candidiasis in a large cohort of HIV-infected patients treated with nucleoside 
analogues. Eur J Clin Microbiol Infect Dis 20:346-349. 
77. Tramsen, L., O. Beck, F. R. Schuster, K. P. Hunfeld, J. P. Latge, J. Sarfati, F. Roger, T. 
Klingebiel, U. Koehl, and T. Lehrnbecher. 2007. Generation and characterization of anti-
Candida T cells as potential immunotherapy in patients with Candida infection after 
allogeneic hematopoietic stem-cell transplant. J Infect Dis 196:485-492. 
78. Beck, O., M. S. Topp, U. Koehl, E. Roilides, M. Simitsopoulou, M. Hanisch, J. Sarfati, J. 
P. Latge, T. Klingebiel, H. Einsele, and T. Lehrnbecher. 2006. Generation of highly 
 185 
purified and functionally active human TH1 cells against Aspergillus fumigatus. Blood 
107:2562-2569. 
79. Cenci, E., S. Perito, K. H. Enssle, P. Mosci, J. P. Latge, L. Romani, and F. Bistoni. 1997. 
Th1 and Th2 cytokines in mice with invasive aspergillosis. Infect Immun 65:564-570. 
80. Stansell, J. D., D. H. Osmond, E. Charlebois, L. LaVange, J. M. Wallace, B. V. 
Alexander, J. Glassroth, P. A. Kvale, M. J. Rosen, L. B. Reichman, J. R. Turner, and P. 
C. Hopewell. 1997. Predictors of Pneumocystis carinii pneumonia in HIV-infected 
persons. Pulmonary Complications of HIV Infection Study Group. Am J Respir Crit Care 
Med 155:60-66. 
81. Hanano, R., K. Reifenberg, and S. H. Kaufmann. 1996. Naturally acquired Pneumocystis 
carinii pneumonia in gene disruption mutant mice: roles of distinct T-cell populations in 
infection. Infect Immun 64:3201-3209. 
82. Roths, J. B., and C. L. Sidman. 1992. Both immunity and hyperresponsiveness to 
Pneumocystis carinii result from transfer of CD4+ but not CD8+ T cells into severe 
combined immunodeficiency mice. J Clin Invest 90:673-678. 
83. Harmsen, A. G., and M. Stankiewicz. 1991. T cells are not sufficient for resistance to 
Pneumocystis carinii pneumonia in mice. J Protozool 38:44S-45S. 
84. Lund, F. E., M. Hollifield, K. Schuer, J. L. Lines, T. D. Randall, and B. A. Garvy. 2006. 
B cells are required for generation of protective effector and memory CD4 cells in 
response to Pneumocystis lung infection. J Immunol 176:6147-6154. 
85. Chen, W., E. A. Havell, L. L. Moldawer, K. W. McIntyre, R. A. Chizzonite, and A. G. 
Harmsen. 1992. Interleukin 1: an important mediator of host resistance against 
Pneumocystis carinii. J Exp Med 176:713-718. 
86. Chen, W., E. A. Havell, and A. G. Harmsen. 1992. Importance of endogenous tumor 
necrosis factor alpha and gamma interferon in host resistance against Pneumocystis 
carinii infection. Infect Immun 60:1279-1284. 
87. McAllister, F., C. Steele, M. Zheng, J. E. Shellito, and J. K. Kolls. 2005. In vitro effector 
activity of Pneumocystis murina-specific T-cytotoxic-1 CD8+ T cells: role of 
granulocyte-macrophage colony-stimulating factor. Infect Immun 73:7450-7457. 
88. Garvy, B. A., R. A. Ezekowitz, and A. G. Harmsen. 1997. Role of gamma interferon in 
the host immune and inflammatory responses to Pneumocystis carinii infection. Infect 
Immun 65:373-379. 
89. Kolls, J. K., S. Habetz, M. K. Shean, C. Vazquez, J. A. Brown, D. Lei, P. 
Schwarzenberger, P. Ye, S. Nelson, W. R. Summer, and J. E. Shellito. 1999. IFN-gamma 
and CD8+ T cells restore host defenses against Pneumocystis carinii in mice depleted of 
CD4+ T cells. J Immunol 162:2890-2894. 
 186 
90. McAllister, F., C. Steele, M. Zheng, E. Young, J. E. Shellito, L. Marrero, and J. K. Kolls. 
2004. T cytotoxic-1 CD8+ T cells are effector cells against pneumocystis in mice. J 
Immunol 172:1132-1138. 
91. Marcotte, H., D. Levesque, K. Delanay, A. Bourgeault, R. de la Durantaye, S. Brochu, 
and M. C. Lavoie. 1996. Pneumocystis carinii infection in transgenic B cell-deficient 
mice. J Infect Dis 173:1034-1037. 
92. Zheng, M., A. J. Ramsay, M. B. Robichaux, K. A. Norris, C. Kliment, C. Crowe, R. R. 
Rapaka, C. Steele, F. McAllister, J. E. Shellito, L. Marrero, P. Schwarzenberger, Q. 
Zhong, and J. K. Kolls. 2005. CD4+ T cell-independent DNA vaccination against 
opportunistic infections. J Clin Invest 115:3536-3544. 
93. Gigliotti, F., C. G. Haidaris, T. W. Wright, and A. G. Harmsen. 2002. Passive intranasal 
monoclonal antibody prophylaxis against murine Pneumocystis carinii pneumonia. Infect 
Immun 70:1069-1074. 
94. Gigliotti, F., and W. T. Hughes. 1988. Passive immunoprophylaxis with specific 
monoclonal antibody confers partial protection against Pneumocystis carinii pneumonitis 
in animal models. J Clin Invest 81:1666-1668. 
95. Wells, J., C. G. Haidaris, T. W. Wright, and F. Gigliotti. 2006. Complement and Fc 
function are required for optimal antibody prophylaxis against Pneumocystis carinii 
pneumonia. Infect Immun 74:390-393. 
96. Lund, F. E., K. Schuer, M. Hollifield, T. D. Randall, and B. A. Garvy. 2003. Clearance of 
Pneumocystis carinii in mice is dependent on B cells but not on P carinii-specific 
antibody. J Immunol 171:1423-1430. 
97. Harmsen, A. G., W. Chen, and F. Gigliotti. 1995. Active immunity to Pneumocystis 
carinii reinfection in T-cell-depleted mice. Infect Immun 63:2391-2395. 
98. Garvy, B. A., J. A. Wiley, F. Gigliotti, and A. G. Harmsen. 1997. Protection against 
Pneumocystis carinii pneumonia by antibodies generated from either T helper 1 or T 
helper 2 responses. Infect Immun 65:5052-5056. 
99. Meissner, N., M. Rutkowski, A. L. Harmsen, S. Han, and A. G. Harmsen. 2007. Type I 
interferon signaling and B cells maintain hemopoiesis during Pneumocystis infection of 
the lung. J Immunol 178:6604-6615. 
100. Lund, F. E. 2008. Cytokine-producing B lymphocytes-key regulators of immunity. Curr 
Opin Immunol. 
101. Crous, P. W., I. H. Rong, A. Wood, S. Lee, H. Glen, W. Botha, B. Slippers, W. Z. de 
Beer, M. J. Wingfield, and D. L. Hawksworth. 2006. How many species of fungi are 
there at the tip of Africa? Stud Mycol 55:13-33. 
 187 
102. Latge, J. P. 2007. The cell wall: a carbohydrate armour for the fungal cell. Mol Microbiol 
66:279-290. 
103. Lesage, G., and H. Bussey. 2006. Cell wall assembly in Saccharomyces cerevisiae. 
Microbiol Mol Biol Rev 70:317-343. 
104. Banks, I. R., C. A. Specht, M. J. Donlin, K. J. Gerik, S. M. Levitz, and J. K. Lodge. 2005. 
A chitin synthase and its regulator protein are critical for chitosan production and growth 
of the fungal pathogen Cryptococcus neoformans. Eukaryot Cell 4:1902-1912. 
105. Nwe, N., W. F. Stevens, D. Montet, S. Tokura, and H. Tamura. 2008. Decomposition of 
myceliar matrix and extraction of chitosan from Gongronella butleri USDB 0201 and 
Absidia coerulea ATCC 14076. Int J Biol Macromol 43:2-7. 
106. Nahar, P., V. Ghormade, and M. V. Deshpande. 2004. The extracellular constitutive 
production of chitin deacetylase in Metarhizium anisopliae: possible edge to 
entomopathogenic fungi in the biological control of insect pests. J Invertebr Pathol 
85:80-88. 
107. Fukamizo, T., T. Ohkawa, K. Sonoda, H. Toyoda, T. Nishiguchi, S. Ouchi, and S. Goto. 
1992. Chitinous components of the cell wall of Fusarium oxysporum. Biosci Biotechnol 
Biochem 56:1632-1636. 
108. Christodoulidou, A., V. Bouriotis, and G. Thireos. 1996. Two sporulation-specific chitin 
deacetylase-encoding genes are required for the ascospore wall rigidity of Saccharomyces 
cerevisiae. J Biol Chem 271:31420-31425. 
109. Briza, P., A. Ellinger, G. Winkler, and M. Breitenbach. 1988. Chemical composition of 
the yeast ascospore wall. The second outer layer consists of chitosan. J Biol Chem 
263:11569-11574. 
110. Cabib, E., Silverman, SJ, Shaw A, Das Gupta S, Park HM, Thomas-Mullins J, Mol, PC 
and Bowers B. 1991. Carbohydrates as structural constituents of yeast cell wall and 
septum. Pure & Appl. Chem. 63:483-489. 
111. Roth, A., J. Wecke, V. Karsten, and K. Janitschke. 1997. Light and electron microscopy 
study of carbohydrate antigens found in the electron-lucent layer of Pneumocystis carinii 
cysts. Parasitol Res 83:177-184. 
112. Matsumoto, Y., S. Matsuda, and T. Tegoshi. 1989. Yeast glucan in the cyst wall of 
Pneumocystis carinii. J Protozool 36:21S-22S. 
113. Nollstadt, K. H., M. A. Powles, H. Fujioka, M. Aikawa, and D. M. Schmatz. 1994. Use 
of beta-1,3-glucan-specific antibody to study the cyst wall of Pneumocystis carinii and 
effects of pneumocandin B0 analog L-733,560. Antimicrob Agents Chemother 38:2258-
2265. 
 188 
114. Schmatz, D. M., M. A. Romancheck, L. A. Pittarelli, R. E. Schwartz, R. A. Fromtling, K. 
H. Nollstadt, F. L. Vanmiddlesworth, K. E. Wilson, and M. J. Turner. 1990. Treatment of 
Pneumocystis carinii pneumonia with 1,3-beta-glucan synthesis inhibitors. Proc Natl 
Acad Sci U S A 87:5950-5954. 
115. Schmatz, D. M., M. A. Powles, D. McFadden, K. Nollstadt, F. A. Bouffard, J. F. 
Dropinski, P. Liberator, and J. Andersen. 1995. New semisynthetic pneumocandins with 
improved efficacies against Pneumocystis carinii in the rat. Antimicrob Agents 
Chemother 39:1320-1323. 
116. Walker, A. N., R. E. Garner, and M. N. Horst. 1990. Immunocytochemical detection of 
chitin in Pneumocystis carinii. Infect Immun 58:412-415. 
117. Cushion, M. T., J. A. DeStefano, and P. D. Walzer. 1988. Pneumocystis carinii: surface 
reactive carbohydrates detected by lectin probes. Exp Parasitol 67:137-147. 
118. Angus, C. W., A. Tu, P. Vogel, M. Qin, and J. A. Kovacs. 1996. Expression of variants 
of the major surface glycoprotein of Pneumocystis carinii. J Exp Med 183:1229-1234. 
119. Di Luzio, N. R., R. McNamee, E. Jones, S. Lassoff, W. Sear, and E. O. Hoffmann. 1976. 
Inhibition of growth and dissemination of Shay myelogenous leukemic tumor in rats by 
glucan and glucan activated macrophages. Adv Exp Med Biol 73 Pt B:397-413. 
120. Morikawa, K., R. Takeda, M. Yamazaki, and D. Mizuno. 1985. Induction of tumoricidal 
activity of polymorphonuclear leukocytes by a linear beta-1,3-D-glucan and other 
immunomodulators in murine cells. Cancer Res 45:1496-1501. 
121. Scaringi, L., P. Marconi, M. Boccanera, L. Tissi, F. Bistoni, and A. Cassone. 1988. Cell 
wall components of Candida albicans as immunomodulators: induction of natural killer 
and macrophage-mediated peritoneal cell cytotoxicity in mice by mannoprotein and 
glucan fractions. J Gen Microbiol 134:1265-1274. 
122. Brown, G. D., and S. Gordon. 2003. Fungal beta-glucans and mammalian immunity. 
Immunity 19:311-315. 
123. Yan, J., V. Vetvicka, Y. Xia, A. Coxon, M. C. Carroll, T. N. Mayadas, and G. D. Ross. 
1999. Beta-glucan, a "specific" biologic response modifier that uses antibodies to target 
tumors for cytotoxic recognition by leukocyte complement receptor type 3 
(CD11b/CD18). J Immunol 163:3045-3052. 
124. Li, B., D. J. Allendorf, R. Hansen, J. Marroquin, C. Ding, D. E. Cramer, and J. Yan. 
2006. Yeast beta-glucan amplifies phagocyte killing of iC3b-opsonized tumor cells via 
complement receptor 3-Syk-phosphatidylinositol 3-kinase pathway. J Immunol 177:1661-
1669. 
 189 
125. Williams, D. L., R. G. Yaeger, H. A. Pretus, I. W. Browder, R. B. McNamee, and E. L. 
Jones. 1989. Immunization against Trypanosoma cruzi: adjuvant effect of glucan. Int J 
Immunopharmacol 11:403-410. 
126. Apostolopoulos, V., G. A. Pietersz, and I. F. McKenzie. 1996. Cell-mediated immune 
responses to MUC1 fusion protein coupled to mannan. Vaccine 14:930-938. 
127. Tan, M. C., A. M. Mommaas, J. W. Drijfhout, R. Jordens, J. J. Onderwater, D. Verwoerd, 
A. A. Mulder, A. N. van der Heiden, D. Scheidegger, L. C. Oomen, T. H. Ottenhoff, A. 
Tulp, J. J. Neefjes, and F. Koning. 1997. Mannose receptor-mediated uptake of antigens 
strongly enhances HLA class II-restricted antigen presentation by cultured dendritic cells. 
Eur J Immunol 27:2426-2435. 
128. Lam, J. S., H. Huang, and S. M. Levitz. 2007. Effect of differential N-linked and O-
linked mannosylation on recognition of fungal antigens by dendritic cells. PLoS ONE 
2:e1009. 
129. Mansour, M. K., E. Latz, and S. M. Levitz. 2006. Cryptococcus neoformans 
glycoantigens are captured by multiple lectin receptors and presented by dendritic cells. J 
Immunol 176:3053-3061. 
130. Nigou, J., T. Vasselon, A. Ray, P. Constant, M. Gilleron, G. S. Besra, I. Sutcliffe, G. 
Tiraby, and G. Puzo. 2008. Mannan chain length controls lipoglycans signaling via and 
binding to TLR2. J Immunol 180:6696-6702. 
131. Zhu, Z., T. Zheng, R. J. Homer, Y. K. Kim, N. Y. Chen, L. Cohn, Q. Hamid, and J. A. 
Elias. 2004. Acidic mammalian chitinase in asthmatic Th2 inflammation and IL-13 
pathway activation. Science 304:1678-1682. 
132. Reese, T. A., H. E. Liang, A. M. Tager, A. D. Luster, N. Van Rooijen, D. Voehringer, 
and R. M. Locksley. 2007. Chitin induces accumulation in tissue of innate immune cells 
associated with allergy. Nature 447:92-96. 
133. McNeela, E. A., I. Jabbal-Gill, L. Illum, M. Pizza, R. Rappuoli, A. Podda, D. J. Lewis, 
and K. H. Mills. 2004. Intranasal immunization with genetically detoxified diphtheria 
toxin induces T cell responses in humans: enhancement of Th2 responses and toxin-
neutralizing antibodies by formulation with chitosan. Vaccine 22:909-914. 
134. Xie, Y., N. J. Zhou, Y. F. Gong, X. J. Zhou, J. Chen, S. J. Hu, N. H. Lu, and X. H. Hou. 
2007. Th immune response induced by H pylori vaccine with chitosan as adjuvant and its 
relation to immune protection. World J Gastroenterol 13:1547-1553. 
135. Ghendon, Y., S. Markushin, G. Krivtsov, and I. Akopova. 2008. Chitosan as an adjuvant 
for parenterally administered inactivated influenza vaccines. Arch Virol 153:831-837. 
 190 
136. Ozdemir, C., D. Yazi, M. Aydogan, T. Akkoc, N. N. Bahceciler, P. Strong, and I. B. 
Barlan. 2006. Treatment with chitin microparticles is protective against lung 
histopathology in a murine asthma model. Clin Exp Allergy 36:960-968. 
137. Vassallo, R., J. E. Standing, and A. H. Limper. 2000. Isolated Pneumocystis carinii cell 
wall glucan provokes lower respiratory tract inflammatory responses. J Immunol 
164:3755-3763. 
138. Saijo, S., N. Fujikado, T. Furuta, S. H. Chung, H. Kotaki, K. Seki, K. Sudo, S. Akira, Y. 
Adachi, N. Ohno, T. Kinjo, K. Nakamura, K. Kawakami, and Y. Iwakura. 2007. Dectin-1 
is required for host defense against Pneumocystis carinii but not against Candida 
albicans. Nat Immunol 8:39-46. 
139. Ariizumi, K., G. L. Shen, S. Shikano, S. Xu, R. Ritter, 3rd, T. Kumamoto, D. Edelbaum, 
A. Morita, P. R. Bergstresser, and A. Takashima. 2000. Identification of a novel, 
dendritic cell-associated molecule, dectin-1, by subtractive cDNA cloning. J Biol Chem 
275:20157-20167. 
140. Underhill, D. M., E. Rossnagle, C. A. Lowell, and R. M. Simmons. 2005. Dectin-1 
activates Syk tyrosine kinase in a dynamic subset of macrophages for reactive oxygen 
production. Blood 106:2543-2550. 
141. Rogers, N. C., E. C. Slack, A. D. Edwards, M. A. Nolte, O. Schulz, E. Schweighoffer, D. 
L. Williams, S. Gordon, V. L. Tybulewicz, G. D. Brown, and C. Reis e Sousa. 2005. Syk-
dependent cytokine induction by Dectin-1 reveals a novel pattern recognition pathway for 
C type lectins. Immunity 22:507-517. 
142. Gross, O., A. Gewies, K. Finger, M. Schafer, T. Sparwasser, C. Peschel, I. Forster, and J. 
Ruland. 2006. Card9 controls a non-TLR signalling pathway for innate anti-fungal 
immunity. Nature 442:651-656. 
143. Brown, G. D. 2006. Dectin-1: a signalling non-TLR pattern-recognition receptor. Nat Rev 
Immunol 6:33-43. 
144. Brown, G. D., and S. Gordon. 2001. Immune recognition. A new receptor for beta-
glucans. Nature 413:36-37. 
145. Brown, G. D., P. R. Taylor, D. M. Reid, J. A. Willment, D. L. Williams, L. Martinez-
Pomares, S. Y. Wong, and S. Gordon. 2002. Dectin-1 is a major beta-glucan receptor on 
macrophages. J Exp Med 196:407-412. 
146. Zhang, C., S. H. Wang, M. E. Lasbury, D. Tschang, C. P. Liao, P. J. Durant, and C. H. 
Lee. 2006. Toll-like receptor 2 mediates alveolar macrophage response to Pneumocystis 
murina. Infect Immun 74:1857-1864. 
147. Casadevall, A. 1995. Antibody immunity and invasive fungal infections. Infect Immun 
63:4211-4218. 
 191 
148. Cutler, J. E., G. S. Deepe, Jr., and B. S. Klein. 2007. Advances in combating fungal 
diseases: vaccines on the threshold. Nat Rev Microbiol 5:13-28. 
149. Matthews, R. C., G. Rigg, S. Hodgetts, T. Carter, C. Chapman, C. Gregory, C. Illidge, 
and J. Burnie. 2003. Preclinical assessment of the efficacy of mycograb, a human 
recombinant antibody against fungal HSP90. Antimicrob Agents Chemother 47:2208-
2216. 
150. Nosanchuk, J. D., J. N. Steenbergen, L. Shi, G. S. Deepe, Jr., and A. Casadevall. 2003. 
Antibodies to a cell surface histone-like protein protect against Histoplasma capsulatum. 
J Clin Invest 112:1164-1175. 
151. Devi, S. J., R. Schneerson, W. Egan, T. J. Ulrich, D. Bryla, J. B. Robbins, and J. E. 
Bennett. 1991. Cryptococcus neoformans serotype A glucuronoxylomannan-protein 
conjugate vaccines: synthesis, characterization, and immunogenicity. Infect Immun 
59:3700-3707. 
152. Mukherjee, J., A. Casadevall, and M. D. Scharff. 1993. Molecular characterization of the 
humoral responses to Cryptococcus neoformans infection and glucuronoxylomannan-
tetanus toxoid conjugate immunization. J Exp Med 177:1105-1116. 
153. Dromer, F., J. Charreire, A. Contrepois, C. Carbon, and P. Yeni. 1987. Protection of mice 
against experimental cryptococcosis by anti-Cryptococcus neoformans monoclonal 
antibody. Infect Immun 55:749-752. 
154. Torosantucci, A., C. Bromuro, P. Chiani, F. De Bernardis, F. Berti, C. Galli, F. Norelli, 
C. Bellucci, L. Polonelli, P. Costantino, R. Rappuoli, and A. Cassone. 2005. A novel 
glyco-conjugate vaccine against fungal pathogens. J Exp Med 202:597-606. 
155. Moragues, M. D., M. J. Omaetxebarria, N. Elguezabal, M. J. Sevilla, S. Conti, L. 
Polonelli, and J. Ponton. 2003. A monoclonal antibody directed against a Candida 
albicans cell wall mannoprotein exerts three anti-C. albicans activities. Infect Immun 
71:5273-5279. 
156. Zhong, Z., and L. A. Pirofski. 1998. Antifungal activity of a human 
antiglucuronoxylomannan antibody. Clinical and diagnostic laboratory immunology 
5:58-64. 
157. Grappel, S. F., and R. A. Calderone. 1976. Effect of antibodies on the respiration and 
morphology of Candida Albicans. Sabouraudia 14:51-60. 
158. Rivera, J., O. Zaragoza, and A. Casadevall. 2005. Antibody-mediated protection against 
Cryptococcus neoformans pulmonary infection is dependent on B cells. Infect Immun 
73:1141-1150. 
 192 
159. Yuan, R. R., A. Casadevall, J. Oh, and M. D. Scharff. 1997. T cells cooperate with 
passive antibody to modify Cryptococcus neoformans infection in mice. Proc Natl Acad 
Sci U S A 94:2483-2488. 
160. Yuan, R., A. Casadevall, G. Spira, and M. D. Scharff. 1995. Isotype switching from IgG3 
to IgG1 converts a nonprotective murine antibody to Cryptococcus neoformans into a 
protective antibody. J Immunol 154:1810-1816. 
161. Mukherjee, J., M. D. Scharff, and A. Casadevall. 1992. Protective murine monoclonal 
antibodies to Cryptococcus neoformans. Infect Immun 60:4534-4541. 
162. McLean, G. R., M. Torres, N. Elguezabal, A. Nakouzi, and A. Casadevall. 2002. Isotype 
can affect the fine specificity of an antibody for a polysaccharide antigen. J Immunol 
169:1379-1386. 
163. Taborda, C. P., and A. Casadevall. 2001. Immunoglobulin M efficacy against 
Cryptococcus neoformans: mechanism, dose dependence, and prozone-like effects in 
passive protection experiments. J Immunol 166:2100-2107. 
164. Taborda, C. P., J. Rivera, O. Zaragoza, and A. Casadevall. 2003. More is not necessarily 
better: prozone-like effects in passive immunization with IgG. J Immunol 170:3621-3630. 
165. Halstead, S. B., and E. J. O'Rourke. 1977. Antibody-enhanced dengue virus infection in 
primate leukocytes. Nature 265:739-741. 
166. Halstead, S. B., J. S. Porterfield, and E. J. O'Rourke. 1980. Enhancement of dengue virus 
infection in monocytes by flavivirus antisera. Am J Trop Med Hyg 29:638-642. 
167. Roths, J. B., and C. L. Sidman. 1993. Single and combined humoral and cell-mediated 
immunotherapy of Pneumocystis carinii pneumonia in immunodeficient scid mice. Infect 
Immun 61:1641-1649. 
168. Empey, K. M., M. Hollifield, K. Schuer, F. Gigliotti, and B. A. Garvy. 2004. Passive 
immunization of neonatal mice against Pneumocystis carinii f. sp. muris enhances control 
of infection without stimulating inflammation. Infect Immun 72:6211-6220. 
169. Baumgarth, N., J. W. Tung, and L. A. Herzenberg. 2005. Inherent specificities in natural 
antibodies: a key to immune defense against pathogen invasion. Springer Semin 
Immunopathol 26:347-362. 
170. Hashimoto, K., H. Handa, K. Umehara, and S. Sasaki. 1978. Germfree mice reared on an 
"antigen-free" diet. Laboratory animal science 28:38-45. 
171. Cukrowska, B., J. Sinkora, Z. Rehakova, M. Sinkora, I. Splichal, L. Tuckova, S. 
Avrameas, A. Saalmuller, R. Barot-Ciorbaru, and H. Tlaskalova-Hogenova. 1996. 
Isotype and antibody specificity of spontaneously formed immunoglobulins in pig fetuses 
and germ-free piglets: production by CD5- B cells. Immunology 88:611-617. 
 193 
172. Lalor, P. A., and G. Morahan. 1990. The peritoneal Ly-1 (CD5) B cell repertoire is 
unique among murine B cell repertoires. Eur J Immunol 20:485-492. 
173. Forster, I., and K. Rajewsky. 1987. Expansion and functional activity of Ly-1+ B cells 
upon transfer of peritoneal cells into allotype-congenic, newborn mice. Eur J Immunol 
17:521-528. 
174. Macpherson, A. J., D. Gatto, E. Sainsbury, G. R. Harriman, H. Hengartner, and R. M. 
Zinkernagel. 2000. A primitive T cell-independent mechanism of intestinal mucosal IgA 
responses to commensal bacteria. Science 288:2222-2226. 
175. Avrameas, S. 1991. Natural autoantibodies: from 'horror autotoxicus' to 'gnothi seauton'. 
Immunology today 12:154-159. 
176. Kantor, A. B., and L. A. Herzenberg. 1993. Origin of murine B cell lineages. Annu Rev 
Immunol 11:501-538. 
177. Pillai, S., A. Cariappa, and S. T. Moran. 2004. Positive selection and lineage commitment 
during peripheral B-lymphocyte development. Immunol Rev 197:206-218. 
178. Adelman, M. K., S. F. Schluter, I. F. Robey, and J. J. Marchalonis. 2007. Natural and 
autoantibodies to human T-cell receptor Vbeta segments: potential roles in 
immunomodulation. Crit Rev Immunol 27:221-232. 
179. Li, W., M. Fu, J. G. An, Y. Xing, P. Zhang, X. Zhang, Y. C. Wang, C. X. Li, R. Tian, W. 
J. Su, H. H. Guan, G. Wang, T. W. Gao, H. Han, and Y. F. Liu. 2007. Host defence 
against C. albicans infections in IgH transgenic mice with V(H) derived from a natural 
anti-keratin antibody. Cell Microbiol 9:306-315. 
180. Fu, M., P. S. Fan, W. Li, C. X. Li, Y. Xing, J. G. An, G. Wang, X. L. Fan, T. W. Gao, Y. 
F. Liu, and S. Ikeda. 2007. Identification of poly-reactive natural IgM antibody that 
recognizes late apoptotic cells and promotes phagocytosis of the cells. Apoptosis 12:355-
362. 
181. Haas, K. M., J. C. Poe, D. A. Steeber, and T. F. Tedder. 2005. B-1a and B-1b cells 
exhibit distinct developmental requirements and have unique functional roles in innate 
and adaptive immunity to S. pneumoniae. Immunity 23:7-18. 
182. Alugupalli, K. R., J. M. Leong, R. T. Woodland, M. Muramatsu, T. Honjo, and R. M. 
Gerstein. 2004. B1b lymphocytes confer T cell-independent long-lasting immunity. 
Immunity 21:379-390. 
183. Alugupalli, K. R., and R. M. Gerstein. 2005. Divide and conquer: division of labor by B-
1 B cells. Immunity 23:1-2. 
 194 
184. Kawahara, T., H. Ohdan, G. Zhao, Y. G. Yang, and M. Sykes. 2003. Peritoneal cavity B 
cells are precursors of splenic IgM natural antibody-producing cells. J Immunol 
171:5406-5414. 
185. Thall, A. D., P. Maly, and J. B. Lowe. 1995. Oocyte Gal alpha 1,3Gal epitopes implicated 
in sperm adhesion to the zona pellucida glycoprotein ZP3 are not required for fertilization 
in the mouse. J Biol Chem 270:21437-21440. 
186. Galili, U., R. E. Mandrell, R. M. Hamadeh, S. B. Shohet, and J. M. Griffiss. 1988. 
Interaction between human natural anti-alpha-galactosyl immunoglobulin G and bacteria 
of the human flora. Infect Immun 56:1730-1737. 
187. Avila, J. L., M. Rojas, and U. Galili. 1989. Immunogenic Gal alpha 1----3Gal 
carbohydrate epitopes are present on pathogenic American Trypanosoma and 
Leishmania. J Immunol 142:2828-2834. 
188. Yang, Y., J. W. Tung, E. E. Ghosn, and L. A. Herzenberg. 2007. Division and 
differentiation of natural antibody-producing cells in mouse spleen. Proc Natl Acad Sci U 
S A 104:4542-4546. 
189. Ha, S. A., M. Tsuji, K. Suzuki, B. Meek, N. Yasuda, T. Kaisho, and S. Fagarasan. 2006. 
Regulation of B1 cell migration by signals through Toll-like receptors. J Exp Med 
203:2541-2550. 
190. Ochsenbein, A. F., and R. M. Zinkernagel. 2000. Natural antibodies and complement link 
innate and acquired immunity. Immunol Today 21:624-630. 
191. Ochsenbein, A. F., T. Fehr, C. Lutz, M. Suter, F. Brombacher, H. Hengartner, and R. M. 
Zinkernagel. 1999. Control of early viral and bacterial distribution and disease by natural 
antibodies. Science 286:2156-2159. 
192. Kinoshita, M., N. Shinomiya, S. Ono, H. Tsujimoto, T. Kawabata, A. Matsumoto, H. 
Hiraide, and S. Seki. 2006. Restoration of natural IgM production from liver B cells by 
exogenous IL-18 improves the survival of burn-injured mice infected with Pseudomonas 
aeruginosa. J Immunol 177:4627-4635. 
193. Kuranaga, N., M. Kinoshita, T. Kawabata, Y. Habu, N. Shinomiya, and S. Seki. 2006. 
Interleukin-18 protects splenectomized mice from lethal Streptococcus pneumoniae 
sepsis independent of interferon-gamma by inducing IgM production. J Infect Dis 
194:993-1002. 
194. Navin, T. R., E. C. Krug, and R. D. Pearson. 1989. Effect of immunoglobulin M from 
normal human serum on Leishmania donovani promastigote agglutination, complement-
mediated killing, and phagocytosis by human monocytes. Infect Immun 57:1343-1346. 
195. Paul, S., S. Karle, S. Planque, H. Taguchi, M. Salas, Y. Nishiyama, B. Handy, R. Hunter, 
A. Edmundson, and C. Hanson. 2004. Naturally occurring proteolytic antibodies: 
 195 
selective immunoglobulin M-catalyzed hydrolysis of HIV gp120. J Biol Chem 
279:39611-39619. 
196. Boes, M., A. P. Prodeus, T. Schmidt, M. C. Carroll, and J. Chen. 1998. A critical role of 
natural immunoglobulin M in immediate defense against systemic bacterial infection. J 
Exp Med 188:2381-2386. 
197. Rajan, B., T. Ramalingam, and T. V. Rajan. 2005. Critical role for IgM in host protection 
in experimental filarial infection. J Immunol 175:1827-1833. 
198. Baumgarth, N., O. C. Herman, G. C. Jager, L. E. Brown, L. A. Herzenberg, and J. Chen. 
2000. B-1 and B-2 cell-derived immunoglobulin M antibodies are nonredundant 
components of the protective response to influenza virus infection. J Exp Med 192:271-
280. 
199. Lehmann, P. F., and E. Reiss. 1980. Comparison by ELISA of serum anti-Candida 
albicans mannan IgG levels of a normal population and in diseased patients. 
Mycopathologia 70:89-93. 
200. Kozel, T. R., R. S. MacGill, A. Percival, and Q. Zhou. 2004. Biological activities of 
naturally occurring antibodies reactive with Candida albicans mannan. Infect Immun 
72:209-218. 
201. Weintraub, A. 2003. Immunology of bacterial polysaccharide antigens. Carbohydr Res 
338:2539-2547. 
202. Vos, Q., A. Lees, Z. Q. Wu, C. M. Snapper, and J. J. Mond. 2000. B-cell activation by T-
cell-independent type 2 antigens as an integral part of the humoral immune response to 
pathogenic microorganisms. Immunol Rev 176:154-170. 
203. Hayakawa, K., and R. R. Hardy. 1988. Normal, autoimmune, and malignant CD5+ B 
cells: the Ly-1 B lineage? Annu Rev Immunol 6:197-218. 
204. Bohnsack, J. F., and E. J. Brown. 1986. The role of the spleen in resistance to infection. 
Annu Rev Med 37:49-59. 
205. Cohn, D. A., and G. Schiffman. 1987. Immunoregulatory role of the spleen in antibody 
responses to pneumococcal polysaccharide antigens. Infect Immun 55:1375-1380. 
206. Martin, F., A. M. Oliver, and J. F. Kearney. 2001. Marginal zone and B1 B cells unite in 
the early response against T-independent blood-borne particulate antigens. Immunity 
14:617-629. 
207. Guinamard, R., M. Okigaki, J. Schlessinger, and J. V. Ravetch. 2000. Absence of 
marginal zone B cells in Pyk-2-deficient mice defines their role in the humoral response. 
Nat Immunol 1:31-36. 
 196 
208. Wu, Z. Q., Q. Vos, Y. Shen, A. Lees, S. R. Wilson, D. E. Briles, W. C. Gause, J. J. 
Mond, and C. M. Snapper. 1999. In vivo polysaccharide-specific IgG isotype responses 
to intact Streptococcus pneumoniae are T cell dependent and require CD40- and B7-
ligand interactions. J Immunol 163:659-667. 
209. Khan, A. Q., A. Lees, and C. M. Snapper. 2004. Differential regulation of IgG anti-
capsular polysaccharide and antiprotein responses to intact Streptococcus pneumoniae in 
the presence of cognate CD4+ T cell help. J Immunol 172:532-539. 
210. Mongini, P. K., K. E. Stein, and W. E. Paul. 1981. T cell regulation of IgG subclass 
antibody production in response to T-independent antigens. J Exp Med 153:1-12. 
211. Elkins, K. L., R. M. Buller, P. W. Stashak, and P. J. Baker. 1991. CD4+ T cells regulate 
the magnitude of the antibody response to several helper T cell independent antigens. 
Immunobiology 183:69-78. 
212. Rademaekers, A., E. Kolsch, and C. Specht. 2001. T cell mediated antibody invariance in 
an immune response against a bacterial carbohydrate antigen requires CD28/B7-1 
costimulation. Dev Immunol 8:243-257. 
213. Sun, K., F. E. Johansen, L. Eckmann, and D. W. Metzger. 2004. An important role for 
polymeric Ig receptor-mediated transport of IgA in protection against Streptococcus 
pneumoniae nasopharyngeal carriage. J Immunol 173:4576-4581. 
214. McHeyzer-Williams, L. J., and M. G. McHeyzer-Williams. 2005. Antigen-specific 
memory B cell development. Annu Rev Immunol 23:487-513. 
215. Slifka, M. K., R. Antia, J. K. Whitmire, and R. Ahmed. 1998. Humoral immunity due to 
long-lived plasma cells. Immunity 8:363-372. 
216. Tarlinton, D., A. Radbruch, F. Hiepe, and T. Dorner. 2008. Plasma cell differentiation 
and survival. Curr Opin Immunol 20:162-169. 
217. Tangye, S. G., Y. J. Liu, G. Aversa, J. H. Phillips, and J. E. de Vries. 1998. Identification 
of functional human splenic memory B cells by expression of CD148 and CD27. J Exp 
Med 188:1691-1703. 
218. Hebeis, B. J., K. Klenovsek, P. Rohwer, U. Ritter, A. Schneider, M. Mach, and T. H. 
Winkler. 2004. Activation of virus-specific memory B cells in the absence of T cell help. 
J Exp Med 199:593-602. 
219. Obukhanych, T. V., and M. C. Nussenzweig. 2006. T-independent type II immune 
responses generate memory B cells. J Exp Med 203:305-310. 
220. Fisk DT, M. S., Kazanjian PH. 2003. Pneumocystis carinii Pneumonia in Patients in the 
Developing World Who Have Acquired Immunodeficiency Syndrome. Clinical 
Infectious Diseases 36:70-78. 
 197 
221. Severe, P., P. Leger, M. Charles, F. Noel, G. Bonhomme, G. Bois, E. George, S. Kenel-
Pierre, P. F. Wright, R. Gulick, W. D. Johnson, Jr., J. W. Pape, and D. W. Fitzgerald. 
2005. Antiretroviral therapy in a thousand patients with AIDS in Haiti. N Engl J Med 
353:2325-2334. 
222. Murray, J. F. 2005. Pulmonary complications of HIV-1 infection among adults living in 
Sub-Saharan Africa. Int J Tuberc Lung Dis 9:826-835. 
223. Graham, S. M. 2005. Non-tuberculosis opportunistic infections and other lung diseases in 
HIV-infected infants and children. Int J Tuberc Lung Dis 9:592-602. 
224. Crothers, K., C. B. Beard, J. Turner, G. Groner, M. Fox, A. Morris, S. Eiser, and L. 
Huang. 2005. Severity and outcome of HIV-associated Pneumocystis pneumonia 
containing Pneumocystis jirovecii dihydropteroate synthase gene mutations. Aids 19:801-
805. 
225. Wiley, J. A., and A. G. Harmsen. 1995. CD40 ligand is required for resolution of 
Pneumocystis carinii pneumonia in mice. J Immunol 155:3525-3529. 
226. Hanano, R., and S. H. Kaufmann. 1999. Effect on parasite eradication of Pneumocystis 
carinii-specific antibodies produced in the presence or absence of CD4(+) alphabeta T 
lymphocytes. Eur J Immunol 29:2464-2475. 
227. Lee, L. H., F. Gigliotti, T. W. Wright, P. J. Simpson-Haidaris, G. A. Weinberg, and C. G. 
Haidaris. 2000. Molecular characterization of KEX1, a kexin-like protease in mouse 
Pneumocystis carinii. Gene 242:141-150. 
228. Peppel, K., D. Crawford, and B. Beutler. 1991. A tumor necrosis factor (TNF) receptor-
IgG heavy chain chimeric protein as a bivalent antagonist of TNF activity. J Exp Med 
174:1483-1489. 
229. Kolls, J., K. Peppel, M. Silva, and B. Beutler. 1994. Prolonged and effective blockade of 
tumor necrosis factor activity through adenovirus-mediated gene transfer. Proc Natl Acad 
Sci U S A 91:215-219. 
230. Read, S. M., G. Currie, and A. Bacic. 1996. Analysis of the structural heterogeneity of 
laminarin by electrospray-ionisation-mass spectrometry. Carbohydr Res 281:187-201. 
231. Galustian, C., C. G. Park, W. Chai, M. Kiso, S. A. Bruening, Y. S. Kang, R. M. 
Steinman, and T. Feizi. 2004. High and low affinity carbohydrate ligands revealed for 
murine SIGN-R1 by carbohydrate array and cell binding approaches, and differing 
specificities for SIGN-R3 and langerin. Int Immunol 16:853-866. 
232. Wild, M. K., M. C. Huang, U. Schulze-Horsel, P. A. van der Merwe, and D. Vestweber. 
2001. Affinity, kinetics, and thermodynamics of E-selectin binding to E-selectin ligand-1. 
J Biol Chem 276:31602-31612. 
 198 
233. Muller-Loennies, S., S. Gronow, L. Brade, R. MacKenzie, P. Kosma, and H. Brade. 
2006. A monoclonal antibody against a carbohydrate epitope in lipopolysaccharide 
differentiates Chlamydophila psittaci from Chlamydophila pecorum, Chlamydophila 
pneumoniae, and Chlamydia trachomatis. Glycobiology 16:184-196. 
234. Vyas, N. K., M. N. Vyas, M. C. Chervenak, D. R. Bundle, B. M. Pinto, and F. A. 
Quiocho. 2003. Structural basis of peptide-carbohydrate mimicry in an antibody-
combining site. Proc Natl Acad Sci U S A 100:15023-15028. 
235. Garcia-Ojeda, P. A., S. Hardy, S. Kozlowski, K. E. Stein, and I. M. Feavers. 2004. 
Surface plasmon resonance analysis of antipolysaccharide antibody specificity: responses 
to meningococcal group C conjugate vaccines and bacteria. Infect Immun 72:3451-3460. 
236. Di Carlo, F. J., and J. V. Fiore. 1958. On the composition of zymosan. Science 127:756-
757. 
237. Nimmerjahn, F., and J. V. Ravetch. 2006. Fcgamma receptors: old friends and new 
family members. Immunity 24:19-28. 
238. Sehra, S., G. Pynaert, K. Tournoy, A. Haegeman, P. Matthys, Y. Tagawa, R. Pauwels, 
and J. Grooten. 2003. Airway IgG counteracts specific and bystander allergen-triggered 
pulmonary inflammation by a mechanism dependent on Fc gamma R and IFN-gamma. J 
Immunol 171:2080-2089. 
239. Kolls, J. K., D. Lei, S. Nelson, W. R. Summer, S. Greenberg, and B. Beutler. 1995. 
Adenovirus-mediated blockade of tumor necrosis factor in mice protects against 
endotoxic shock yet impairs pulmonary host defense. J Infect Dis 171:570-575. 
240. Kolls, J. K., D. Lei, G. Odom, S. Nelson, W. R. Summer, M. A. Gerber, and J. E. 
Shellito. 1996. Use of transient CD4 lymphocyte depletion to prolong transgene 
expression of E1-deleted adenoviral vectors. Hum Gene Ther 7:489-497. 
241. Spiekermann, G. M., P. W. Finn, E. S. Ward, J. Dumont, B. L. Dickinson, R. S. 
Blumberg, and W. I. Lencer. 2002. Receptor-mediated immunoglobulin G transport 
across mucosal barriers in adult life: functional expression of FcRn in the mammalian 
lung. J Exp Med 196:303-310. 
242. Meissner, N. N., F. E. Lund, S. Han, and A. Harmsen. 2005. CD8 T cell-mediated lung 
damage in response to the extracellular pathogen pneumocystis is dependent on MHC 
class I expression by radiation-resistant lung cells. J Immunol 175:8271-8279. 
243. Chen, W., J. W. Mills, and A. G. Harmsen. 1992. Development and resolution of 
Pneumocystis carinii pneumonia in severe combined immunodeficient mice: a 
morphological study of host inflammatory responses. International journal of 
experimental pathology 73:709-720. 
 199 
244. Mason, G. R., C. H. Hashimoto, P. S. Dickman, L. F. Foutty, and C. J. Cobb. 1989. 
Prognostic implications of bronchoalveolar lavage neutrophilia in patients with 
Pneumocystis carinii pneumonia and AIDS. The American review of respiratory disease 
139:1336-1342. 
245. Gantner, B. N., R. M. Simmons, and D. M. Underhill. 2005. Dectin-1 mediates 
macrophage recognition of Candida albicans yeast but not filaments. Embo J 24:1277-
1286. 
246. Netea, M. G., N. A. Gow, C. A. Munro, S. Bates, C. Collins, G. Ferwerda, R. P. Hobson, 
G. Bertram, H. B. Hughes, T. Jansen, L. Jacobs, E. T. Buurman, K. Gijzen, D. L. 
Williams, R. Torensma, A. McKinnon, D. M. MacCallum, F. C. Odds, J. W. Van der 
Meer, A. J. Brown, and B. J. Kullberg. 2006. Immune sensing of Candida albicans 
requires cooperative recognition of mannans and glucans by lectin and Toll-like 
receptors. J Clin Invest 116:1642-1650. 
247. Hohl, T. M., H. L. Van Epps, A. Rivera, L. A. Morgan, P. L. Chen, M. Feldmesser, and 
E. G. Pamer. 2005. Aspergillus fumigatus Triggers Inflammatory Responses by Stage-
Specific beta-Glucan Display. PLoS Pathog 1:e30. 
248. Viriyakosol, S., J. Fierer, G. D. Brown, and T. N. Kirkland. 2005. Innate immunity to the 
pathogenic fungus Coccidioides posadasii is dependent on Toll-like receptor 2 and 
Dectin-1. Infect Immun 73:1553-1560. 
249. Taylor, P. R., S. V. Tsoni, J. A. Willment, K. M. Dennehy, M. Rosas, H. Findon, K. 
Haynes, C. Steele, M. Botto, S. Gordon, and G. D. Brown. 2007. Dectin-1 is required for 
beta-glucan recognition and control of fungal infection. Nature immunology 8:31-38. 
250. Hohl, T. M., and E. G. Pamer. 2006. Cracking the fungal armor. Nature medicine 12:730-
732. 
251. Kottom, T. J., and A. H. Limper. 2000. Cell wall assembly by Pneumocystis carinii. 
Evidence for a unique gsc-1 subunit mediating beta -1,3-glucan deposition. J Biol Chem 
275:40628-40634. 
252. Bartlett, M. S., W. L. Current, M. P. Goheen, C. J. Boylan, C. H. Lee, M. M. Shaw, S. F. 
Queener, and J. W. Smith. 1996. Semisynthetic echinocandins affect cell wall deposition 
of Pneumocystis carinii in vitro and in vivo. Antimicrob Agents Chemother 40:1811-
1816. 
253. Beck, J. M., M. B. Blackmon, C. M. Rose, S. L. Kimzey, A. M. Preston, and J. M. Green. 
2003. T cell costimulatory molecule function determines susceptibility to infection with 
Pneumocystis carinii in mice. J Immunol 171:1969-1977. 
254. Gantner, B. N., R. M. Simmons, S. J. Canavera, S. Akira, and D. M. Underhill. 2003. 
Collaborative induction of inflammatory responses by dectin-1 and Toll-like receptor 2. J 
Exp Med 197:1107-1117. 
 200 
255. Lasbury, M. E., P. J. Durant, C. A. Ray, D. Tschang, R. Schwendener, and C. H. Lee. 
2006. Suppression of alveolar macrophage apoptosis prolongs survival of rats and mice 
with pneumocystis pneumonia. J Immunol 176:6443-6453. 
256. Yasuoka, A., N. Tachikawa, K. Shimada, S. Kimura, and S. Oka. 1996. (1-->3) beta-D-
glucan as a quantitative serological marker for Pneumocystis carinii pneumonia. Clin 
Diagn Lab Immunol 3:197-199. 
257. Allen, M. J., A. Laederach, P. J. Reilly, and R. J. Mason. 2001. Polysaccharide 
recognition by surfactant protein D: novel interactions of a C-type lectin with 
nonterminal glucosyl residues. Biochemistry 40:7789-7798. 
258. Atochina, E. N., A. J. Gow, J. M. Beck, A. Haczku, A. Inch, H. Kadire, Y. Tomer, C. 
Davis, A. M. Preston, F. Poulain, S. Hawgood, and M. F. Beers. 2004. Delayed clearance 
of pneumocystis carinii infection, increased inflammation, and altered nitric oxide 
metabolism in lungs of surfactant protein-D knockout mice. J Infect Dis 189:1528-1539. 
259. Zhang, M. X., D. M. Lupan, and T. R. Kozel. 1997. Mannan-specific immunoglobulin G 
antibodies in normal human serum mediate classical pathway initiation of C3 binding to 
Candida albicans. Infect Immun 65:3822-3827. 
260. Zhang, M. X., and T. R. Kozel. 1998. Mannan-specific immunoglobulin G antibodies in 
normal human serum accelerate binding of C3 to Candida albicans via the alternative 
complement pathway. Infect Immun 66:4845-4850. 
261. Stehle, S. E., R. A. Rogers, A. G. Harmsen, and R. A. Ezekowitz. 2000. A soluble 
mannose receptor immunoadhesin enhances phagocytosis of Pneumocystis carinii by 
human polymorphonuclear leukocytes in vitro. Scandinavian journal of immunology 
52:131-137. 
262. O'Riordan, D. M., J. E. Standing, and A. H. Limper. 1995. Pneumocystis carinii 
glycoprotein A binds macrophage mannose receptors. Infect Immun 63:779-784. 
263. Marty, F. M., S. Koo, J. Bryar, and L. R. Baden. 2007. (1->3)beta-D-glucan assay 
positivity in patients with Pneumocystis (carinii) jiroveci pneumonia. Ann Intern Med 
147:70-72. 
264. Persat, F., S. Ranque, F. Derouin, A. Michel-Nguyen, S. Picot, and A. Sulahian. 2008. 
Contribution of the (1-->3)-beta-D-glucan assay for diagnosis of invasive fungal 
infections. J Clin Microbiol 46:1009-1013. 
265. Diamond, M. S., E. M. Sitati, L. D. Friend, S. Higgs, B. Shrestha, and M. Engle. 2003. A 
critical role for induced IgM in the protection against West Nile virus infection. J Exp 
Med 198:1853-1862. 
 201 
266. Boes, M., C. Esau, M. B. Fischer, T. Schmidt, M. Carroll, and J. Chen. 1998. Enhanced 
B-1 cell development, but impaired IgG antibody responses in mice deficient in secreted 
IgM. J Immunol 160:4776-4787. 
267. Lim, S. K., W. C. Eveland, and R. J. Porter. 1973. Development and evaluation of a 
direct fluorescent antibody method for the diagnosis of Pneumocystis carinii infections in 
experimental animals. Appl Microbiol 26:666-671. 
268. Itakura, A., M. Szczepanik, R. A. Campos, V. Paliwal, M. Majewska, H. Matsuda, K. 
Takatsu, and P. W. Askenase. 2005. An hour after immunization peritoneal B-1 cells are 
activated to migrate to lymphoid organs where within 1 day they produce IgM antibodies 
that initiate elicitation of contact sensitivity. J Immunol 175:7170-7178. 
269. Chen, W., E. A. Havell, F. Gigliotti, and A. G. Harmsen. 1993. Interleukin-6 production 
in a murine model of Pneumocystis carinii pneumonia: relation to resistance and 
inflammatory response. Infect Immun 61:97-102. 
270. Rapaka, R. R., E. S. Goetzman, M. Zheng, J. Vockley, L. McKinley, J. K. Kolls, and C. 
Steele. 2007. Enhanced defense against Pneumocystis carinii mediated by a novel dectin-
1 receptor Fc fusion protein. J Immunol 178:3702-3712. 
271. Qureshi, M. H., A. G. Harmsen, and B. A. Garvy. 2003. IL-10 modulates host responses 
and lung damage induced by Pneumocystis carinii infection. J Immunol 170:1002-1009. 
272. Ouyang, W., J. K. Kolls, and Y. Zheng. 2008. The biological functions of T helper 17 
cell effector cytokines in inflammation. Immunity 28:454-467. 
273. Aujla, S. J., P. J. Dubin, and J. K. Kolls. 2007. Th17 cells and mucosal host defense. 
Semin Immunol 19:377-382. 
274. Ozaki, K., R. Spolski, C. G. Feng, C. F. Qi, J. Cheng, A. Sher, H. C. Morse, 3rd, C. Liu, 
P. L. Schwartzberg, and W. J. Leonard. 2002. A critical role for IL-21 in regulating 
immunoglobulin production. Science 298:1630-1634. 
275. Wei, L., A. Laurence, K. M. Elias, and J. J. O'Shea. 2007. IL-21 is produced by Th17 
cells and drives IL-17 production in a STAT3-dependent manner. J Biol Chem 
282:34605-34610. 
276. Xia, Y., V. Vetvicka, J. Yan, M. Hanikyrova, T. Mayadas, and G. D. Ross. 1999. The 
beta-glucan-binding lectin site of mouse CR3 (CD11b/CD18) and its function in 
generating a primed state of the receptor that mediates cytotoxic activation in response to 
iC3b-opsonized target cells. J Immunol 162:2281-2290. 
277. Elias, J. A., R. J. Homer, Q. Hamid, and C. G. Lee. 2005. Chitinases and chitinase-like 
proteins in T(H)2 inflammation and asthma. J Allergy Clin Immunol 116:497-500. 
 202 
278. Szczepanik, M., M. Akahira-Azuma, K. Bryniarski, R. F. Tsuji, I. Kawikova, W. Ptak, C. 
Kiener, R. A. Campos, and P. W. Askenase. 2003. B-1 B cells mediate required early T 
cell recruitment to elicit protein-induced delayed-type hypersensitivity. J Immunol 
171:6225-6235. 
279. Mouthon, L., A. Nobrega, N. Nicolas, S. V. Kaveri, C. Barreau, A. Coutinho, and M. D. 
Kazatchkine. 1995. Invariance and restriction toward a limited set of self-antigens 
characterize neonatal IgM antibody repertoires and prevail in autoreactive repertoires of 
healthy adults. Proc Natl Acad Sci U S A 92:3839-3843. 
280. Zhou, Z. H., Y. Zhang, Y. F. Hu, L. M. Wahl, J. O. Cisar, and A. L. Notkins. 2007. The 
broad antibacterial activity of the natural antibody repertoire is due to polyreactive 
antibodies. Cell Host Microbe 1:51-61. 
281. Vermaelen, K. Y., I. Carro-Muino, B. N. Lambrecht, and R. A. Pauwels. 2001. Specific 
migratory dendritic cells rapidly transport antigen from the airways to the thoracic lymph 
nodes. J Exp Med 193:51-60. 
282. Shibuya, A., N. Sakamoto, Y. Shimizu, K. Shibuya, M. Osawa, T. Hiroyama, H. J. Eyre, 
G. R. Sutherland, Y. Endo, T. Fujita, T. Miyabayashi, S. Sakano, T. Tsuji, E. Nakayama, 
J. H. Phillips, L. L. Lanier, and H. Nakauchi. 2000. Fc alpha/mu receptor mediates 
endocytosis of IgM-coated microbes. Nat Immunol 1:441-446. 
283. Sakamoto, N., K. Shibuya, Y. Shimizu, K. Yotsumoto, T. Miyabayashi, S. Sakano, T. 
Tsuji, E. Nakayama, H. Nakauchi, and A. Shibuya. 2001. A novel Fc receptor for IgA 
and IgM is expressed on both hematopoietic and non-hematopoietic tissues. Eur J 
Immunol 31:1310-1316. 
284. Blazquez, A. B., and M. C. Berin. 2008. Gastrointestinal dendritic cells promote Th2 
skewing via OX40L. J Immunol 180:4441-4450. 
285. Arora, M., L. Chen, M. Paglia, I. Gallagher, J. E. Allen, Y. M. Vyas, A. Ray, and P. Ray. 
2006. Simvastatin promotes Th2-type responses through the induction of the chitinase 
family member Ym1 in dendritic cells. Proc Natl Acad Sci U S A 103:7777-7782. 
286. Miyahara, N., H. Ohnishi, H. Matsuda, S. Miyahara, K. Takeda, T. Koya, S. Matsubara, 
M. Okamoto, A. Dakhama, B. Haribabu, and E. W. Gelfand. 2008. Leukotriene B4 
receptor 1 expression on dendritic cells is required for the development of Th2 responses 
and allergen-induced airway hyperresponsiveness. J Immunol 181:1170-1178. 
287. Cenci, E., A. Mencacci, G. Del Sero, A. Bacci, C. Montagnoli, C. F. d'Ostiani, P. Mosci, 
M. Bachmann, F. Bistoni, M. Kopf, and L. Romani. 1999. Interleukin-4 causes 
susceptibility to invasive pulmonary aspergillosis through suppression of protective type I 
responses. J Infect Dis 180:1957-1968. 
288. Muller, U., W. Stenzel, G. Kohler, C. Werner, T. Polte, G. Hansen, N. Schutze, R. K. 
Straubinger, M. Blessing, A. N. McKenzie, F. Brombacher, and G. Alber. 2007. IL-13 
 203 
induces disease-promoting type 2 cytokines, alternatively activated macrophages and 
allergic inflammation during pulmonary infection of mice with Cryptococcus 
neoformans. J Immunol 179:5367-5377. 
289. Lamhamedi-Cherradi, S. E., R. E. Martin, T. Ito, F. Kheradmand, D. B. Corry, Y. J. Liu, 
and M. Moyle. 2008. Fungal proteases induce Th2 polarization through limited dendritic 
cell maturation and reduced production of IL-12. J Immunol 180:6000-6009. 
290. Rivera, A., G. Ro, H. L. Van Epps, T. Simpson, I. Leiner, D. B. Sant'Angelo, and E. G. 
Pamer. 2006. Innate immune activation and CD4+ T cell priming during respiratory 
fungal infection. Immunity 25:665-675. 
291. Zelante, T., A. De Luca, P. Bonifazi, C. Montagnoli, S. Bozza, S. Moretti, M. L. 
Belladonna, C. Vacca, C. Conte, P. Mosci, F. Bistoni, P. Puccetti, R. A. Kastelein, M. 
Kopf, and L. Romani. 2007. IL-23 and the Th17 pathway promote inflammation and 
impair antifungal immune resistance. Eur J Immunol 37:2695-2706. 
292. Romani, L. 2008. Cell mediated immunity to fungi: a reassessment. Med Mycol:1-15. 
293. McKinley, L., A. J. Logar, F. McAllister, M. Zheng, C. Steele, and J. K. Kolls. 2006. 
Regulatory T cells dampen pulmonary inflammation and lung injury in an animal model 
of pneumocystis pneumonia. J Immunol 177:6215-6226. 
294. Shellito, J. E., C. Tate, S. Ruan, and J. Kolls. 2000. Murine CD4+ T lymphocyte subsets 
and host defense against Pneumocystis carinii. J Infect Dis 181:2011-2017. 
295. Theus, S. A., N. Sawhney, A. G. Smulian, and P. D. Walzer. 1998. Proliferative and 
cytokine responses of human T lymphocytes isolated from human immunodeficiency 
virus-infected patients to the major surface glycoprotein of Pneumocystis carinii. J Infect 
Dis 177:238-241. 
296. Purkerson, J. M., and P. C. Isakson. 1992. Interleukin 5 (IL-5) provides a signal that is 
required in addition to IL-4 for isotype switching to immunoglobulin (Ig) G1 and IgE. J 
Exp Med 175:973-982. 
297. Purkerson, J., and P. Isakson. 1992. A two-signal model for regulation of 
immunoglobulin isotype switching. FASEB J 6:3245-3252. 
298. Moir, S., and A. S. Fauci. 2008. Pathogenic mechanisms of B-lymphocyte dysfunction in 
HIV disease. J Allergy Clin Immunol 122:12-19; quiz 20-11. 
299. Smulian, A. G., D. W. Sullivan, and S. A. Theus. 2000. Immunization with recombinant 
Pneumocystis carinii p55 antigen provides partial protection against infection: 
characterization of epitope recognition associated with immunization. Microbes Infect 
2:127-136. 
 204 
300. Theus, S. A., A. G. Smulian, P. Steele, M. J. Linke, and P. D. Walzer. 1998. 
Immunization with the major surface glycoprotein of Pneumocystis carinii elicits a 
protective response. Vaccine 16:1149-1157. 
301. Gigliotti, F., J. A. Wiley, and A. G. Harmsen. 1998. Immunization with Pneumocystis 
carinii gpA is immunogenic but not protective in a mouse model of P. carinii pneumonia. 
Infect Immun 66:3179-3182. 
302. Russian, D. A., V. Andrawis-Sorial, M. P. Goheen, J. C. Edman, P. Vogel, R. E. Turner, 
D. L. Klivington, C. W. Angus, and J. A. Kovacs. 1999. Characterization of a multicopy 
family of genes encoding a surface-expressed serine endoprotease in rat Pneumocystis 
carinii. Proc Assoc Am Physicians 111:347-356. 
303. Kutty, G., F. Maldarelli, G. Achaz, and J. A. Kovacs. 2008. Variation in the Major 
Surface Glycoprotein Genes in Pneumocystis jirovecii. J Infect Dis. 
304. Kutty, G., S. N. Huang, and J. A. Kovacs. 2003. Characterization of thioredoxin 
reductase genes (trr1) from Pneumocystis carinii and Pneumocystis jiroveci. Gene 
310:175-183. 
305. Thomas, C. F., Jr., and A. H. Limper. 2007. Current insights into the biology and 
pathogenesis of Pneumocystis pneumonia. Nat Rev Microbiol 5:298-308. 
306. Xu, W., B. He, A. Chiu, A. Chadburn, M. Shan, M. Buldys, A. Ding, D. M. Knowles, P. 
A. Santini, and A. Cerutti. 2007. Epithelial cells trigger frontline immunoglobulin class 
switching through a pathway regulated by the inhibitor SLPI. Nat Immunol 8:294-303. 
307. He, B., W. Xu, P. A. Santini, A. D. Polydorides, A. Chiu, J. Estrella, M. Shan, A. 
Chadburn, V. Villanacci, A. Plebani, D. M. Knowles, M. Rescigno, and A. Cerutti. 2007. 
Intestinal bacteria trigger T cell-independent immunoglobulin A(2) class switching by 
inducing epithelial-cell secretion of the cytokine APRIL. Immunity 26:812-826. 
308. Kataoka, K., K. Fujihashi, S. Sekine, T. Fukuiwa, R. Kobayashi, H. Suzuki, H. Nagata, 
K. Takatsu, S. Shizukuishi, and J. R. McGhee. 2007. Nasal cholera toxin elicits IL-5 and 
IL-5 receptor alpha-chain expressing B-1a B cells for innate mucosal IgA antibody 
responses. J Immunol 178:6058-6065. 
309. Tezuka, H., Y. Abe, M. Iwata, H. Takeuchi, H. Ishikawa, M. Matsushita, T. Shiohara, S. 
Akira, and T. Ohteki. 2007. Regulation of IgA production by naturally occurring 
TNF/iNOS-producing dendritic cells. Nature 448:929-933. 
310. McAllister, F., S. Ruan, C. Steele, M. Zheng, L. McKinley, L. Ulrich, L. Marrero, J. E. 
Shellito, and J. K. Kolls. 2006. CXCR3 and IFN protein-10 in Pneumocystis pneumonia. 
J Immunol 177:1846-1854. 
 
 
